

Chagas disease

Lancet, The

375, 1388-1402

DOI: [10.1016/s0140-6736\(10\)60061-x](https://doi.org/10.1016/s0140-6736(10)60061-x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Chagas Disease. , 0, , 44-51.		0
2	Captopril increases the intensity of monocyte infection by <i>Trypanosoma cruzi</i> and induces human T helper type 17 cells. <i>Clinical and Experimental Immunology</i> , 2010, 162, 528-536.	2.6	25
3	Experimental and Natural Recombination in <i>Trypanosoma cruzi</i> . , 2010, , 459-474.		2
4	Clinical Phases and Forms of Chagas Disease. , 2010, , 709-741.		9
5	Advances in Chagas disease drug development: 2009–2010. <i>Current Opinion in Infectious Diseases</i> , 2010, 23, 609-616.	3.1	60
6	Importance of Nonenteric Protozoan Infections in Immunocompromised People. <i>Clinical Microbiology Reviews</i> , 2010, 23, 795-836.	13.6	89
7	A randomized trial of the effects of exercise training in Chagas cardiomyopathy. <i>European Journal of Heart Failure</i> , 2010, 12, 866-873.	7.1	58
8	Congenital <i>Trypanosoma cruzi</i> Infection in Neonates and Infants from Two Regions of Chile Where Chagas' Disease Is Endemic. <i>Journal of Clinical Microbiology</i> , 2010, 48, 3824-3826.	3.9	10
9	TcTASV: A Novel Protein Family in <i>Trypanosoma cruzi</i> Identified from a Subtractive Trypomastigote cDNA Library. <i>PLoS Neglected Tropical Diseases</i> , 2010, 4, e841.	3.0	24
10	Chagas Cardiomyopathy Manifestations and <i>Trypanosoma cruzi</i> Genotypes Circulating in Chronic Chagasic Patients. <i>PLoS Neglected Tropical Diseases</i> , 2010, 4, e899.	3.0	137
11	The Potential Economic Value of a <i>Trypanosoma cruzi</i> (Chagas Disease) Vaccine in Latin America. <i>PLoS Neglected Tropical Diseases</i> , 2010, 4, e916.	3.0	65
12	Chagas Disease: 101 Years of Solitude!. <i>Stroke</i> , 2010, 41, 2453-2454.	2.0	6
13	Tolerance and Safety of Nifurtimox in Patients with Chronic Chagas Disease. <i>Clinical Infectious Diseases</i> , 2010, 51, e69-e75.	5.8	176
14	The endless race between <i>Trypanosoma cruzi</i> and host immunity: lessons for and beyond Chagas disease. <i>Expert Reviews in Molecular Medicine</i> , 2010, 12, e29.	3.9	158
15	Antitrypanosomal agents: treatment or threat?. <i>Lancet</i> , The, 2010, 376, 768.	13.7	29
16	Molecular Identification of <i>Trypanosoma cruzi</i> Discrete Typing Units in End-stage Chronic Chagas Heart Disease and Reactivation after Heart Transplantation. <i>Clinical Infectious Diseases</i> , 2010, 51, 485-495.	5.8	173
17	<i>Trypanosoma cruzi</i> and Chagas' Disease in the United States. <i>Clinical Microbiology Reviews</i> , 2011, 24, 655-681.	13.6	582
18	Nifurtimox Activation by Trypanosomal Type I Nitroreductases Generates Cytotoxic Nitrile Metabolites. <i>Journal of Biological Chemistry</i> , 2011, 286, 13088-13095.	3.4	195

#	ARTICLE	IF	CITATIONS
19	A Platform for the Detection of Trypanosomes via Selective Small Molecule Recognition. ACS Medicinal Chemistry Letters, 2011, 2, 555-558.	2.8	2
20	Evaluaci3n de la variabilidad gen3tica de aislamientos colombianos de Trypanosoma cruzi mediante marcadores microsati3lites. Infectio, 2011, 15, 227-234.	0.4	5
21	Matrix metalloproteinase inhibitor properties of tetracyclines: Therapeutic potential in cardiovascular diseases. Pharmacological Research, 2011, 64, 551-560.	7.1	80
22	Chagas Disease: Coming to a Place Near You. Dermatologic Clinics, 2011, 29, 53-62.	1.7	29
23	Intraphagosomal Peroxynitrite as a Macrophage-derived Cytotoxin against Internalized Trypanosoma cruzi. Journal of Biological Chemistry, 2011, 286, 6627-6640.	3.4	197
24	Interpretation of Remotely Downloaded Pocket-Size Cardiac Ultrasound Images on a Web-Enabled Smartphone: Validation Against Workstation Evaluation. Journal of the American Society of Echocardiography, 2011, 24, 1325-1330.	2.8	77
25	Current status of Chagas disease chemotherapy. Expert Review of Anti-Infective Therapy, 2011, 9, 609-620.	4.4	102
26	In Vitro and in Vivo Trypanocidal Activity of Flavonoids from <i>Delphinium staphisagria</i> against Chagas Disease. Journal of Natural Products, 2011, 74, 744-750.	3.0	63
27	Economic evaluation of Chagas disease screening of pregnant Latin American women and of their infants in a non endemic area. Acta Tropica, 2011, 118, 110-117.	2.0	92
28	Tigutcystatin, a cysteine protease inhibitor from Triatoma infestans midgut expressed in response to Trypanosoma cruzi. Biochemical and Biophysical Research Communications, 2011, 413, 241-247.	2.1	14
29	Identification of HLA-A*02:01-restricted CTL epitopes in Trypanosoma cruzi heat shock protein-70 recognized by Chagas disease patients. Microbes and Infection, 2011, 13, 1025-1032.	1.9	21
30	Should tissue Doppler echocardiography be used to improve prediction of mortality risk in patients with Chagas cardiomyopathy?. International Journal of Cardiology, 2011, 149, 134-135.	1.7	2
31	Zanthoxylum chiloperone leaves extract: First sustainable Chagas disease treatment. Journal of Ethnopharmacology, 2011, 133, 986-993.	4.1	37
32	Trypanosoma cruzi l3 in southern Brazil causing individual and mixed infections in humans, sylvatic reservoirs and triatomines. Acta Tropica, 2011, 120, 167-172.	2.0	38
33	The Trypanosoma cruzi genome; conserved core genes and extremely variable surface molecule families. Research in Microbiology, 2011, 162, 619-625.	2.1	21
34	Acute and Congenital Chagas Disease. Advances in Parasitology, 2011, 75, 19-47.	3.2	97
35	Gastrointestinal Chagas disease in migrants to Spain: prevalence and methods for early diagnosis. Annals of Tropical Medicine and Parasitology, 2011, 105, 25-29.	1.6	35
36	Cell-Based Therapy in Chagas Disease. Advances in Parasitology, 2011, 75, 49-63.	3.2	4

#	ARTICLE	IF	CITATIONS
37	Vaccine Development Against <i>Trypanosoma cruzi</i> and Chagas Disease. <i>Advances in Parasitology</i> , 2011, 75, 121-146.	3.2	62
38	Genetic Epidemiology of Chagas Disease. <i>Advances in Parasitology</i> , 2011, 75, 147-167.	3.2	12
39	Preface. <i>Advances in Parasitology</i> , 2011, 75, xxi-xxvi.	3.2	1
40	Kinetoplastid Parasites. <i>Topics in Medicinal Chemistry</i> , 2011, , 181-241.	0.8	6
41	Chagas' disease and Duffy antigen/receptor for chemokine (DARC): a mini-review. <i>Journal of Venomous Animals and Toxins Including Tropical Diseases</i> , 2011, 17, 264-270.	1.4	1
42	Gastrointestinal Infection with Mexican <i>Trypanosoma cruzi</i> strains: Different Degrees of Colonization and Diverse Immune Responses. <i>International Journal of Biological Sciences</i> , 2011, 7, 1357-1370.	6.4	18
43	Epidemiología molecular de enfermedades parasitarias. <i>Biomedica</i> , 2011, 31, 146.	0.7	0
44	Paratransgenic Control of Vector Borne Diseases. <i>International Journal of Biological Sciences</i> , 2011, 7, 1334-1344.	6.4	81
46	The Role of Heme and Reactive Oxygen Species in Proliferation and Survival of <i>Trypanosoma cruzi</i> . <i>Journal of Parasitology Research</i> , 2011, 2011, 1-8.	1.2	26
47	Evasion of immune responses by <i>Trypanosoma cruzi</i> , the etiological agent of Chagas disease. <i>Brazilian Journal of Medical and Biological Research</i> , 2011, 44, 84-90.	1.5	38
48	Multilocus Sequence Typing (MLST) for Lineage Assignment and High Resolution Diversity Studies in <i>Trypanosoma cruzi</i> . <i>PLoS Neglected Tropical Diseases</i> , 2011, 5, e1049.	3.0	94
49	Update in treatment of Chagas disease. <i>Current Opinion in Infectious Diseases</i> , 2011, 24, 428-434.	3.1	54
50	Timeless makes some time for itself. <i>Cell Cycle</i> , 2011, 10, 2254-2254.	2.6	0
51	Guidelines on the Treatment of Chronic Coinfection by <i>Trypanosoma cruzi</i> and HIV Outside Endemic Areas. <i>HIV Clinical Trials</i> , 2011, 12, 287-298.	2.0	50
53	Effects of <i>Trypanosoma cruzi</i> infection on myocardial morphology, single cardiomyocyte contractile function and exercise tolerance in rats. <i>International Journal of Experimental Pathology</i> , 2011, 92, 299-307.	1.3	23
54	Chagas disease in Latin American migrants: a Spanish challenge. <i>Clinical Microbiology and Infection</i> , 2011, 17, 1108-1113.	6.0	82
55	Recommendations for management of Chagas disease in organ and hematopoietic tissue transplantation programs in nonendemic areas. <i>Transplantation Reviews</i> , 2011, 25, 91-101.	2.9	95
56	Applicability of an optimized non-conventional flow cytometry method to detect anti- <i>Trypanosoma cruzi</i> immunoglobulin G for the serological diagnosis and cure assessment following chemotherapeutic treatment of Chagas disease. <i>Journal of Immunological Methods</i> , 2011, 369, 22-32.	1.4	14

#	ARTICLE	IF	CITATIONS
57	Vector-borne parasitic zoonoses: Emerging scenarios and new perspectives. <i>Veterinary Parasitology</i> , 2011, 182, 14-21.	1.8	185
58	Synthesis, trypanocidal activity and molecular modeling studies of 2-alkylaminomethylquinoline derivatives. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 3696-3703.	5.5	31
59	Activation and inhibition of CTP synthase from <i>Trypanosoma brucei</i> , the causative agent of African sleeping sickness. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 5188-5190.	2.2	11
60	Identification of small-molecule inhibitors of <i>Trypanosoma cruzi</i> replication. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 7197-7200.	2.2	12
61	Antitrypanosomal Therapy for Chronic Chagas' Disease. <i>New England Journal of Medicine</i> , 2011, 364, 2527-2534.	27.0	234
62	Effects of platelet-activating factor on the interaction of <i>Trypanosoma cruzi</i> with <i>Rhodnius prolixus</i> . <i>Parasitology Research</i> , 2011, 108, 1473-1478.	1.6	4
63	<i>Trypanosoma cruzi</i> : evaluation of (âˆ™)-cubebin derivatives activity in the messenger RNAs processing. <i>Parasitology Research</i> , 2011, 109, 445-451.	1.6	12
64	Short-term follow-up of chagasic patients after benznidazole treatment using multiple serological markers. <i>BMC Infectious Diseases</i> , 2011, 11, 206.	2.9	42
65	Gene discovery in <i>Triatoma infestans</i> . <i>Parasites and Vectors</i> , 2011, 4, 39.	2.5	7
66	Schistosomicidal and trypanocidal structureâ€™ activity relationships for (Â±)-licarin A and its (âˆ™)- and (+)-enantiomers. <i>Phytochemistry</i> , 2011, 72, 1424-1430.	2.9	45
67	Generation of novel Chagas vaccines. , 2011, , .		0
68	Natural and Synthetic Naphthoquinones Active Against <i>Trypanosoma Cruzi</i> : An Initial Step Towards New Drugs for Chagas Disease. <i>Current Medicinal Chemistry</i> , 2011, 18, 144-161.	2.4	98
69	Influence of Pregnancy on <i>Trypanosoma cruzi</i> Parasitemia in Chronically Infected Women in a Rural Bolivian Community. <i>American Journal of Tropical Medicine and Hygiene</i> , 2011, 84, 808-812.	1.4	7
70	Neurotrophin Receptor TrkC Is an Entry Receptor for <i>Trypanosoma cruzi</i> in Neural, Glial, and Epithelial Cells. <i>Infection and Immunity</i> , 2011, 79, 4081-4087.	2.2	25
71	Evaluation of a Recombinant <i>Trypanosoma cruzi</i> Mucin-Like Antigen for Serodiagnosis of Chagas' Disease. <i>Vaccine Journal</i> , 2011, 18, 1850-1855.	3.1	46
72	Requirement of UNC93B1 Reveals a Critical Role for TLR7 in Host Resistance to Primary Infection with <i>Trypanosoma cruzi</i> . <i>Journal of Immunology</i> , 2011, 187, 1903-1911.	0.8	67
73	Advances and challenges towards a vaccine against Chagas disease. <i>Hum Vaccin</i> , 2011, 7, 1184-1191.	2.4	76
74	A Patient with Erythema Nodosus Leprosum and Chagas Cardiopathy: Challenges in Patient Management and Review of the Literature. <i>American Journal of Tropical Medicine and Hygiene</i> , 2011, 84, 973-977.	1.4	3

#	ARTICLE	IF	CITATIONS
75	Same stem cells but different: Isogenic embryonic stem cells harboring different p53 mutants. <i>Cell Cycle</i> , 2011, 10, 2248-2248.	2.6	0
76	Resetting gene expression in chronic Chagas heart disease. <i>Cell Cycle</i> , 2011, 10, 2250-2250.	2.6	0
77	An Ezh way to turn off Nanog. <i>Cell Cycle</i> , 2011, 10, 2253-2253.	2.6	1
78	Epigenetic Nanog regulation and the role of functional heterogeneity. <i>Cell Cycle</i> , 2011, 10, 2252-2252.	2.6	2
79	That's amore: Bone marrow cells compete for the heart in Chagas disease. <i>Cell Cycle</i> , 2011, 10, 2251-2251.	2.6	0
80	Expanding the p53 toolkit: A new platform for rapid engineering of the p53 locus in vivo. <i>Cell Cycle</i> , 2011, 10, 2249-2249.	2.6	0
81	The efficacy of novel arylimidamides against <i>Trypanosoma cruzi</i> in vitro. <i>Parasitology</i> , 2011, 138, 1863-1869.	1.5	8
82	Therapy of vector-borne protozoan infections in nonendemic settings. <i>Expert Review of Anti-Infective Therapy</i> , 2011, 9, 583-608.	4.4	3
83	Antitrypanosomal Therapy for Chronic Chagas' Disease. <i>New England Journal of Medicine</i> , 2011, 365, 1258-1259.	27.0	10
84	Genetic and Functional Role of TNF-alpha in the Development <i>Trypanosoma cruzi</i> Infection. <i>PLoS Neglected Tropical Diseases</i> , 2011, 5, e976.	3.0	36
85	Testing the Efficacy of a Multi-Component DNA-Prime/DNA-Boost Vaccine against <i>Trypanosoma cruzi</i> Infection in Dogs. <i>PLoS Neglected Tropical Diseases</i> , 2011, 5, e1050.	3.0	52
86	Shotgun Sequencing Analysis of <i>Trypanosoma cruzi</i> I Sylvio X10/1 and Comparison with <i>T. cruzi</i> VI CL Brener. <i>PLoS Neglected Tropical Diseases</i> , 2011, 5, e984.	3.0	129
87	Chagas Disease among the Latin American Adult Population Attending in a Primary Care Center in Barcelona, Spain. <i>PLoS Neglected Tropical Diseases</i> , 2011, 5, e1135.	3.0	50
88	Crystal Structure of the Complex mAb 17.2 and the C-Terminal Region of <i>Trypanosoma cruzi</i> P21 ² Protein: Implications in Cross-Reactivity. <i>PLoS Neglected Tropical Diseases</i> , 2011, 5, e1375.	3.0	6
89	A Latin American Man with Palpitations, Dizziness, Episodes of Nonsustained Ventricular Tachycardia, and an Apical Aneurysm. <i>PLoS Neglected Tropical Diseases</i> , 2011, 5, e852.	3.0	6
90	Untreated Human Infections by <i>Trypanosoma brucei gambiense</i> Are Not 100% Fatal. <i>PLoS Neglected Tropical Diseases</i> , 2012, 6, e1691.	3.0	163
91	Regulation of Biotransformation Systems and ABC Transporters by Benznidazole in HepG2 Cells: Involvement of Pregnane X-Receptor. <i>PLoS Neglected Tropical Diseases</i> , 2012, 6, e1951.	3.0	20
92	Multiple Mitochondrial Introgression Events and Heteroplasmy in <i>Trypanosoma cruzi</i> Revealed by Maxicircle MLST and Next Generation Sequencing. <i>PLoS Neglected Tropical Diseases</i> , 2012, 6, e1584.	3.0	104

#	ARTICLE	IF	CITATIONS
93	A Simple Strain Typing Assay for <i>Trypanosoma cruzi</i> : Discrimination of Major Evolutionary Lineages from a Single Amplification Product. <i>PLoS Neglected Tropical Diseases</i> , 2012, 6, e1777.	3.0	64
94	Geographical Distribution of <i>Trypanosoma cruzi</i> Genotypes in Venezuela. <i>PLoS Neglected Tropical Diseases</i> , 2012, 6, e1707.	3.0	76
95	Geographic Distribution of Chagas Disease Vectors in Brazil Based on Ecological Niche Modeling. <i>Journal of Tropical Medicine</i> , 2012, 2012, 1-15.	1.7	185
96	Sensitivity and Specificity of an Operon Immunochromatographic Test in Serum and Whole-Blood Samples for the Diagnosis of <i>Trypanosoma cruzi</i> Infection in Spain, an Area of Nonendemicity. <i>Vaccine Journal</i> , 2012, 19, 1353-1359.	3.1	15
97	IFN- γ Plays a Unique Role in Protection against Low Virulent <i>Trypanosoma cruzi</i> Strain. <i>PLoS Neglected Tropical Diseases</i> , 2012, 6, e1598.	3.0	42
98	Sensitive and Specific Detection of <i>Trypanosoma cruzi</i> DNA in Clinical Specimens Using a Multi-Target Real-Time PCR Approach. <i>PLoS Neglected Tropical Diseases</i> , 2012, 6, e1689.	3.0	88
99	Chagas Disease: "The New HIV/AIDS of the Americas" <i>PLoS Neglected Tropical Diseases</i> , 2012, 6, e1498.	3.0	184
100	Diverse Inhibitor Chemotypes Targeting <i>Trypanosoma cruzi</i> CYP51. <i>PLoS Neglected Tropical Diseases</i> , 2012, 6, e1736.	3.0	54
101	The Receptor Slamf1 on the Surface of Myeloid Lineage Cells Controls Susceptibility to Infection by <i>Trypanosoma cruzi</i> . <i>PLoS Pathogens</i> , 2012, 8, e1002799.	4.7	21
102	Inducible Nitric Oxide Synthase in Heart Tissue and Nitric Oxide in Serum of <i>Trypanosoma cruzi</i> -Infected Rhesus Monkeys: Association with Heart Injury. <i>PLoS Neglected Tropical Diseases</i> , 2012, 6, e1644.	3.0	54
103	CD8+ T-Cells Expressing Interferon Gamma or Perforin Play Antagonistic Roles in Heart Injury in Experimental <i>Trypanosoma Cruzi</i> -Elicited Cardiomyopathy. <i>PLoS Pathogens</i> , 2012, 8, e1002645.	4.7	105
104	Chagas™ Disease. , 2012, , 2021-2025.		0
105	Defects of mtDNA Replication Impaired Mitochondrial Biogenesis During <i>Trypanosoma cruzi</i> Infection in Human Cardiomyocytes and Chagasic Patients: The Role of Nrf1/2 and Antioxidant Response. <i>Journal of the American Heart Association</i> , 2012, 1, e003855.	3.7	54
106	Chagas disease in the immunosuppressed host. <i>Current Opinion in Infectious Diseases</i> , 2012, 25, 450-457.	3.1	94
107	Cell Therapy in Chagas Cardiomyopathy (Chagas Arm of the Multicenter Randomized Trial of Cell) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.6	63
108	Targeting the Substrate Preference of a Type I Nitroreductase To Develop Antitrypanosomal Quinone-Based Prodrugs. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5821-5830.	3.2	32
109	Mannose-Binding Lectin and Toll-Like Receptor Polymorphisms and Chagas Disease in Chile. <i>American Journal of Tropical Medicine and Hygiene</i> , 2012, 86, 229-232.	1.4	29
110	An unusual myosuppressin from the blood-feeding bug <i>Rhodnius prolixus</i> . <i>Journal of Experimental Biology</i> , 2012, 215, 2088-2095.	1.7	37

#	ARTICLE	IF	CITATIONS
111	The Potential of Secondary Metabolites from Plants as Drugs or Leads Against Protozoan Neglected Diseases - Part I. <i>Current Medicinal Chemistry</i> , 2012, 19, 2128-2175.	2.4	207
112	Innovative Lead Compounds and Formulation Strategies As Newer Kinetoplastid Therapies. <i>Current Medicinal Chemistry</i> , 2012, 19, 4259-4288.	2.4	42
113	Modeling the economic value of a Chagasâ€™ disease therapeutic vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 1293-1301.	3.3	62
114	Congenital Chagas disease: time to screen pregnant women?. <i>Expert Review of Anti-Infective Therapy</i> , 2012, 10, 1279-1282.	4.4	6
115	Serum Proteomic Signature of Human Chagasic Patients for the Identification of Novel Potential Protein Biomarkers of Disease. <i>Molecular and Cellular Proteomics</i> , 2012, 11, 435-452.	3.8	34
116	Darwinian Dyspepsia: An Extraordinary Scientist, an Ordinary Illness, Great Dignity. <i>American Journal of Gastroenterology</i> , 2012, 107, 161-164.	0.4	12
117	Biological and Structural Characterization of <i>Trypanosoma cruzi</i> Phosphodiesterase C and Implications for Design of Parasite Selective Inhibitors. <i>Journal of Biological Chemistry</i> , 2012, 287, 11788-11797.	3.4	30
118	Current understanding of the <i>Trypanosoma cruzi</i> -cardiomyocyte interaction. <i>Frontiers in Immunology</i> , 2012, 3, 327.	4.8	25
119	Resting and Dynamic Electrocardiography in Dogs with Experimental Chagas Cardiomyopathy. <i>Epidemiology Research International</i> , 2012, 2012, 1-6.	0.2	3
120	Role of PPARs in <i>Trypanosoma cruzi</i> Infection: Implications for Chagas Disease Therapy. <i>PPAR Research</i> , 2012, 2012, 1-8.	2.4	12
121	Lysophosphatidylcholine: A Novel Modulator of <i>Trypanosoma cruzi</i> Transmission. <i>Journal of Parasitology Research</i> , 2012, 2012, 1-8.	1.2	14
122	(2E)-Nâ€™-[(E)-Benzylidene]-3-phenylprop-2-enohydrazide from synchrotron radiation. <i>Acta Crystallographica Section E: Structure Reports Online</i> , 2012, 68, o2255-o2256.	0.2	2
123	Genotoxicity profile of fexinidazole—a drug candidate in clinical development for human African trypanomiasis (sleeping sickness). <i>Mutagenesis</i> , 2012, 27, 523-532.	2.6	41
125	Congenital Transmission of Chagas Diseaseâ€™ Virginia, 2010. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 1624.	7.4	22
126	Diagnosis and management of Chagas disease and cardiomyopathy. <i>Nature Reviews Cardiology</i> , 2012, 9, 576-589.	13.7	277
127	Neglected tropical diseases: diagnosis, clinical management, treatment and control. <i>Swiss Medical Weekly</i> , 2012, 142, w13727.	1.6	181
128	<i>In silico</i> analysis of trypanosomatids' helicases. <i>FEMS Microbiology Letters</i> , 2012, 335, 123-129.	1.8	15
129	Mortality prediction in Chagas heart disease. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 1173-1184.	1.5	40

#	ARTICLE	IF	CITATIONS
130	Essential oils for the control of reduviid insects. <i>Phytochemistry Reviews</i> , 2012, 11, 361-369.	6.5	18
131	Intraspecies Variation in <i>Trypanosoma cruzi</i> GPI-Mucins: Biological Activities and Differential Expression of I±-Galactosyl Residues. <i>American Journal of Tropical Medicine and Hygiene</i> , 2012, 87, 87-96.	1.4	34
133	Proteome Expression and Carbonylation Changes During <i>Trypanosoma cruzi</i> Infection and Chagas Disease in Rats. <i>Molecular and Cellular Proteomics</i> , 2012, 11, M111.010918.	3.8	15
134	Ventricular Tachycardia in Nonischemic Dilated Cardiomyopathy. , 2012, , 594-600.		0
135	Management of trypanosomiasis and leishmaniasis. <i>British Medical Bulletin</i> , 2012, 104, 175-196.	6.9	240
136	Accelerating the development of a therapeutic vaccine for human Chagas disease: rationale and prospects. <i>Expert Review of Vaccines</i> , 2012, 11, 1043-1055.	4.4	117
137	Structural Investigation of Anti- <i>Trypanosoma cruzi</i> 2-Iminothiazolidin-4-ones Allows the Identification of Agents with Efficacy in Infected Mice. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 10918-10936.	6.4	55
138	American Trypanosomiasis (Chagas Disease). <i>Infectious Disease Clinics of North America</i> , 2012, 26, 275-291.	5.1	433
139	Novel 3-Nitro-1 <i>H</i> -1,2,4-triazole-Based Amides and Sulfonamides as Potential Antitrypanosomal Agents. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 5554-5565.	6.4	96
140	Natural and emergent <i>Trypanosoma cruzi</i> I genotypes revealed by mitochondrial (Cytb) and nuclear (SSU rDNA) genetic markers. <i>Experimental Parasitology</i> , 2012, 132, 487-494.	1.2	27
141	Recent developments in sterol 14-demethylase inhibitors for Chagas disease. <i>International Journal for Parasitology: Drugs and Drug Resistance</i> , 2012, 2, 236-242.	3.4	85
143	Chagas Heart Disease. <i>Cardiology in Review</i> , 2012, 20, 53-65.	1.4	90
144	Laboratory Diagnosis of Tropical Infections. <i>Infectious Disease Clinics of North America</i> , 2012, 26, 513-554.	5.1	9
145	<i>Trypanosoma cruzi</i> infection alters glucose metabolism at rest and during exercise without modifying the morphology of pancreatic islets in rats. <i>Pathology Research and Practice</i> , 2012, 208, 480-488.	2.3	5
146	The TGF- β Pathway as an Emerging Target for Chagas Disease Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 92, 613-621.	4.7	46
147	Congenital Transmission of <i>Trypanosoma cruzi</i> in Non-Endemic Areas: Evaluation of a Screening Program in a Tertiary Care Hospital in Barcelona, Spain. <i>American Journal of Tropical Medicine and Hygiene</i> , 2012, 87, 832-836.	1.4	17
148	Indole Alkaloids from <i>Geissospermum reticulatum</i> . <i>Journal of Natural Products</i> , 2012, 75, 928-934.	3.0	44
149	Redox-Active Antiparasitic Drugs. <i>Antioxidants and Redox Signaling</i> , 2012, 17, 555-582.	5.4	76

#	ARTICLE	IF	CITATIONS
150	Thiol-Based Posttranslational Modifications in Parasites. Antioxidants and Redox Signaling, 2012, 17, 657-673.	5.4	23
151	Bisphosphonate metal complexes as selective inhibitors of Trypanosoma cruzi farnesyl diphosphate synthase. Dalton Transactions, 2012, 41, 6468.	3.3	32
152	Congenital parasitic infections: A review. Acta Tropica, 2012, 121, 55-70.	2.0	147
153	Rabbit serum against K1 peptide, an immunogenic epitope of the Trypanosoma cruzi KMP-11, decreases parasite invasion to cells. Acta Tropica, 2012, 123, 224-229.	2.0	6
154	Critical importance of the de novo pyrimidine biosynthesis pathway for Trypanosoma cruzi growth in the mammalian host cell cytoplasm. Biochemical and Biophysical Research Communications, 2012, 417, 1002-1006.	2.1	24
155	The GTPase TcRjl of the human pathogen Trypanosoma cruzi is involved in the cell growth and differentiation. Biochemical and Biophysical Research Communications, 2012, 419, 38-42.	2.1	16
156	Molecular characterization of the Trypanosoma cruzi specific RNA binding protein TcRBP40 and its associated mRNAs. Biochemical and Biophysical Research Communications, 2012, 420, 302-307.	2.1	18
157	Quantitative proteomics of <i>Trypanosoma cruzi</i> during metacyclogenesis. Proteomics, 2012, 12, 2694-2703.	2.2	71
158	A genomic scale map of genetic diversity in Trypanosoma cruzi. BMC Genomics, 2012, 13, 736.	2.8	16
159	Chagasic patients are able to respond against a viral antigen from influenza virus. BMC Infectious Diseases, 2012, 12, 198.	2.9	7
160	Impact of pharmaceutical care on the quality of life of patients with Chagas disease and heart failure: randomized clinical trial. Trials, 2012, 13, 244.	1.6	15
161	North American import? Charting the origins of an enigmatic Trypanosoma cruzi domestic genotype. Parasites and Vectors, 2012, 5, 226.	2.5	48
162	A novel triazolic naphthofuranquinone induces autophagy in reservosomes and impairment of mitosis in <i>Trypanosoma cruzi</i> . Parasitology, 2012, 139, 26-36.	1.5	48
163	Phthalazine Derivatives Containing Imidazole Rings Behave as Fe-SOD Inhibitors and Show Remarkable Anti-T. cruzi Activity in Immunodeficient-Mouse Mode of Infection. Journal of Medicinal Chemistry, 2012, 55, 9900-9913.	6.4	41
164	Trypanosoma cruzi trans-Sialidase in Complex with a Neutralizing Antibody: Structure/Function Studies towards the Rational Design of Inhibitors. PLoS Pathogens, 2012, 8, e1002474.	4.7	36
165	In Vitro and in Vivo Trypanosomicidal Activity of Pyrazole-Containing Macrocyclic and Macrobicyclic Polyamines: Their Action on Acute and Chronic Phases of Chagas Disease. Journal of Medicinal Chemistry, 2012, 55, 4231-4243.	6.4	30
166	High resolution manometric findings in patients with Chagas' disease esophagopathy. Asian Pacific Journal of Tropical Medicine, 2012, 5, 110-112.	0.8	13
167	Effects of amiodarone and posaconazole on the growth and ultrastructure of Trypanosoma cruzi. International Journal of Antimicrobial Agents, 2012, 40, 61-71.	2.5	65

#	ARTICLE	IF	CITATIONS
168	Evaluation of benznidazole treatment combined with nifurtimox, posaconazole or AmBisome® in mice infected with Trypanosoma cruzi strains. <i>International Journal of Antimicrobial Agents</i> , 2012, 40, 527-532.	2.5	66
169	Trypanosoma cruzi-induced depressive-like behavior is independent of meningoencephalitis but responsive to parasiticide and TNF-targeted therapeutic interventions. <i>Brain, Behavior, and Immunity</i> , 2012, 26, 1136-1149.	4.1	34
170	Design and synthesis of new (E)-cinnamic N-acylhydrazones as potent antitrypanosomal agents. <i>European Journal of Medicinal Chemistry</i> , 2012, 54, 512-521.	5.5	65
171	Chronic Chagas disease with cardiodigestive involvement and the TcVI infective form of Trypanosoma cruzi. A case report. <i>Parasitology International</i> , 2012, 61, 735-737.	1.3	7
172	Trypanosoma cruzi uses macropinocytosis as an additional entry pathway into mammalian host cell. <i>Microbes and Infection</i> , 2012, 14, 1340-1351.	1.9	39
173	Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy. , 2012, 11, CD009077.		11
174	Preliminary in vitro evaluation of N-((benzofuroxan-5-yl)methylene benzohydrazide derivatives as potential anti-Trypanosoma cruzi agents. <i>MedChemComm</i> , 2012, 3, 824.	3.4	9
175	The development and validation of a risk score for household infestation by Triatoma infestans, a Bolivian vector of Chagas disease. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2012, 106, 677-682.	1.8	11
176	Characterization of an Immunodominant Antigenic Epitope from Trypanosoma cruzi as a Biomarker of Chronic Chagas' Disease Pathology. <i>Vaccine Journal</i> , 2012, 19, 167-173.	3.1	21
177	Antitrypanosomal Alkaloids from the Marine Bacterium Bacillus pumilus. <i>Molecules</i> , 2012, 17, 11146-11155.	3.8	48
179	Neglected Infections of Poverty in Texas and the Rest of the United States: Management and Treatment Options. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 92, 170-181.	4.7	15
180	Review. <i>Advances in Parasitology</i> , 2012, 79, 375-428.	3.2	25
181	Chagasic cardiomyopathy, from acute to chronic: is this mediated by host susceptibility factors?. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2012, 106, 521-527.	1.8	29
182	The Ontology for Parasite Lifecycle (OPL): towards a consistent vocabulary of lifecycle stages in parasitic organisms. <i>Journal of Biomedical Semantics</i> , 2012, 3, 5.	1.6	4
183	Protective Human Leucocyte Antigen Haplotype, HLA-DRB1*01-B*14, against Chronic Chagas Disease in Bolivia. <i>PLoS Neglected Tropical Diseases</i> , 2012, 6, e1587.	3.0	23
184	A New Endemic Focus of Chagas Disease in the Northern Region of Veraguas Province, Western Half Panama, Central America. <i>PLoS ONE</i> , 2012, 7, e34657.	2.5	17
185	Development of an Aptamer-Based Concentration Method for the Detection of Trypanosoma cruzi in Blood. <i>PLoS ONE</i> , 2012, 7, e43533.	2.5	41
186	Diagnostic Peptide Discovery: Prioritization of Pathogen Diagnostic Markers Using Multiple Features. <i>PLoS ONE</i> , 2012, 7, e50748.	2.5	36

#	ARTICLE	IF	CITATIONS
187	Autophagy in Trypanosomatids. <i>Cells</i> , 2012, 1, 346-371.	4.1	29
188	Effects of an exercise program on the functional capacity of patients with chronic Chagas' heart disease, evaluated by cardiopulmonary testing. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2012, 45, 220-224.	0.9	26
189	Seroprevalence Survey of American Trypanosomiasis in Central Valley of Toluca. <i>Scientific World Journal</i> , The, 2012, 2012, 1-3.	2.1	2
190	Synanthropic triatomines (Hemiptera, Reduviidae) in the state of Pernambuco, Brazil: geographical distribution and natural Trypanosoma infection rates between 2006 and 2007. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2012, 45, 60-65.	0.9	34
191	Transplante card��aco na doen��a de Chagas. , 2012, 91, 229.	0.1	0
192	Chagas Disease in Non-Endemic Countries: Epidemiology, Clinical Presentation and Treatment. <i>Current Infectious Disease Reports</i> , 2012, 14, 263-274.	3.0	74
193	Assignment of Putative Functions to Membrane "Hypothetical Proteins" from the Trypanosoma cruzi Genome. <i>Journal of Membrane Biology</i> , 2012, 245, 125-129.	2.1	6
194	The effects of density on the topological structure of the mitochondrial DNA from trypanosomes. <i>Journal of Mathematical Biology</i> , 2012, 64, 1087-1108.	1.9	26
195	Activation of cord blood myeloid dendritic cells by Trypanosoma cruzi and parasite-specific antibodies, proliferation of CD8+ T cells, and production of IFN-��3. <i>Medical Microbiology and Immunology</i> , 2012, 201, 157-169.	4.8	13
196	Trypanosoma cruzi activates cord blood myeloid dendritic cells independently of cell infection. <i>Medical Microbiology and Immunology</i> , 2012, 201, 287-296.	4.8	5
197	Multiple effects of pepstatin A on Trypanosoma cruzi epimastigote forms. <i>Parasitology Research</i> , 2012, 110, 2533-2540.	1.6	10
198	Host cell invasion by <i>Trypanosoma cruzi</i> : a unique strategy that promotes persistence. <i>FEMS Microbiology Reviews</i> , 2012, 36, 734-747.	8.6	112
199	Radiofrequency Ablation of a Left Accessory Pathway Unmasks Classic Chagas�� disease ECG Pattern. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2012, 35, e38-9.	1.2	1
200	Maladie de Chagas��: une parasitose am��ricaine ��mergente en Europe. <i>Journal Des Anti-infectieux</i> , 2012, 14, 27-34.	0.1	0
201	On the search for potential anti-Trypanosoma cruzi drugs: Synthesis and biological evaluation of 2-hydroxy-3-methylamino and 1,2,3-triazolic naphthoquinoidal compounds obtained by click chemistry reactions. <i>European Journal of Medicinal Chemistry</i> , 2012, 52, 304-312.	5.5	62
202	Phosphonium lipocations as antiparasitic agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 2976-2979.	2.2	27
203	The United States <i>Trypanosoma cruzi</i> Infection Study: evidence for vector��borne transmission of the parasite that causes Chagas disease among United States blood donors. <i>Transfusion</i> , 2012, 52, 1922-1930.	1.6	145
204	Novel Cruzain Inhibitors for the Treatment of Chagas�� Disease. <i>Chemical Biology and Drug Design</i> , 2012, 80, 398-405.	3.2	33

#	ARTICLE	IF	CITATIONS
205	Phylogenetic evidence based on <i>Trypanosoma cruzi</i> nuclear gene sequences and information entropy suggest that inter-strain intragenic recombination is a basic mechanism underlying the allele diversity of hybrid strains. <i>Infection, Genetics and Evolution</i> , 2012, 12, 1064-1071.	2.3	19
206	Role of trypanosomatid's arginase in polyamine biosynthesis and pathogenesis. <i>Molecular and Biochemical Parasitology</i> , 2012, 181, 85-93.	1.1	49
207	Matrix metalloproteinases as therapeutic targets in protozoan parasitic infections. , 2012, 133, 257-279.		98
208	Functional genomics of trypanosomatids. <i>Parasite Immunology</i> , 2012, 34, 72-79.	1.5	22
209	Metabolic, mental health, behavioural and socioeconomic characteristics of migrants with Chagas disease in a non-endemic country. <i>Tropical Medicine and International Health</i> , 2012, 17, 595-603.	2.3	30
210	Antiparasitical chemotherapy in Chagas' disease cardiomyopathy: current evidence. <i>Tropical Medicine and International Health</i> , 2012, 17, 1057-1065.	2.3	27
211	<i>Trypanosoma cruzi</i> infection: a review with emphasis on cutaneous manifestations. <i>International Journal of Dermatology</i> , 2012, 51, 501-508.	1.0	50
212	Skin lesions, malaise, and heart failure in a renal transplant recipient. <i>Transplant Infectious Disease</i> , 2012, 14, 391-397.	1.7	19
213	Mechanisms of <i>Trypanosoma cruzi</i> persistence in Chagas disease. <i>Cellular Microbiology</i> , 2012, 14, 634-643.	2.1	133
214	First Century of Chagas' Disease: An Overview on Novel Approaches to Nifurtimox and Benznidazole Delivery Systems. <i>Journal of Pharmaceutical Sciences</i> , 2012, 101, 888-894.	3.3	67
215	<i>Trypanosoma</i> spp. in Swedish game animals. <i>Parasitology Research</i> , 2012, 110, 135-139.	1.6	10
216	Benznidazole treatment in chronic children infected with <i>Trypanosoma cruzi</i> : Serological and molecular follow-up of patients and identification of Discrete Typing Units. <i>Acta Tropica</i> , 2013, 128, 130-136.	2.0	20
217	Electrophysiological and pharmacological evaluation of the nicotinic cholinergic system in chagasic rats. <i>BMC Pharmacology & Toxicology</i> , 2013, 14, 2.	2.4	9
218	Protection of vascular endothelium by aspirin in a murine model of chronic Chagas' disease. <i>Parasitology Research</i> , 2013, 112, 2731-2739.	1.6	24
219	Antimalarial and Other Antiprotozoal Products from African Medicinal Plants. , 2013, , 661-709.		12
220	Novel quinoxaline 1,4-di-N-oxide derivatives as new potential antichagasic agents. <i>European Journal of Medicinal Chemistry</i> , 2013, 66, 324-334.	5.5	44
221	Inositol 1,4,5-trisphosphate receptor regulates replication, differentiation, infectivity and virulence of the parasitic protist <i>Trypanosoma cruzi</i> . <i>Molecular Microbiology</i> , 2013, 87, 1133-1150.	2.5	60
222	A Patient with Syncope. <i>New England Journal of Medicine</i> , 2013, 369, 966-972.	27.0	7

#	ARTICLE	IF	CITATIONS
223	Natural Product Derived Antiprotozoal Agents: Synthesis, Biological Evaluation, and Structure-Activity Relationships of Novel Chromene and Chromane Derivatives. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 7442-7448.	6.4	48
224	Novel 3-nitro-1H-1,2,4-triazole-based piperazines and 2-amino-1,3-benzothiazoles as antichagasic agents. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 6600-6607.	3.0	37
225	Design and exploratory data analysis of a second generation of dendrimer prodrugs potentially antichagasic and leishmanicide. <i>Molecular Diversity</i> , 2013, 17, 711-720.	3.9	13
226	Chronic use of Amiodarone aGAISt Implantable cardioverter-defibrillator therapy for primary prevention of death in patients with Chagas cardiomyopathy Study: Rationale and design of a randomized clinical trial. <i>American Heart Journal</i> , 2013, 166, 976-982.e4.	2.7	31
227	Effects of benznidazole:cyclodextrin complexes on the drug bioavailability upon oral administration to rats. <i>International Journal of Biological Macromolecules</i> , 2013, 62, 543-548.	7.5	50
228	A Brucella Virulence Factor Targets Macrophages to Trigger B-cell Proliferation. <i>Journal of Biological Chemistry</i> , 2013, 288, 20208-20216.	3.4	16
229	The Assassin: Chagas Cardiomyopathy. <i>American Journal of Medicine</i> , 2013, 126, 864-867.	1.5	2
230	Design or screening of drugs for the treatment of Chagas disease: what shows the most promise?. <i>Expert Opinion on Drug Discovery</i> , 2013, 8, 1479-1489.	5.0	25
232	Trypanocidal Activity of Marine Natural Products. <i>Marine Drugs</i> , 2013, 11, 4058-4082.	4.6	40
233	Heart Transplantation for Chagas Cardiomyopathy in the United States. <i>American Journal of Transplantation</i> , 2013, 13, 3262-3268.	4.7	55
234	aCSM: noise-free graph-based signatures to large-scale receptor-based ligand prediction. <i>Bioinformatics</i> , 2013, 29, 855-861.	4.1	52
235	Synthesis of quinoidal molecules: Strategies towards bioactive compounds with an emphasis on lapachones. <i>European Journal of Medicinal Chemistry</i> , 2013, 69, 678-700.	5.5	96
236	A pharmacophore-based virtual screening approach for the discovery of <i>Trypanosoma cruzi</i> GAPDH inhibitors. <i>Future Medicinal Chemistry</i> , 2013, 5, 2019-2035.	2.3	21
237	<i>Trypanosoma cruzi</i> mitochondrial swelling and membrane potential collapse as primary evidence of the mode of action of naphthoquinone analogues. <i>BMC Microbiology</i> , 2013, 13, 196.	3.3	45
238	Identification of Bloodmeal Sources and <i>Trypanosoma cruzi</i> Infection in Triatomine Bugs (Hemiptera: Reduviidae) From Residential Settings in Texas, the United States. <i>Journal of Medical Entomology</i> , 2013, 50, 1126-1139.	1.8	82
239	5-Nitro-2-furfuriliden derivatives as potential anti- <i>Trypanosoma cruzi</i> agents: Design, synthesis, bioactivity evaluation, cytotoxicity and exploratory data analysis. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 5395-5406.	3.0	21
240	Chagas' cardiomyopathy: The economic burden of an expensive and neglected disease. <i>International Journal of Cardiology</i> , 2013, 168, 2375-2380.	1.7	49
241	Rational Development of 4-Aminopyridyl-Based Inhibitors Targeting <i>Trypanosoma cruzi</i> CYP51 as Anti-Chagas Agents. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 7651-7668.	6.4	43

#	ARTICLE	IF	CITATIONS
242	Nanotechnological Strategies for the Treatment of Neglected Diseases. <i>Current Pharmaceutical Design</i> , 2013, 19, 7316-7329.	1.9	30
243	Osteopontin-dependent regulation of Th1 and Th17 cytokine responses in <i>Trypanosoma cruzi</i> -infected C57BL/6 mice. <i>Cytokine</i> , 2013, 61, 491-498.	3.2	19
244	Proteomic Analysis of <i>Trypanosoma cruzi</i> Secretome: Characterization of Two Populations of Extracellular Vesicles and Soluble Proteins. <i>Journal of Proteome Research</i> , 2013, 12, 883-897.	3.7	235
245	Evaluation of the in vivo therapeutic properties of (α)-cubebin and (α)-hinokinin against <i>Trypanosoma cruzi</i> . <i>Experimental Parasitology</i> , 2013, 133, 442-446.	1.2	22
246	Parasitic disease vaccines. , 2013, , 1154-1160.		1
247	<i>Trypanosoma cruzi</i> Antioxidant Enzymes As Virulence Factors in Chagas Disease. <i>Antioxidants and Redox Signaling</i> , 2013, 19, 723-734.	5.4	97
248	Results of lookback for Chagas disease since the inception of donor screening at New York Blood Center. <i>Transfusion</i> , 2013, 53, 1083-1087.	1.6	33
249	Antibody levels correlate with detection of <i>Trypanosoma cruzi</i> DNA by sensitive polymerase chain reaction assays in seropositive blood donors and possible resolution of infection over time. <i>Transfusion</i> , 2013, 53, 1257-1265.	1.6	40
250	Risk Factors and Primary Prevention of Congenital Chagas Disease in a Nonendemic Country. <i>Clinical Infectious Diseases</i> , 2013, 56, 496-502.	5.8	82
251	Congenital and oral transmission of American trypanosomiasis: an overview of physiopathogenic aspects. <i>Parasitology</i> , 2013, 140, 147-159.	1.5	55
253	Trypanocidal activity of 1,3,7-trihydroxy-2-(3-methylbut-2-enyl)-xanthone isolated from <i>Kielmeyera coriacea</i> . <i>Parasitology International</i> , 2013, 62, 405-411.	1.3	9
255	The toxicity of nitrofurantoin compounds on melanoma and neuroblastoma cells is enhanced by Olaparib and ameliorated by melanin pigment. <i>DNA Repair</i> , 2013, 12, 1000-1006.	2.8	15
257	Preventive and therapeutic DNA vaccination partially protect dogs against an infectious challenge with <i>Trypanosoma cruzi</i> . <i>Vaccine</i> , 2013, 31, 2246-2252.	3.8	39
258	Cyclic Voltammetric Study of Some Anti-Chagas-Active 1,4-Dioxidoquinoxalin-2-yl Ketone Derivatives. <i>Helvetica Chimica Acta</i> , 2013, 96, 217-227.	1.6	9
259	Antiprotozoal activity of <i>Khaya anthotheca</i> , (Welv.) C.D.C. a plant used by chimpanzees for self-medication. <i>Journal of Ethnopharmacology</i> , 2013, 147, 220-223.	4.1	28
260	<i>Trypanosoma cruzi</i> infection induces morphological reorganization of the myocardium parenchyma and stroma, and modifies the mechanical properties of atrial and ventricular cardiomyocytes in rats. <i>Cardiovascular Pathology</i> , 2013, 22, 270-279.	1.6	45
261	Childhood Parasitic Infections Endemic to the United States. <i>Pediatric Clinics of North America</i> , 2013, 60, 471-485.	1.8	65
265	<i>Trypanosoma cruzi</i> hijacks TrkC to enter cardiomyocytes and cardiac fibroblasts while exploiting TrkA for cardioprotection against oxidative stress. <i>Cellular Microbiology</i> , 2013, 15, 1357-1366.	2.1	11

#	ARTICLE	IF	CITATIONS
266	Association Between the Lymphotoxin-Alpha Gene Polymorphism and Chagasic Cardiopathy. <i>Journal of Interferon and Cytokine Research</i> , 2013, 33, 130-135.	1.2	12
267	Oral transmission of Chagas disease: Typing of <i>Trypanosoma cruzi</i> from five outbreaks occurred in Venezuela shows multiclonal and common infections in patients, vectors and reservoirs. <i>Infection, Genetics and Evolution</i> , 2013, 17, 113-122.	2.3	38
268	Probing the biophysical interplay between a viral genome and its capsid. <i>Nature Chemistry</i> , 2013, 5, 502-509.	13.6	117
269	<i>Trypanosoma cruzi</i> Response to Sterol Biosynthesis Inhibitors: Morphophysiological Alterations Leading to Cell Death. <i>PLoS ONE</i> , 2013, 8, e55497.	2.5	70
270	Chagas disease (American trypanosomiasis) in Mexico: An update. <i>Acta Tropica</i> , 2013, 127, 126-135.	2.0	81
271	Dynamical behavior of an epidemic model for a vector-borne disease with direct transmission. <i>Chaos, Solitons and Fractals</i> , 2013, 46, 54-64.	5.1	6
272	The role of nanogold in human tropical diseases: research, detection and therapy. <i>Gold Bulletin</i> , 2013, 46, 65-79.	2.4	4
273	Innovation for the "Bottom 100 Million": Eliminating Neglected Tropical Diseases in the Americas. <i>Advances in Experimental Medicine and Biology</i> , 2013, 764, 1-12.	1.6	45
274	Oxidative Stress and DNA Lesions: The Role of 8-Oxoguanine Lesions in <i>Trypanosoma cruzi</i> Cell Viability. <i>PLoS Neglected Tropical Diseases</i> , 2013, 7, e2279.	3.0	71
275	Chagas Disease. <i>Journal of the American College of Cardiology</i> , 2013, 62, 767-776.	2.8	329
276	A new series of heteroleptic oxidovanadium(IV) compounds with phenanthroline-derived co-ligands: selective <i>Trypanosoma cruzi</i> growth inhibitors. <i>Dalton Transactions</i> , 2013, 42, 11900.	3.3	56
277	Serological and parasitological response in chronic Chagas patients 3 years after nifurtimox treatment. <i>BMC Infectious Diseases</i> , 2013, 13, 85.	2.9	30
278	Bradyarrhythmias and Pacemaker Therapy in Dogs with Chagas Disease. <i>Journal of Veterinary Internal Medicine</i> , 2013, 27, 890-894.	1.6	18
279	American Trypanosomiasis (Chagas disease). , 2013, , 725-738.		3
280	Ecohealth Interventions Limit Triatomine Reinfestation following Insecticide Spraying in La Brea, Guatemala. <i>American Journal of Tropical Medicine and Hygiene</i> , 2013, 88, 630-637.	1.4	44
281	Myocarditis/Inflammatory Cardiomyopathy. , 2013, , 133-146.		0
282	Fine-scale genetic structure in populations of the Chagas disease vector <i>Triatoma infestans</i> (Hemiptera, Reduviidae). <i>Genetica</i> , 2013, 141, 107-117.	1.1	25
283	Towards the establishment of a consensus real-time qPCR to monitor <i>Trypanosoma cruzi</i> parasitemia in patients with chronic Chagas disease cardiomyopathy: A substudy from the BENEFIT trial. <i>Acta Tropica</i> , 2013, 125, 23-31.	2.0	131

#	ARTICLE	IF	CITATIONS
284	Identification by Q-PCR of <i>Trypanosoma cruzi</i> lineage and determination of blood meal sources in triatomine gut samples in México. <i>Parasitology International</i> , 2013, 62, 36-43.	1.3	36
285	Effects of omega-3 polyunsaturated fatty acid supplementation in patients with chronic chagasic cardiomyopathy: study protocol for a randomized controlled trial. <i>Trials</i> , 2013, 14, 379.	1.6	10
286	In Vitro and in Vivo Antileishmanial and Trypanocidal Studies of New <i>N</i> -Benzene- and <i>N</i> -Naphthalenesulfonamide Derivatives. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 8984-8998.	6.4	38
287	Molecular Epidemiologic Source Tracking of Orally Transmitted Chagas Disease, Venezuela. <i>Emerging Infectious Diseases</i> , 2013, 19, 1098-1101.	4.3	33
288	Benznidazole Treatment of Chagasic Encephalitis in Pregnant Woman with AIDS. <i>Emerging Infectious Diseases</i> , 2013, 19, 1490-1492.	4.3	23
289	Innate Immune Responses and Antioxidant/Oxidant Imbalance Are Major Determinants of Human Chagas Disease. <i>PLoS Neglected Tropical Diseases</i> , 2013, 7, e2364.	3.0	29
290	<i>Trypanosoma cruzi</i> : Entry into Mammalian Host Cells and Parasitophorous Vacuole Formation. <i>Frontiers in Immunology</i> , 2013, 4, 186.	4.8	77
291	In Vitro Antiparasitic Activity and Chemical Composition of the Essential Oil Obtained from the Fruits of <i>Piper cubeba</i> . <i>Planta Medica</i> , 2013, 79, 1653-1655.	1.3	33
292	Prevalence of <i>Trypanosoma cruzi</i> Infection among People Aged 15 to 89 Years Inhabiting the Department of Casanare (Colombia). <i>PLoS Neglected Tropical Diseases</i> , 2013, 7, e2113.	3.0	16
293	Fertility, Gestation Outcome and Parasite Congenital Transmissibility in Mice Infected with TcI, TcII and TcVI Genotypes of <i>Trypanosoma cruzi</i> . <i>PLoS Neglected Tropical Diseases</i> , 2013, 7, e2271.	3.0	25
294	Epidemiology of and Impact of Insecticide Spraying on Chagas Disease in Communities in the Bolivian Chaco. <i>PLoS Neglected Tropical Diseases</i> , 2013, 7, e2358.	3.0	84
295	Mode of Death on Chagas Heart Disease: Comparison with Other Etiologies. A Subanalysis of the REMADHE Prospective Trial. <i>PLoS Neglected Tropical Diseases</i> , 2013, 7, e2176.	3.0	47
296	Atypical Human Infections by Animal Trypanosomes. <i>PLoS Neglected Tropical Diseases</i> , 2013, 7, e2256.	3.0	134
297	Barriers to Treatment Access for Chagas Disease in Mexico. <i>PLoS Neglected Tropical Diseases</i> , 2013, 7, e2488.	3.0	81
298	Monocytes Play an IL-12-Dependent Crucial Role in Driving Cord Blood NK Cells to Produce IFN- γ in Response to <i>Trypanosoma cruzi</i> . <i>PLoS Neglected Tropical Diseases</i> , 2013, 7, e2291.	3.0	15
299	Chagas Disease in Latin American Immigrants With Dilated Cardiomyopathy in New York City. <i>Clinical Infectious Diseases</i> , 2013, 57, e7-e7.	5.8	51
300	Current epidemiological profile of Chagasic megaesophagus in Central Brazil. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2013, 46, 316-321.	0.9	23
301	Infection With <i>Trypanosoma cruzi</i> and Progression to Cardiomyopathy. <i>Circulation</i> , 2013, 127, 1095-1097.	1.6	11

#	ARTICLE	IF	CITATIONS
302	Ten-Year Incidence of Chagas Cardiomyopathy Among Asymptomatic <i>Trypanosoma cruzi</i> Seropositive Former Blood Donors. <i>Circulation</i> , 2013, 127, 1105-1115.	1.6	145
303	Letter by Rassi and Rassi Regarding Article, "Ten-Year Incidence of Chagas Cardiomyopathy Among Asymptomatic, <i>Trypanosoma cruzi</i> Seropositive Former Blood Donors". <i>Circulation</i> , 2013, 128, e135.	1.6	1
304	Modulation of Biotransformation Systems and ABC Transporters by Benznidazole in Rats. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4894-4902.	3.2	20
305	Chronic Chagas disease: from basics to laboratory medicine. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 271-294.	2.3	27
306	Structure of the <i>Triatoma virus</i> capsid. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2013, 69, 1026-1037.	2.5	36
307	Response to Letters Regarding Article, "Ten-Year Incidence of Chagas Cardiomyopathy Among Asymptomatic, <i>Trypanosoma cruzi</i> Seropositive Former Blood Donors". <i>Circulation</i> , 2013, 128, e137-8.	1.6	1
308	Role of Gap Junctions and Hemichannels in Parasitic Infections. <i>BioMed Research International</i> , 2013, 2013, 1-17.	1.9	11
310	MnSOD Mice Control Myocardial Inflammatory and Oxidative Stress and Remodeling Responses Elicited in Chronic Chagas Disease. <i>Journal of the American Heart Association</i> , 2013, 2, e000302.	3.7	28
311	Predictive value of transforming growth factor- β 1 in Chagas disease: towards a biomarker surrogate of clinical outcome. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2013, 107, 518-525.	1.8	22
312	Novel 3-nitro-1H-1,2,4-triazole-based compounds as potential anti-Chagasic drugs: <i>in vivo</i> studies. <i>Future Medicinal Chemistry</i> , 2013, 5, 1763-1776.	2.3	32
313	Evaluating Chagas disease progression and cure through blood-derived biomarkers: a systematic review. <i>Expert Review of Anti-Infective Therapy</i> , 2013, 11, 957-976.	4.4	46
314	Dried Blood as an Alternative to Plasma or Serum for <i>Trypanosoma cruzi</i> IgG Detection in Screening Programs. <i>Vaccine Journal</i> , 2013, 20, 1197-1202.	3.1	17
315	The Absence of Myocardial Calcium-Independent Phospholipase A ₂ Results in Impaired Prostaglandin E ₂ Production and Decreased Survival in Mice with Acute <i>Trypanosoma cruzi</i> Infection. <i>Infection and Immunity</i> , 2013, 81, 2278-2287.	2.2	14
316	Challenges and perspectives of Chagas disease: a review. <i>Journal of Venomous Animals and Toxins Including Tropical Diseases</i> , 2013, 19, 34.	1.4	51
317	Utility of the NavX® Electroanatomic Mapping System for Permanent Pacemaker Implantation in a Pregnant Patient with Chagas Disease. <i>Indian Pacing and Electrophysiology Journal</i> , 2013, 13, 34-37.	0.6	14
318	Article Synthesis and Trypanocidal Activity of Novel 2,4,5-Triaryl-N-Hydroxylimidazole Derivatives. <i>Molecules</i> , 2013, 18, 3445-3457.	3.8	21
319	SEROPREVALENCE OF CHAGASIC INFECTION IN YOUNG INDIVIDUALS IN A BLOOD CENTER IN THE STATE OF SAO PAULO, BRAZIL. <i>Revista Do Instituto De Medicina Tropical De Sao Paulo</i> , 2013, 55, 245-250.	1.1	4
320	Seroepidemiological Study of Chagas Disease in the Southern Amazon Region of Ecuador. <i>Tropical Medicine and Health</i> , 2013, 41, 21-25.	2.8	10

#	ARTICLE	IF	CITATIONS
321	Características do estudo eletrofisiológico na Doença de Chagas. Einstein (Sao Paulo, Brazil), 2013, 11, 291-295.	0.7	8
322	Evaluation of CD4+CD25+ T lymphocyte response time kinetics in patients with chronic Chagas disease after in vitro stimulation with recombinant Trypanosoma cruzi antigens. Revista Da Sociedade Brasileira De Medicina Tropical, 2013, 46, 362-366.	0.9	2
323	Evaluation of natural foci of Panstrongylus megistus in a forest fragment in Porto Alegre, State of Rio Grande do Sul, Brazil. Revista Da Sociedade Brasileira De Medicina Tropical, 2013, 46, 575-583.	0.9	10
324	Utility of a novel risk score for prediction of ventricular tachycardia and cardiac death in chronic Chagas disease - the SEARCH-RIO study. Brazilian Journal of Medical and Biological Research, 2013, 46, 974-984.	1.5	15
325	Targeting UDP-Galactopyranose Mutases from Eukaryotic Human Pathogens. Current Pharmaceutical Design, 2013, 19, 2561-2573.	1.9	19
326	Certifying the interruption of Chagas disease transmission by native vectors: cui bono?. Memorias Do Instituto Oswaldo Cruz, 2013, 108, 251-254.	1.6	84
327	A Parent-of-Origin Effect Determines the Susceptibility of a Non-Informative F1 Population to Trypanosoma cruzi Infection In Vivo. PLoS ONE, 2013, 8, e56347.	2.5	10
328	Trypanosoma cruzi Coaxes Cardiac Fibroblasts into Preventing Cardiomyocyte Death by Activating Nerve Growth Factor Receptor TrkA. PLoS ONE, 2013, 8, e57450.	2.5	16
329	Detection of Soluble Antigen and DNA of Trypanosoma cruzi in Urine Is Independent of Renal Injury in the Guinea Pig Model. PLoS ONE, 2013, 8, e58480.	2.5	15
330	Discovery of Trypanosomatid Parasites in Globally Distributed Drosophila Species. PLoS ONE, 2013, 8, e61937.	2.5	17
331	Plasmid Vectors and Molecular Building Blocks for the Development of Genetic Manipulation Tools for Trypanosoma cruzi. PLoS ONE, 2013, 8, e80217.	2.5	13
332	Putative Panmixia in Restricted Populations of Trypanosoma cruzi Isolated from Wild Triatoma infestans in Bolivia. PLoS ONE, 2013, 8, e82269.	2.5	15
333	Pathogenesis of Chronic Chagasic Myocarditis. , 0, , .		1
334	Molecular Diagnosis of Vector-Borne Parasitic Diseases. Air & Water Borne Diseases, 2013, 02, .	0.3	4
335	Identification of a Novel Nucleocytoplasmic Shuttling RNA Helicase of Trypanosomes. PLoS ONE, 2014, 9, e109521.	2.5	15
336	Trypanosomatid Aquaporins: Roles in Physiology and Drug Response. Diseases (Basel, Switzerland), 2014, 2, 3-23.	2.5	9
337	Additional Evidence of the Trypanocidal Action of (â~)-Elatol on Amastigote Forms through the Involvement of Reactive Oxygen Species. Marine Drugs, 2014, 12, 4973-4983.	4.6	10
338	Optical Absorption of the Antitrypanocidal Drug Benznidazole in Water. Molecules, 2014, 19, 4145-4156.	3.8	10

#	ARTICLE	IF	CITATIONS
339	Interruption of vector transmission by native vectors and the art of the possible. Memorias Do Instituto Oswaldo Cruz, 2014, 109, 122-130.	1.6	34
340	Geographical distribution of Trypanosoma cruzi in triatomine vectors in the State of Mato Grosso do Sul, Brazil. Revista Da Sociedade Brasileira De Medicina Tropical, 2014, 47, 747-755.	0.9	13
341	Synthesis of divalent ligands of Î²-thio- and Î²-galactopyranosides and related lactosides and their evaluation as substrates and inhibitors of Trypanosoma cruzi trans-sialidase. Beilstein Journal of Organic Chemistry, 2014, 10, 3073-3086.	2.2	15
342	Current situation and perspectives regarding human Chagas disease in midwestern of the state of Minas Gerais, Brazil. Memorias Do Instituto Oswaldo Cruz, 2014, 109, 374-378.	1.6	11
343	Diagnostic reliability of an immunochromatographic test for Chagas disease screening at a primary health care centre in a rural endemic area. Memorias Do Instituto Oswaldo Cruz, 2014, 109, 984-988.	1.6	11
344	Metallothionein-1 and nitric oxide expression are inversely correlated in a murine model of Chagas disease. Memorias Do Instituto Oswaldo Cruz, 2014, 109, 174-181.	1.6	3
345	Epicardial Ablation for Ventricular Tachycardia in Chronic Chagas Heart Disease. Arquivos Brasileiros De Cardiologia, 2014, 102, 524-8.	0.8	20
346	Infectious Diseases and Immune Deficiencies. , 2014, , 83-105.		1
347	Trypanosomatids topoisomerase re-visited. New structural findings and role in drug discovery. International Journal for Parasitology: Drugs and Drug Resistance, 2014, 4, 326-337.	3.4	39
348	American Trypanosomiasis. , 2014, , 622-630.e1.		1
349	Chagas Disease Awareness Among Latin American Immigrants Living in Los Angeles, California. American Journal of Tropical Medicine and Hygiene, 2014, 91, 915-919.	1.4	37
350	Immunization with Hexon Modified Adenoviral Vectors Integrated with gp83 Epitope Provides Protection against Trypanosoma cruzi Infection. PLoS Neglected Tropical Diseases, 2014, 8, e3089.	3.0	18
351	A Genome-Wide Analysis of Genetic Diversity in Trypanosoma cruzi Intergenic Regions. PLoS Neglected Tropical Diseases, 2014, 8, e2839.	3.0	8
352	Opportunity Cost for Early Treatment of Chagas Disease in Mexico. PLoS Neglected Tropical Diseases, 2014, 8, e2776.	3.0	36
353	Hyperendemic Chagas Disease and the Unmet Need for Pacemakers in the Bolivian Chaco. PLoS Neglected Tropical Diseases, 2014, 8, e2801.	3.0	12
354	Tumor Necrosis Factor Is a Therapeutic Target for Immunological Unbalance and Cardiac Abnormalities in Chronic Experimental Chagas™ Heart Disease. Mediators of Inflammation, 2014, 2014, 1-16.	3.0	65
355	Benznidazole Biotransformation and Multiple Targets in Trypanosoma cruzi Revealed by Metabolomics. PLoS Neglected Tropical Diseases, 2014, 8, e2844.	3.0	90
356	Computational Studies on Sirtuins from Trypanosoma cruzi: Structures, Conformations and Interactions with Phytochemicals. PLoS Neglected Tropical Diseases, 2014, 8, e2689.	3.0	24

#	ARTICLE	IF	CITATIONS
357	The Double-Edged Sword in Pathogenic Trypanosomatids: The Pivotal Role of Mitochondria in Oxidative Stress and Bioenergetics. <i>BioMed Research International</i> , 2014, 2014, 1-14.	1.9	94
358	Health Policies to Control Chagas Disease Transmission in European Countries. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e3245.	3.0	86
359	High Throughput Screening for Anti- <i>Trypanosoma cruzi</i> Drug Discovery. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e3259.	3.0	32
360	Phylogeny and Niche Conservatism in North and Central American Triatomine Bugs (Hemiptera: Tj ETQq1 1 0.784314 rgBT /Overlock 50	3.0	50
361	Biomarkers in <i>Trypanosoma cruzi</i> -Infected and Uninfected Individuals with Varying Severity of Cardiomyopathy in Santa Cruz, Bolivia. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e3227.	3.0	31
362	Hunting, Swimming, and Worshipping: Human Cultural Practices Illuminate the Blood Meal Sources of Cave Dwelling Chagas Vectors (<i>Triatoma dimidiata</i>) in Guatemala and Belize. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e3047.	3.0	20
363	Use of a Novel Chagas Urine Nanoparticle Test (Chunap) for Diagnosis of Congenital Chagas Disease. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e3211.	3.0	38
364	Chagas Disease Vector Control in a Hyperendemic Setting: The First 11 Years of Intervention in Cochabamba, Bolivia. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e2782.	3.0	22
365	Cytokine Production but Lack of Proliferation in Peripheral Blood Mononuclear Cells from Chronic Chagas' Disease Cardiomyopathy Patients in Response to <i>T. cruzi</i> Ribosomal P Proteins. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e2906.	3.0	31
366	Memantine, an Antagonist of the NMDA Glutamate Receptor, Affects Cell Proliferation, Differentiation and the Intracellular Cycle and Induces Apoptosis in <i>Trypanosoma cruzi</i> . <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e2717.	3.0	20
367	Presence of Antigen-Experienced T Cells with Low Grade of Differentiation and Proliferative Potential in Chronic Chagas Disease Myocarditis. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e2989.	3.0	31
368	Global Metabolomic Profiling of Acute Myocarditis Caused by <i>Trypanosoma cruzi</i> Infection. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e3337.	3.0	62
369	Biochemical and genetic characterization of <i>Trypanosoma cruzi</i> N-myristoyltransferase. <i>Biochemical Journal</i> , 2014, 459, 323-332.	3.7	28
370	An Integrated Lab-on-Chip for Rapid Identification and Simultaneous Differentiation of Tropical Pathogens. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e3043.	3.0	33
371	Ruthenium Complex with Benzimidazole and Nitric Oxide as a New Candidate for the Treatment of Chagas Disease. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e3207.	3.0	26
372	Analysis of Children's Perception of Triatomine Vectors of Chagas Disease through Drawings: Opportunities for Targeted Health Education. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e3217.	3.0	16
373	Immunopathological Aspects of Experimental <i>Trypanosoma cruzi</i> Reinfections. <i>BioMed Research International</i> , 2014, 2014, 1-9.	1.9	11
374	Repellence Produced by Monoterpenes on <i>Rhodnius prolixus</i> (Hemiptera: Reduviidae) Decreases After Continuous Exposure to These Compounds. <i>Journal of Insect Science</i> , 2014, 14, .	1.5	8

#	ARTICLE	IF	CITATIONS
375	Characterization of Guinea Pig Antibody Responses to Salivary Proteins of <i>Triatoma infestans</i> for the Development of a Triatomine Exposure Marker. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e2783.	3.0	8
376	Implantable cardioverter-defibrillators for treatment of sustained ventricular arrhythmias in patients with Chagas' heart disease: comparison with a control group treated with amiodarone alone. <i>Europace</i> , 2014, 16, 674-680.	1.7	50
377	The need for global collaboration to tackle hidden public health crisis of Chagas disease. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 393-395.	4.4	14
378	Alternative Sites for Right Ventricular Pacing in Chagas Disease: A Comparative Study of the Midâ€Septum and Inflow Tract. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2014, 37, 1166-1173.	1.2	6
379	Unveiling Benznidazole's mechanism of action through overexpression of DNA repair proteins in <i>Trypanosoma cruzi</i> . <i>Environmental and Molecular Mutagenesis</i> , 2014, 55, 309-321.	2.2	70
380	Quality of life determinants in a population of pacemaker patients with a high prevalence of Chagas disease. <i>International Journal of Cardiology</i> , 2014, 177, 1137-1139.	1.7	5
381	Chagas Cardiomyopathy is Associated With Higher Incidence of Stroke: A Meta-analysis of Observational Studies. <i>Journal of Cardiac Failure</i> , 2014, 20, 931-938.	1.7	39
382	Donors deferred for self-reported Chagas disease history: does it reduce risk?. <i>Transfusion</i> , 2014, 54, 2092-2097.	1.6	13
383	Impaired Coronary Flow Reserve in Patients with Indeterminate Form of Chagasâ€™ Disease. <i>Echocardiography</i> , 2014, 31, 67-73.	0.9	18
384	Systematic review: Prevalence of Chagas disease in pregnant women and congenital transmission of <i>Trypanosoma cruzi</i> in Brazil: a systematic review and meta-analysis. <i>Tropical Medicine and International Health</i> , 2014, 19, 943-957.	2.3	37
385	Binding Mode and Potency of <i>N</i> -Indolylloxopyridinyl-4-aminopropanyl-Based Inhibitors Targeting <i>Trypanosoma cruzi</i> CYP51. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 10162-10175.	6.4	22
386	<i>Trypanosoma cruzi</i> infection in a non-endemic country: epidemiological and clinical profile. <i>Clinical Microbiology and Infection</i> , 2014, 20, 706-712.	6.0	55
387	Respiratory Muscle Strength, the Six-Minute Walk Test and Quality of Life in Chagas Cardiomyopathy. <i>Physiotherapy Research International</i> , 2014, 19, 8-15.	1.5	18
388	Effect of the Metal Ion on the anti <i>T. cruzi</i> Activity and Mechanism of Action of 5â€Nitrofurylâ€Containing Thiosemicarbazone Metal Complexes. <i>European Journal of Inorganic Chemistry</i> , 2014, 2014, 4677-4689.	2.0	26
389	Shelter Dogs as Sentinels for <i>Trypanosoma cruzi</i> Transmission across Texas. <i>Emerging Infectious Diseases</i> , 2014, 20, 1323-1326.	4.3	84
390	Clinical Reasoning: A 32-year-old woman with right-sided numbness and word-finding difficulties. <i>Neurology</i> , 2014, 83, e98-102.	1.1	0
391	<i>Trypanosoma cruzi</i> parasites fight for control of the JAK-STAT pathway by disarming their host. <i>Jak-stat</i> , 2014, 3, e1012964.	2.2	10
392	Increase in the Expression of CD4 + CD25+ Lymphocytic T Cells in the Indeterminate Clinical Form of Human Chagas Disease After Stimulation With Recombinant Antigens of <i>Trypanosoma cruzi</i> . <i>Journal of Clinical Immunology</i> , 2014, 34, 991-998.	3.8	4

#	ARTICLE	IF	CITATIONS
393	Panstrongylus geniculatus and four other species of triatomine bug involved in the Trypanosoma cruzi enzootic cycle: high risk factors for Chagas's™ disease transmission in the Metropolitan District of Caracas, Venezuela. Parasites and Vectors, 2014, 7, 602.	2.5	35
394	Management of Trypanosoma cruzi coinfection in HIV-positive individuals outside endemic areas. Current Opinion in Infectious Diseases, 2014, 27, 9-15.	3.1	21
395	Pediatric Chagas Disease in Europe. Pediatric Infectious Disease Journal, 2014, 33, 458-462.	2.0	19
396	An approach to the management of <i>Trypanosoma cruzi</i> infection (Chagas's™ disease) in immunocompromised patients. Expert Review of Anti-Infective Therapy, 2014, 12, 357-373.	4.4	16
397	Epidemiological Aspects of Chagas Disease - a Review. Journal of Ancient Diseases & Preventive Remedies, 2014, 02, .	0.2	4
398	Chagas disease in solid organ and heart transplantation. Current Opinion in Infectious Diseases, 2014, 27, 418-424.	3.1	58
399	Haeme oxygenase activity protects the host against excessive cardiac inflammation during experimental Trypanosoma cruzi infection. Microbes and Infection, 2014, 16, 28-39.	1.9	11
400	cDNA isolation and characterization of two vitellogenin genes in the Chagas' disease vector Triatoma infestans (Hemiptera, Reduviidae). Gene, 2014, 543, 118-124.	2.2	9
401	Seizures and ST-segment Elevation: Chagas Disease. American Journal of Medicine, 2014, 127, 714-716.	1.5	0
402	Conformational restriction of aryl thiosemicarbazones produces potent and selective anti- <i>Trypanosoma cruzi</i> compounds which induce apoptotic parasite death. European Journal of Medicinal Chemistry, 2014, 75, 467-478.	5.5	46
403	Structural Design, Synthesis and Structure-Activity Relationships of Thiazolidinones with Enhanced Anti- <i>Trypanosoma cruzi</i> Activity. ChemMedChem, 2014, 9, 177-188.	3.2	39
404	<i>Trypanosoma cruzi</i> chemical proteomics using immobilized benznidazole. Experimental Parasitology, 2014, 140, 33-38.	1.2	14
405	Multicomponent synthesis of 4,4-dimethyl sterol analogues and their effect on eukaryotic cells. Steroids, 2014, 84, 1-6.	1.8	7
406	Evidence based palaeopathology: Meta-analysis of Pubmed®-listed scientific studies on pre-Columbian, South American mummies. HOMO- Journal of Comparative Human Biology, 2014, 65, 214-231.	0.7	7
407	The Eyelid Sign: A Clue to Bed Bug Bites. Pediatric Dermatology, 2014, 31, 353-355.	0.9	16
408	Chagas disease in Australia and New Zealand: risks and needs for public health interventions. Tropical Medicine and International Health, 2014, 19, 212-218.	2.3	69
409	Regulatory effects of IL-18 on cytokine profiles and development of myocarditis during <i>Trypanosoma cruzi</i> infection. Microbes and Infection, 2014, 16, 481-490.	1.9	27
410	Randomized Trial of Posaconazole and Benznidazole for Chronic Chagas' Disease. New England Journal of Medicine, 2014, 370, 1899-1908.	27.0	499

#	ARTICLE	IF	CITATIONS
411	Role of Autoimmunity in Heart Disease: Is Chagas Heart Disease the Definitive Proof?. Canadian Journal of Cardiology, 2014, 30, 267-269.	1.7	2
412	Correlation between Presence of Trypanosoma cruzi DNA in Heart Tissue of Baboons and Cynomolgus Monkeys, and Lymphocytic Myocarditis. American Journal of Tropical Medicine and Hygiene, 2014, 90, 627-633.	1.4	19
413	Frequency of the congenital transmission of <i>Trypanosoma cruzi</i> : a systematic review and meta-analysis. BJOG: an International Journal of Obstetrics and Gynaecology, 2014, 121, 22-33.	2.3	195
414	Epidemiology of Chagas disease in Europe: many calculations, little knowledge. Clinical Research in Cardiology, 2014, 103, 1-10.	3.3	66
416	Toxic and therapeutic effects of Nifurtimox and Benznidazol on Trypanosoma cruzi ex vivo infection of human placental chorionic villi explants. Acta Tropica, 2014, 132, 112-118.	2.0	27
417	Congenital co-infection with different Trypanosoma cruzi lineages. Parasitology International, 2014, 63, 138-139.	1.3	11
418	Biology of Human Pathogenic Trypanosomatids: Epidemiology, Lifecycle and Ultrastructure. Sub-Cellular Biochemistry, 2014, 74, 1-42.	2.4	87
419	Imidazolium compounds are active against all stages of Trypanosoma cruzi. International Journal of Antimicrobial Agents, 2014, 43, 262-268.	2.5	17
420	Drug Strategies Targeting CYP51 in Neglected Tropical Diseases. Chemical Reviews, 2014, 114, 11242-11271.	47.7	74
421	Cerebral trypanosomiasis in a renal transplant recipient. Transplant Infectious Disease, 2014, 16, 813-817.	1.7	14
422	Flight Behavior and Performance of Rhodnius pallescens (Hemiptera: Reduviidae) on a Tethered Flight Mill. Journal of Medical Entomology, 2014, 51, 1010-1018.	1.8	25
423	Field Evaluation of the InBios Chagas Detect Plus Rapid Test in Serum and Whole-Blood Specimens in Bolivia. Vaccine Journal, 2014, 21, 1645-1649.	3.1	35
424	A vital role for complement in heart disease. Molecular Immunology, 2014, 61, 126-134.	2.2	61
425	Transformation of Personal Computers and Mobile Phones into Genetic Diagnostic Systems. Analytical Chemistry, 2014, 86, 9236-9241.	6.5	28
426	Quantitative Proteomic and Phosphoproteomic Analysis of Trypanosoma cruzi Amastigogenesis. Molecular and Cellular Proteomics, 2014, 13, 3457-3472.	3.8	39
427	4-Aminopyridyl-Based CYP51 Inhibitors as Anti- <i>Trypanosoma cruzi</i> Drug Leads with Improved Pharmacokinetic Profile and in Vivo Potency. Journal of Medicinal Chemistry, 2014, 57, 6989-7005.	6.4	43
428	Optimisation and standardisation of an immunoagglutination assay for the diagnosis of <i>Trypanosoma cruzi</i> infection based on latex-(recombinant antigen) complexes. Tropical Medicine and International Health, 2014, 19, 37-46.	2.3	12
429	Novel nitro(triazole/imidazole)-based heteroarylamides/sulfonamides as potential antitrypanosomal agents. European Journal of Medicinal Chemistry, 2014, 87, 79-88.	5.5	39

#	ARTICLE	IF	CITATIONS
430	Limited antigenic variation in the <i>Trypanosoma cruzi</i> candidate vaccine antigen TSA. <i>Parasite Immunology</i> , 2014, 36, 708-712.	1.5	7
431	Emerging and Reemerging Neglected Tropical Diseases: a Review of Key Characteristics, Risk Factors, and the Policy and Innovation Environment. <i>Clinical Microbiology Reviews</i> , 2014, 27, 949-979.	13.6	150
432	Structural Basis for Rational Design of Inhibitors Targeting <i>Trypanosoma cruzi</i> Sterol 14 α -Demethylase: Two Regions of the Enzyme Molecule Potentiate Its Inhibition. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 6704-6717.	6.4	35
433	Furofuran lignans display schistosomicidal and trypanocidal activities. <i>Phytochemistry</i> , 2014, 107, 119-125.	2.9	8
434	A Clinical Adverse Drug Reaction Prediction Model for Patients with Chagas Disease Treated with Benznidazole. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6371-6377.	3.2	39
435	Kinases as Druggable Targets in Trypanosomatid Protozoan Parasites. <i>Chemical Reviews</i> , 2014, 114, 11280-11304.	47.7	55
436	Sialylation of lactosyl lipids in membrane microdomains by <i>T. cruzi</i> trans-sialidase. <i>Organic and Biomolecular Chemistry</i> , 2014, 12, 9272-9278.	2.8	13
437	Wild <i>Trypanosoma cruzi</i> genetic diversity in Brazil suggests admixture and disturbance in parasite populations from the Atlantic Forest region. <i>Parasites and Vectors</i> , 2014, 7, 263.	2.5	29
438	Neglected Parasitic Infections in the United States: Chagas Disease. <i>American Journal of Tropical Medicine and Hygiene</i> , 2014, 90, 814-818.	1.4	116
439	<i>Trypanosoma cruzi</i> Meningoencephalitis in a Patient with Acquired Immunodeficiency Syndrome. <i>American Journal of Tropical Medicine and Hygiene</i> , 2014, 91, 84-85.	1.4	23
440	Innovations in diagnosis and post-therapeutic monitoring of Chagas disease: Simultaneous flow cytometric detection of IgG1 antibodies anti-live amastigote, anti-live trypomastigote, and anti-fixed epimastigote forms of <i>Trypanosoma cruzi</i> . <i>Journal of Immunological Methods</i> , 2014, 413, 32-44.	1.4	12
441	Serum-Mediated Activation of Macrophages Reflects TcVac2 Vaccine Efficacy against Chagas Disease. <i>Infection and Immunity</i> , 2014, 82, 1382-1389.	2.2	25
442	Antibodies against Mucin-Based Glycopeptides Affect <i>Trypanosoma cruzi</i> Cell Invasion and Tumor Cell Viability. <i>ChemBioChem</i> , 2014, 15, 1495-1507.	2.6	16
443	Parasite-Derived Neurotrophic Factor/trans-Sialidase of <i>Trypanosoma cruzi</i> Links Neurotrophic Signaling to Cardiac Innate Immune Response. <i>Infection and Immunity</i> , 2014, 82, 3687-3696.	2.2	7
444	Antitrypanosomal Activity of Fexinidazole Metabolites, Potential New Drug Candidates for Chagas Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4362-4370.	3.2	57
445	Atomic force microscopy-based bioanalysis for the study of disease. <i>Analytical Methods</i> , 2014, 6, 4932-4955.	2.7	18
446	Bone marrow cells migrate to the heart and skeletal muscle and participate in tissue repair after <i>Trypanosoma cruzi</i> infection in mice. <i>International Journal of Experimental Pathology</i> , 2014, 95, 321-329.	1.3	10
447	Water-Soluble Ruthenium Complexes Bearing Activity Against Protozoan Parasites. <i>Biological Trace Element Research</i> , 2014, 159, 379-392.	3.5	21

#	ARTICLE	IF	CITATIONS
448	Unraveling the Differences of the Hydrolytic Activity of <i>Trypanosoma cruzi</i> Sialidase and <i>Trypanosoma rangeli</i> Sialidase: A Quantum Mechanics Molecular Mechanics Modeling Study. <i>Journal of Physical Chemistry B</i> , 2014, 118, 5807-5816.	2.6	13
449	Rickettsiae, protozoa, and opisthokonta/metazoa. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2014, 121, 1403-1443.	1.8	9
450	Left ventricular apical aneurysm in chronic Chagas cardiomyopathy—A case report. <i>Journal of Cardiology Cases</i> , 2014, 10, 88-90.	0.5	0
451	Advances in Understanding and Treatment of Human African Trypanosomiasis: Divergent Diseases Caused by Distinct Parasites. , 2014, , 901-917.		4
452	Potential new clinical therapies for Chagas disease. <i>Expert Review of Clinical Pharmacology</i> , 2014, 7, 317-325.	3.1	35
453	Determinants of disease phenotype in trypanosomatid parasites. <i>Trends in Parasitology</i> , 2014, 30, 342-349.	3.3	58
454	Smuggling across the Border: How Arthropod-Borne Pathogens Evade and Exploit the Host Defense System of the Skin. <i>Journal of Investigative Dermatology</i> , 2014, 134, 1211-1219.	0.7	39
455	Sesquiterpene Lactone in Nanostructured Parenteral Dosage Form Is Efficacious in Experimental Chagas Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2067-2075.	3.2	52
456	Design, synthesis and biological evaluation of hybrid bioisoster derivatives of N-acylhydrazone and furoxan groups with potential and selective anti- <i>Trypanosoma cruzi</i> activity. <i>European Journal of Medicinal Chemistry</i> , 2014, 82, 418-425.	5.5	45
457	Assessing the vulnerability of Brazilian municipalities to the vectorial transmission of <i>Trypanosoma cruzi</i> using multi-criteria decision analysis. <i>Acta Tropica</i> , 2014, 137, 105-110.	2.0	39
458	Hinokinin, an Emerging Bioactive Lignan. <i>Molecules</i> , 2014, 19, 14862-14878.	3.8	32
459	Severity of chronic experimental Chagas' heart disease parallels tumour necrosis factor and nitric oxide levels in the serum: models of mild and severe disease. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2014, 109, 289-298.	1.6	41
460	Chagas disease in the 21st Century: a public health success or an emerging threat?. <i>Parasite</i> , 2014, 21, 11.	2.0	133
461	Use of Kidneys From <i>Trypanosoma Cruzi</i> Infected Donors in Naive Transplant Recipients Without Prophylactic Therapy. <i>Transplantation</i> , 2014, 97, e3-e4.	1.0	14
462	Belatacept-Based Immunosuppression in a Chagasic Adult Recipient of En Bloc Pediatric Kidneys. <i>Transplantation</i> , 2014, 98, e34-e35.	1.0	3
463	DTU I isolates of <i>Trypanosoma cruzi</i> induce upregulation of Galectin-3 in murine myocarditis and fibrosis. <i>Parasitology</i> , 2014, 141, 849-858.	1.5	23
464	Immune defence mechanisms of triatomines against bacteria, viruses, fungi and parasites. <i>Bulletin of Entomological Research</i> , 2015, 105, 523-532.	1.0	41
465	Diagnostic performance of surface electrocardiogram in early detection of chagasic cardiomyopathy. <i>Medicina Clínica (English Edition)</i> , 2015, 144, 254-256.	0.2	1

#	ARTICLE	IF	CITATIONS
466	Cryptococcosis Presenting as a Colonic Ulcer in a Kidney Transplant Recipient: A Case Report. Transplantation Proceedings, 2015, 47, 2786-2787.	0.6	5
467	Antigen Discovery for the Identification of Vaccine Candidates and Biomarkers Using a T Cell Driven Approach in Combination with Positional Scanning Peptide Libraries. Procedia in Vaccinology, 2015, 9, 91-95.	0.4	5
472	How urbanization affects the epidemiology of emerging infectious diseases. Infection Ecology and Epidemiology, 2015, 5, 27060.	0.8	369
473	Vesicles from different <i>Trypanosoma cruzi</i> strains trigger differential innate and chronic immune responses. Journal of Extracellular Vesicles, 2015, 4, 28734.	12.2	99
474	Myocardial tissue characterization in Chagas' heart disease by cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance, 2015, 17, 97.	3.3	51
475	Chagas disease reactivation in a heart transplant patient infected by domestic <i>Trypanosoma cruzi</i> discrete typing unit I (TcIDOM). Parasites and Vectors, 2015, 8, 435.	2.5	10
476	Quantitative analyses and modelling to support achievement of the 2020 goals for nine neglected tropical diseases. Parasites and Vectors, 2015, 8, 630.	2.5	80
477	Does <i>Triatoma brasiliensis</i> occupy the same environmental niche space as <i>Triatoma melanica</i> ?. Parasites and Vectors, 2015, 8, 361.	2.5	14
478	Broad patterns in domestic vector-borne <i>Trypanosoma cruzi</i> transmission dynamics: synanthropic animals and vector control. Parasites and Vectors, 2015, 8, 537.	2.5	30
479	Risks associated with dispersive nocturnal flights of sylvatic Triatominae to artificial lights in a model house in the northeastern plains of Colombia. Parasites and Vectors, 2015, 8, 600.	2.5	28
480	Neglected diseases prioritized in Brazil under the perspective of metabolomics: A review. Electrophoresis, 2015, 36, 2336-2347.	2.4	8
481	Molecular mechanisms of myocarditis caused by <i>Trypanosoma cruzi</i> . Current Opinion in Infectious Diseases, 2015, 28, 246-252.	3.1	18
482	Chagas disease as a cause of heart failure and ventricular arrhythmias in patients long removed from endemic areas. Journal of Cardiovascular Medicine, 2015, 16, 817-823.	1.5	13
483	Nitric oxide-releasing polymeric nanoparticles against <i>Trypanosoma cruzi</i> . Journal of Physics: Conference Series, 2015, 617, 012020.	0.4	12
484	The Uptake of GABA in <i>Trypanosoma cruzi</i> . Journal of Eukaryotic Microbiology, 2015, 62, 629-636.	1.7	7
485	Protein 2DE reference map of the anterior midgut of the blood-sucking bug <i>Rhodnius prolixus</i> . Proteomics, 2015, 15, 3901-3904.	2.2	19
486	A Family Cluster of Chagas Disease Detected through Selective Screening of Blood Donors: A Case Report and Brief Review. Canadian Journal of Infectious Diseases and Medical Microbiology, 2015, 26, 157-161.	1.9	7
487	FIRST REPORT OF ACUTE CHAGAS DISEASE BY VECTOR TRANSMISSION IN RIO DE JANEIRO STATE, BRAZIL. Revista Do Instituto De Medicina Tropical De Sao Paulo, 2015, 57, 361-364.	1.1	4

#	ARTICLE	IF	CITATIONS
488	Esophagectomy with gastroplasty in advanced megaesophagus: late results of omeprazole use. <i>Revista Do Colegio Brasileiro De Cirurgioes</i> , 2015, 42, 299-304.	0.6	4
489	Human Leucocyte Antigen-G (HLA-G) and Its Murine Functional Homolog Qa2 in the <i>Trypanosoma cruzi</i> Infection. <i>Mediators of Inflammation</i> , 2015, 2015, 1-16.	3.0	9
490	Translational challenges of animal models in Chagas disease drug development: a review. <i>Drug Design, Development and Therapy</i> , 2015, 9, 4807.	4.3	96
491	Serological diagnosis of Chagas disease in HIV-infected patients. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2015, 48, 331-333.	0.9	5
492	Behavioural alterations are independent of sickness behaviour in chronic experimental Chagas disease. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2015, 110, 1042-1050.	1.6	18
493	Use of tumor necrosis factor alpha (TNF $\hat{\pm}$) antagonists in a patient with psoriasis and Chagas disease. <i>Anais Brasileiros De Dermatologia</i> , 2015, 90, 171-174.	1.1	6
494	Trypanocidal Activity of Long Chain Diamines and Aminoalcohols. <i>Molecules</i> , 2015, 20, 11554-11568.	3.8	4
495	Molecular basis of peripheral olfactory plasticity in <i>Rhodnius prolixus</i> , a Chagas disease vector. <i>Frontiers in Ecology and Evolution</i> , 2015, 3, .	2.2	17
496	Effect of mild aerobic training on the myocardium of mice with chronic Chagas disease. <i>Biologics: Targets and Therapy</i> , 2015, 9, 87.	3.2	4
497	Pharmacophore Modeling for Anti-Chagas Drug Design Using the Fragment Molecular Orbital Method. <i>PLoS ONE</i> , 2015, 10, e0125829.	2.5	33
498	<i>Trypanosoma cruzi</i> -Infected Pregnant Women without Vector Exposure Have Higher Parasitemia Levels: Implications for Congenital Transmission Risk. <i>PLoS ONE</i> , 2015, 10, e0119527.	2.5	52
499	Target Product Profile (TPP) for Chagas Disease Point-of-Care Diagnosis and Assessment of Response to Treatment. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0003697.	3.0	63
500	Machine Learning Models and Pathway Genome Data Base for <i>Trypanosoma cruzi</i> Drug Discovery. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0003878.	3.0	74
501	Adipose Tissue-Derived Mesenchymal Stromal Cells Protect Mice Infected with <i>Trypanosoma cruzi</i> from Cardiac Damage through Modulation of Anti-parasite Immunity. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0003945.	3.0	26
502	First Documented Transmission of <i>Trypanosoma cruzi</i> Infection through Blood Transfusion in a Child with Sickle-Cell Disease in Belgium. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0003986.	3.0	17
503	Development of a Fluorescence-based <i>Trypanosoma cruzi</i> CYP51 Inhibition Assay for Effective Compound Triaging in Drug Discovery Programmes for Chagas Disease. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0004014.	3.0	43
504	Gut Microbiome of an 11th Century A.D. Pre-Columbian Andean Mummy. <i>PLoS ONE</i> , 2015, 10, e0138135.	2.5	97
505	Utilizing Chemical Genomics to Identify Cytochrome b as a Novel Drug Target for Chagas Disease. <i>PLoS Pathogens</i> , 2015, 11, e1005058.	4.7	52

#	ARTICLE	IF	CITATIONS
506	Update on oral Chagas disease outbreaks in Venezuela: epidemiological, clinical and diagnostic approaches. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2015, 110, 377-386.	1.6	115
507	Trypanocidal, trichomonacidal and cytotoxic components of cultivated <i>Artemisia absinthium</i> Linnaeus (Asteraceae) essential oil. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2015, 110, 693-699.	1.6	44
508	Revisiting the Posttherapeutic Cure Criterion in Chagas Disease: Time for New Methods, More Questions, Doubts, and Polemics or Time to Change Old Concepts?. <i>BioMed Research International</i> , 2015, 2015, 1-10.	1.9	17
509	Stem Cell-Based Therapies in Chagasic Cardiomyopathy. <i>BioMed Research International</i> , 2015, 2015, 1-5.	1.9	3
510	Mitral Subvalvular Aneurysm in a Patient with Chagas Disease and Recurrent Episodes of Ventricular Tachycardia. <i>Case Reports in Cardiology</i> , 2015, 2015, 1-5.	0.2	3
511	<i>Trypanosoma</i> Species (American Trypanosomiasis, Chagas' Disease). , 2015, , 3108-3115.e2.		13
512	Chagas disease: from Latin America to the world. <i>Reports in Parasitology</i> , 0, , 7.	0.5	10
513	Arrhythmias in Chagasic Cardiomyopathy. <i>Cardiac Electrophysiology Clinics</i> , 2015, 7, 251-268.	1.7	34
514	An ecological overview on the factors that drives to <i>Trypanosoma cruzi</i> oral transmission. <i>Acta Tropica</i> , 2015, 151, 94-102.	2.0	63
515	Synthesis and biological evaluation of quinones derived from natural product komaroviquinone as anti- <i>Trypanosoma cruzi</i> agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 2967-2971.	2.2	13
516	Chagas Heart Disease: An Update. <i>American Journal of Medicine</i> , 2015, 128, 1251.e7-1251.e9.	1.5	27
517	Optimizing Treatment for Children in the Developing World. , 2015, , .		2
518	Neglected Diseases: Drug Development for Chagas Disease as an Example. , 2015, , 203-211.		0
519	Expanding the family of heteroleptic oxidovanadium(IV) compounds with salicylaldehyde semicarbazones and polypyridyl ligands showing anti- <i>Trypanosoma cruzi</i> activity. <i>Journal of Inorganic Biochemistry</i> , 2015, 147, 116-125.	3.5	31
520	Molecular Genotyping of <i>Trypanosoma cruzi</i> for Lineage Assignment and Population Genetics. <i>Methods in Molecular Biology</i> , 2015, 1201, 297-337.	0.9	15
521	The Epidemiology, Clinical Manifestations, and Management of Chagas Heart Disease. <i>Clinical Cardiology</i> , 2015, 38, 565-569.	1.8	76
522	Looks Can be Deceiving: Cryptic Species and Phenotypic Variation in <i>Rhodnius</i> spp., Chagas Disease Vectors. , 2015, , 345-372.		2
523	Acute chagas outbreaks: molecular and biological features of <i>Trypanosoma cruzi</i> isolates, and clinical aspects of acute cases in Santander, Colombia. <i>Parasites and Vectors</i> , 2015, 8, 608.	2.5	10

#	ARTICLE	IF	CITATIONS
524	Ecology, Evolution and Control of Chagas Disease: A Century of Neglected Modelling and a Promising Future. <i>Advances in Parasitology</i> , 2015, 87, 135-191.	3.2	54
525	Detection of <i>Trypanosoma cruzi</i> DNA in blood by PCR is associated with Chagas cardiomyopathy and disease severity. <i>European Journal of Heart Failure</i> , 2015, 17, 416-423.	7.1	57
526	Evidence of Autochthonous Chagas Disease in Southeastern Texas. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015, 92, 325-330.	1.4	104
527	Deficiency of Antigen-Specific B Cells Results in Decreased <i>Trypanosoma cruzi</i> Systemic but Not Mucosal Immunity Due to CD8 T Cell Exhaustion. <i>Journal of Immunology</i> , 2015, 194, 1806-1818.	0.8	34
528	Tolerance of Benznidazole in a United States Chagas Disease Clinic. <i>Clinical Infectious Diseases</i> , 2015, 60, 1237-1240.	5.8	48
529	AKT Network of Genes and Impaired Myocardial Contractility During Murine Acute Chagasic Myocarditis. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015, 92, 523-529.	1.4	6
530	Novel 3-Nitrotriazole-Based Amides and Carbinols as Bifunctional Antichagasic Agents. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 1307-1319.	6.4	46
531	Mapping Antigenic Motifs in the Trypomastigote Small Surface Antigen from <i>Trypanosoma cruzi</i> . <i>Vaccine Journal</i> , 2015, 22, 304-312.	3.1	25
532	Nanomedicines against Chagas disease: an update on therapeutics, prophylaxis and diagnosis. <i>Nanomedicine</i> , 2015, 10, 465-481.	3.3	52
533	Cardiac Imaging in Latin America: Chagas Heart Disease. <i>Current Cardiovascular Imaging Reports</i> , 2015, 8, 1.	0.6	6
534	A National Survey to Determine Prevalence of <i>Trypanosoma cruzi</i> Infection Among Pregnant Women in Ecuador. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015, 92, 807-810.	1.4	8
535	Evidence of meaningful levels of <i>Trypanosoma cruzi</i> in platelet concentrates from seropositive blood donors. <i>Transfusion</i> , 2015, 55, 1249-1255.	1.6	31
536	<i>Trypanosoma cruzi</i> trans-Sialidase Prevents Elicitation of Th1 Cell Response via Interleukin 10 and Downregulates Th1 Effector Cells. <i>Infection and Immunity</i> , 2015, 83, 2099-2108.	2.2	24
537	Chagas™ Disease. <i>New England Journal of Medicine</i> , 2015, 373, 456-466.	27.0	625
538	Concomitant Benznidazole and Suramin Chemotherapy in Mice Infected with a Virulent Strain of <i>Trypanosoma cruzi</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5999-6006.	3.2	35
539	Tetrafluorophenoxymethyl ketone cruzain inhibitors with improved pharmacokinetic properties as therapeutic leads for Chagas™ disease. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 4834-4837.	2.2	15
540	Old and new challenges in Chagas disease. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 1347-1356.	9.1	88
541	An immunoinformatic approach for identification of <i>Trypanosoma cruzi</i> HLA-A2-restricted CD8 ⁺ T cell epitopes. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 2322-2328.	3.3	12

#	ARTICLE	IF	CITATIONS
542	Low Frequency of Circulating CD8+ T Stem Cell Memory Cells in Chronic Chagasic Patients with Severe Forms of the Disease. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e3432.	3.0	67
543	Prevalence of Chagas Disease in Latin-American Migrants Living in Europe: A Systematic Review and Meta-analysis. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0003540.	3.0	262
544	Using Hospital Discharge Database to Characterize Chagas Disease Evolution in Spain: There Is a Need for a Systematic Approach towards Disease Detection and Control. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0003710.	3.0	9
545	A Human Type 5 Adenovirus-Based <i>Trypanosoma cruzi</i> Therapeutic Vaccine Re-programs Immune Response and Reverses Chronic Cardiomyopathy. <i>PLoS Pathogens</i> , 2015, 11, e1004594.	4.7	88
546	Limited Ability of Posaconazole To Cure both Acute and Chronic <i>Trypanosoma cruzi</i> Infections Revealed by Highly Sensitive <i>In Vivo</i> Imaging. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 4653-4661.	3.2	124
547	Prevalence and Transmission of <i>Trypanosoma cruzi</i> in People of Rural Communities of the High Jungle of Northern Peru. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0003779.	3.0	28
548	A change of heart: oxidative stress in governing muscle function?. <i>Biophysical Reviews</i> , 2015, 7, 321-341.	3.2	28
549	Aromatic amine N-oxide organometallic compounds: searching for prospective agents against infectious diseases. <i>Dalton Transactions</i> , 2015, 44, 14453-14464.	3.3	38
550	Sustained Domestic Vector Exposure Is Associated With Increased Chagas Cardiomyopathy Risk but Decreased Parasitemia and Congenital Transmission Risk Among Young Women in Bolivia. <i>Clinical Infectious Diseases</i> , 2015, 61, 918-926.	5.8	49
552	On palms, bugs, and Chagas disease in the Americas. <i>Acta Tropica</i> , 2015, 151, 126-141.	2.0	73
553	Prevalence and Impact of Chagas Disease Among Latin American Immigrants With Nonischemic Cardiomyopathy in Los Angeles, California. <i>Circulation: Heart Failure</i> , 2015, 8, 938-943.	3.9	51
554	Chalcone scaffolds as anti-infective agents: Structural and molecular target perspectives. <i>European Journal of Medicinal Chemistry</i> , 2015, 101, 496-524.	5.5	147
555	Synthesis and structure-activity relationship study of a new series of antiparasitic aryloxyl thiosemicarbazones inhibiting <i>Trypanosoma cruzi</i> cruzain. <i>European Journal of Medicinal Chemistry</i> , 2015, 101, 818-835.	5.5	54
556	Between a bug and a hard place: <i>Trypanosoma cruzi</i> genetic diversity and the clinical outcomes of Chagas disease. <i>Expert Review of Anti-Infective Therapy</i> , 2015, 13, 995-1029.	4.4	146
557	Follow-up of an Asymptomatic Chagas Disease Population of Children after Treatment with Nifurtimox (Lampit) in a Sylvatic Endemic Transmission Area of Colombia. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0003465.	3.0	41
558	<i>Rhodnius prolixus</i> Life History Outcomes Differ when Infected with Different <i>Trypanosoma cruzi</i> I Strains. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015, 93, 564-572.	1.4	28
559	Automated High-Content Assay for Compounds Selectively Toxic to <i>Trypanosoma cruzi</i> in a Myoblastic Cell Line. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0003493.	3.0	52
560	Evidence of Reversible Bradycardia and Arrhythmias Caused by Immunogenic Proteins Secreted by <i>T. cruzi</i> in Isolated Rat Hearts. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0003512.	3.0	7

#	ARTICLE	IF	CITATIONS
561	Deep Sequencing of the Trypanosoma cruzi GP63 Surface Proteases Reveals Diversity and Diversifying Selection among Chronic and Congenital Chagas Disease Patients. PLoS Neglected Tropical Diseases, 2015, 9, e0003458.	3.0	50
562	Pentoxifylline Reverses Chronic Experimental Chagasic Cardiomyopathy in Association with Repositioning of Abnormal CD8+ T-Cell Response. PLoS Neglected Tropical Diseases, 2015, 9, e0003659.	3.0	51
564	In vitro metacyclogenesis of Trypanosoma cruzi induced by starvation correlates with a transient adenylyl cyclase stimulation as well as with a constitutive upregulation of adenylyl cyclase expression. Molecular and Biochemical Parasitology, 2015, 200, 9-18.	1.1	28
565	Economic evaluation of Chagas disease screening in Spain. Acta Tropica, 2015, 148, 77-88.	2.0	36
566	NMR structure and dynamics of Q4D059, a kinetoplastid-specific and conserved protein from Trypanosoma cruzi. Journal of Structural Biology, 2015, 190, 11-20.	2.8	2
567	Development and evaluation of a SPR-based immunosensor for detection of anti-Trypanosoma cruzi antibodies in human serum. Sensors and Actuators B: Chemical, 2015, 212, 287-296.	7.8	19
568	Differences in inferred genome-wide signals of positive selection during the evolution of Trypanosoma cruzi and Leishmania spp. lineages: A result of disparities in host and tissue infection ranges?. Infection, Genetics and Evolution, 2015, 33, 37-46.	2.3	4
569	Galactofuranose Biosynthesis: Discovery, Mechanisms and Therapeutic Relevance. RSC Drug Discovery Series, 2015, , 209-241.	0.3	8
570	Chagas Disease. Neglected Tropical Diseases, 2015, , 45-71.	0.4	8
571	Chagas, a cardiomyopathy emerging from obscurity. European Journal of Heart Failure, 2015, 17, 355-357.	7.1	5
572	Ecological host fitting of Trypanosoma cruzi in Bolivia: mosaic population structure, hybridization and a role for humans in Andean parasite dispersal. Molecular Ecology, 2015, 24, 2406-2422.	3.9	41
573	Enalapril in Combination with Benznidazole Reduces Cardiac Inflammation and Creatine Kinases in Mice Chronically Infected with Trypanosoma cruzi. American Journal of Tropical Medicine and Hygiene, 2015, 93, 976-982.	1.4	31
574	Inhibitory Receptor Expression on CD8+ T Cells Is Linked to Functional Responses against Trypanosoma cruzi Antigens in Chronic Chagasic Patients. Journal of Immunology, 2015, 195, 3748-3758.	0.8	62
576	Introduction: Some Historical and Geographical Aspects and the Relevance of Chagas Disease Among Foodborne Infections. SpringerBriefs in Food, Health and Nutrition, 2015, , 1-6.	0.5	1
577	Epidemiological Factors Related to Foodborne Transmission of Chagas Disease. SpringerBriefs in Food, Health and Nutrition, 2015, , 41-51.	0.5	2
578	Mechanisms of Infection in Chagas Disease. SpringerBriefs in Food, Health and Nutrition, 2015, , 21-32.	0.5	2
579	Synthesis and evaluation of in vitro and in vivo trypanocidal properties of a new imidazole-containing nitrone derivative. European Journal of Medicinal Chemistry, 2015, 106, 106-119.	5.5	23
580	Trypanosoma cruzi infection in a Spanish liver transplant recipient. Clinical Microbiology and Infection, 2015, 21, e1687-e1687.	6.0	14

#	ARTICLE	IF	CITATIONS
581	Multicomponent reaction-based synthesis and biological evaluation of tricyclic heterofused quinolines with multi-trypanosomatid activity. <i>European Journal of Medicinal Chemistry</i> , 2015, 105, 120-137.	5.5	52
582	Parasitic disease in the pediatric intensive care unit - A review of severe manifestations of pediatric parasitic disease. <i>Journal of Pediatric Intensive Care</i> , 2015, 03, 291-304.	0.8	0
583	Towards High-throughput Immunomics for Infectious Diseases: Use of Next-generation Peptide Microarrays for Rapid Discovery and Mapping of Antigenic Determinants. <i>Molecular and Cellular Proteomics</i> , 2015, 14, 1871-1884.	3.8	80
584	Chagas Disease: A Neglected Disease. , 2015, , 159-182.		0
585	Trypanosomes of Australian Mammals: Knowledge Gaps Regarding Transmission and Biosecurity. <i>Trends in Parasitology</i> , 2015, 31, 553-562.	3.3	19
586	Controlled but not cured: Structural processes and explanatory models of Chagas disease in tropical Bolivia. <i>Social Science and Medicine</i> , 2015, 145, 7-16.	3.8	21
587	Immunity and immune modulation in <i>Trypanosoma cruzi</i> infection. <i>Pathogens and Disease</i> , 2015, 73, ftv082.	2.0	75
588	Evaluation of Cytokine Profile and HLA Association in Benznidazole Related Cutaneous Reactions in Patients With Chagas Disease. <i>Clinical Infectious Diseases</i> , 2015, 61, civ690.	5.8	29
589	Discovery of potent nitrotriazole-based antitrypanosomal agents: In vitro and in vivo evaluation. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 6467-6476.	3.0	36
590	In vitro and in vivo antiparasitic activity of <i>Physalis angulata</i> L. concentrated ethanolic extract against <i>Trypanosoma cruzi</i> . <i>Phytomedicine</i> , 2015, 22, 969-974.	5.3	39
591	Toxic Profile of Benznidazole in Patients with Chronic Chagas Disease: Risk Factors and Comparison of the Product from Two Different Manufacturers. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 6125-6131.	3.2	76
592	Randomized Trial of Benznidazole for Chronic Chagasâ€™ Cardiomyopathy. <i>New England Journal of Medicine</i> , 2015, 373, 1295-1306.	27.0	807
593	The impact of landscape transformation on the reinfestation rates of <i>Rhodnius prolixus</i> in the Orinoco Region, Colombia. <i>Acta Tropica</i> , 2015, 151, 73-79.	2.0	12
594	Seroprevalence of <i>Trypanosoma cruzi</i> Infection in Schoolchildren and in Pregnant Women from an Amazonian Region in Orellana Province, Ecuador. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015, 93, 774-778.	1.4	12
595	Prevention of Cardiovascular Diseases. , 2015, , .		1
596	On the investigation of hybrid quinones: synthesis, electrochemical studies and evaluation of trypanocidal activity. <i>RSC Advances</i> , 2015, 5, 78047-78060.	3.6	43
597	Globalization of Chagas Disease Burden and New Treatment Perspectives. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1190-1192.	2.8	11
598	Structural design, synthesis and pharmacological evaluation of 4-thiazolidinones against <i>Trypanosoma cruzi</i> . <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 7478-7486.	3.0	35

#	ARTICLE	IF	CITATIONS
599	Gene-deleted live-attenuated <i>Trypanosoma cruzi</i> parasites as vaccines to protect against Chagas disease. <i>Expert Review of Vaccines</i> , 2015, 14, 681-697.	4.4	27
600	Reevaluating the <i>Trypanosoma cruzi</i> proteomic map: The shotgun description of bloodstream trypomastigotes. <i>Journal of Proteomics</i> , 2015, 115, 58-65.	2.4	44
601	Identification of a New Amide-Containing Thiazole as a Drug Candidate for Treatment of Chagas' Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1398-1404.	3.2	39
602	Development of Chagas Cardiac Manifestations Among Texas Blood Donors. <i>American Journal of Cardiology</i> , 2015, 115, 113-117.	1.6	30
603	Rehabilitation Practice Patterns for Patients with Heart Failure. <i>Heart Failure Clinics</i> , 2015, 11, 73-82.	2.1	9
605	Neglected Tropical Diseases, Bioinformatics, and Vaccines. <i>Journal of Infectious Diseases</i> , 2015, 211, 175-177.	4.0	2
606	Synthesis and biological evaluation of novel 2,3-disubstituted quinoxaline derivatives as antileishmanial and antitrypanosomal agents. <i>European Journal of Medicinal Chemistry</i> , 2015, 90, 107-123.	5.5	56
607	Circulating Serum Markers and QRS Scar Score in Chagas Cardiomyopathy. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015, 92, 39-44.	1.4	32
608	Parasite Genomics Protocols. <i>Methods in Molecular Biology</i> , 2015, 1201, v-vi.	0.9	2
609	High-Throughput Screening Platform for Natural Product-Based Drug Discovery Against 3 Neglected Tropical Diseases: Human African Trypanosomiasis, Leishmaniasis, and Chagas Disease. <i>Journal of Biomolecular Screening</i> , 2015, 20, 82-91.	2.6	70
610	Antisense Oligonucleotides Targeting Parasite Inositol 1,4,5-Trisphosphate Receptor Inhibits Mammalian Host Cell Invasion by <i>Trypanosoma cruzi</i> . <i>Scientific Reports</i> , 2015, 4, 4231.	3.3	17
611	Chagas Disease Drug Discovery: Toward a New Era. <i>Journal of Biomolecular Screening</i> , 2015, 20, 22-35.	2.6	227
612	Oral Multicomponent DNA Vaccine Delivered by Attenuated <i>Salmonella</i> Elicited Immunoprotection Against American Trypanosomiasis. <i>Journal of Infectious Diseases</i> , 2015, 211, 698-707.	4.0	30
613	Interactions of human galectins with <i>Trypanosoma cruzi</i> : Binding profile correlate with genetic clustering of lineages. <i>Glycobiology</i> , 2015, 25, 197-210.	2.5	33
614	Lead Identification to Clinical Candidate Selection: Drugs for Chagas Disease. <i>Journal of Biomolecular Screening</i> , 2015, 20, 101-111.	2.6	27
616	Expanding the knowledge of the chemical structure of glycoconjugates from <i>Trypanosoma cruzi</i> TcI genotype. Contribution to taxonomic studies. <i>Anais Da Academia Brasileira De Ciencias</i> , 2016, 88, 1519-1529.	0.8	4
617	<i>Trypanosoma cruzi</i> seroprevalence and associated risk factors in cancer patients from Southern Brazil. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2016, 49, 768-771.	0.9	7
618	A simple, biologically sound, and potentially useful working classification of Chagas disease vectors. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2016, 111, 649-651.	1.6	19

#	ARTICLE	IF	CITATIONS
619	Conhecimentos sobre triatomíneos e sobre a doença de Chagas em localidades com diferentes níveis de infestação vetorial. <i>Ciencia E Saude Coletiva</i> , 2016, 21, 2293-2304.	0.5	17
620	Cardiac rehabilitation program in patients with Chagas heart failure: a single-arm pilot study. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2016, 49, 319-328.	0.9	30
621	Bug Smash, Bug Splash: A Case Report of an Unusual Transmission of American Trypanosomiasis with a Brief Review of the Literature. <i>American Journal of Case Reports</i> , 2016, 17, 993-996.	0.8	0
622	Community resilience and Chagas disease in a rural region of Mexico. <i>Revista De Saude Publica</i> , 2016, 50, 46.	1.7	1
623	Cubebin and semisynthetic dibenzyl butyrolactone derivatives: Biological activities. <i>African Journal of Pharmacy and Pharmacology</i> , 2016, 10, 526-532.	0.3	2
624	Correlation between infection rate of triatomines and Chagas Disease in Southwest of Bahia, Brazil: a warning sign?. <i>Anais Da Academia Brasileira De Ciencias</i> , 2016, 88, 1941-1951.	0.8	3
625	POSTFUNDOPPLICATION DYSPHAGIA CAUSES SIMILAR WATER INGESTION DYNAMICS AS ACHALASIA. <i>Arquivos De Gastroenterologia</i> , 2016, 53, 98-102.	0.8	2
626	Chagas Disease in Mexico: Report of 14 Cases of Chagasic Cardiomyopathy in Children. <i>Tohoku Journal of Experimental Medicine</i> , 2016, 240, 243-249.	1.2	21
627	Natural Sesquiterpene Lactones as Potential Trypanocidal Therapeutic Agents: A Review. <i>Natural Product Communications</i> , 2016, 11, 1934578X1601101.	0.5	6
628	The CXCL10/CXCR3 Axis and Cardiac Inflammation: Implications for Immunotherapy to Treat Infectious and Noninfectious Diseases of the Heart. <i>Journal of Immunology Research</i> , 2016, 2016, 1-12.	2.2	61
629	A Novel Vaccine Approach for Chagas Disease Using Rare Adenovirus Serotype 48 Vectors. <i>Viruses</i> , 2016, 8, 78.	3.3	12
630	Here, There, and Everywhere: The Ubiquitous Distribution of the Immunosignaling Molecule Lysophosphatidylcholine and Its Role on Chagas Disease. <i>Frontiers in Immunology</i> , 2016, 7, 62.	4.8	17
631	The Ly49E Receptor Inhibits the Immune Control of Acute <i>Trypanosoma cruzi</i> Infection. <i>Frontiers in Immunology</i> , 2016, 7, 472.	4.8	5
632	Chronic Chagas' Disease: Targeting the Interleukin-2 Axis and Regulatory T Cells in a Condition for Which There Is No Treatment. <i>Frontiers in Microbiology</i> , 2016, 7, 675.	3.5	5
633	Evasion and Immuno-Endocrine Regulation in Parasite Infection: Two Sides of the Same Coin in Chagas Disease?. <i>Frontiers in Microbiology</i> , 2016, 7, 704.	3.5	16
634	Dendritic Cells: A Double-Edged Sword in Immune Responses during Chagas Disease. <i>Frontiers in Microbiology</i> , 2016, 7, 1076.	3.5	28
635	Synthesis of Xylitan Derivatives and Preliminary Evaluation of in Vitro Trypanocidal Activity. <i>Molecules</i> , 2016, 21, 1342.	3.8	11
636	The Potential of Secondary Metabolites from Plants as Drugs or Leads against Protozoan Neglected Diseases—Part III: In-Silico Molecular Docking Investigations. <i>Molecules</i> , 2016, 21, 1389.	3.8	29

#	ARTICLE	IF	CITATIONS
637	Systems Biology Approach to Model the Life Cycle of <i>Trypanosoma cruzi</i> . <i>PLoS ONE</i> , 2016, 11, e0146947.	2.5	10
638	Risk Factors and Screening for <i>Trypanosoma cruzi</i> Infection of Dutch Blood Donors. <i>PLoS ONE</i> , 2016, 11, e0151038.	2.5	10
639	Inflammation Enhances the Risks of Stroke and Death in Chronic Chagas Disease Patients. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004669.	3.0	19
640	Chemical Characterization and Trypanocidal, Leishmanicidal and Cytotoxicity Potential of <i>Lantana camara</i> L. (Verbenaceae) Essential Oil. <i>Molecules</i> , 2016, 21, 209.	3.8	28
641	Spatial distribution of triatomines in domiciles of an urban area of the Brazilian Southeast Region. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2016, 111, 43-50.	1.6	28
642	2 nd Brazilian Consensus on Chagas Disease, 2015. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2016, 49, 3-60.	0.9	239
644	Role of Monokine Induced by Interferon Gamma in Discrimination and Prognosis of Patients With Chagas' Disease and Idiopathic Dilated Cardiomyopathy. <i>Journal of Cardiovascular Pharmacology</i> , 2016, 67, 427-432.	1.9	3
645	Bioenergetic profiling of <i>Trypanosoma cruzi</i> life stages using Seahorse extracellular flux technology. <i>Molecular and Biochemical Parasitology</i> , 2016, 208, 91-95.	1.1	24
646	The Prevalence of Atrial Fibrillation and Conduction Abnormalities in Chagasâ€™ Disease: A Metaâ€™Analysis. <i>Journal of Cardiovascular Electrophysiology</i> , 2016, 27, 161-169.	1.7	20
647	Analysis of association of <i>FOXO3</i> gene with <i>Trypanosoma cruzi</i> infection and chronic Chagasic cardiomyopathy. <i>Hla</i> , 2016, 87, 449-452.	0.6	3
648	Antisense antimicrobial therapeutics. <i>Current Opinion in Microbiology</i> , 2016, 33, 47-55.	5.1	100
650	Neuropeptidomics in <i>Triatoma infestans</i> . Comparative transcriptomic analysis among triatomines. <i>Journal of Physiology (Paris)</i> , 2016, 110, 83-98.	2.1	26
651	Autochthonous Transmission of <i>Trypanosoma Cruzi</i> in Southern California. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw227.	0.9	26
652	Nifurtimox Is Effective Against Neural Tumor Cells and Is Synergistic with Buthionine Sulfoximine. <i>Scientific Reports</i> , 2016, 6, 27458.	3.3	18
654	Unaccompanied Immigrant Minors: Where to Begin. <i>Journal of Pediatric Health Care</i> , 2016, 30, 231-240.	1.2	30
655	Simple methodology to directly genotype <i>Trypanosoma cruzi</i> discrete typing units in single and mixed infections from human blood samples. <i>Infection, Genetics and Evolution</i> , 2016, 43, 123-129.	2.3	11
656	Effects of aspirin-triggered resolvin D1 on peripheral blood mononuclear cells from patients with Chagas' heart disease. <i>European Journal of Pharmacology</i> , 2016, 777, 26-32.	3.5	10
657	Variable-selection approaches to generate QSAR models for a set of antichagasic semicarbazones and analogues. <i>Chemometrics and Intelligent Laboratory Systems</i> , 2016, 154, 137-149.	3.5	27

#	ARTICLE	IF	CITATIONS
658	In silico investigation by conceptual DFT and molecular docking of antitrypanosomal compounds for understanding cruzain inhibition. <i>Journal of Theoretical and Computational Chemistry</i> , 2016, 15, 1650021.	1.8	2
659	A 12-mer repetitive antigenic epitope from <i>Trypanosoma cruzi</i> is a potential marker of therapeutic efficacy in chronic Chagas' disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2005-2009.	3.0	10
660	Tcl Isolates of <i>Trypanosoma cruzi</i> Exploit the Antioxidant Network for Enhanced Intracellular Survival in Macrophages and Virulence in Mice. <i>Infection and Immunity</i> , 2016, 84, 1842-1856.	2.2	34
661	Serological Diagnosis of Chronic Chagas Disease: Is It Time for a Change?. <i>Journal of Clinical Microbiology</i> , 2016, 54, 1566-1572.	3.9	52
662	Modulation of inflammatory and oxidative status by exercise attenuates cardiac morphofunctional remodeling in experimental Chagas cardiomyopathy. <i>Life Sciences</i> , 2016, 152, 210-219.	4.3	26
663	Clomipramine and Benznidazole Act Synergistically and Ameliorate the Outcome of Experimental Chagas Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3700-3708.	3.2	22
664	Status of vaccine research and development of vaccines for Chagas disease. <i>Vaccine</i> , 2016, 34, 2996-3000.	3.8	56
665	Detection and Quantification of Viable and Nonviable <i>Trypanosoma cruzi</i> Parasites by a Propidium Monoazide Real-Time Polymerase Chain Reaction Assay. <i>American Journal of Tropical Medicine and Hygiene</i> , 2016, 94, 1282-1289.	1.4	13
666	Antiparasitic evaluation of betulinic acid derivatives reveals effective and selective anti- <i>Trypanosoma cruzi</i> inhibitors. <i>Experimental Parasitology</i> , 2016, 166, 108-115.	1.2	33
667	Combination Chemotherapy with Suboptimal Doses of Benznidazole and Pentoxifylline Sustains Partial Reversion of Experimental Chagas' Heart Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4297-4309.	3.2	48
668	A prime-boost immunization with Tc52 N-terminal domain DNA and the recombinant protein expressed in <i>Pichia pastoris</i> protects against <i>Trypanosoma cruzi</i> infection. <i>Vaccine</i> , 2016, 34, 3243-3251.	3.8	20
669	A Case of Cardboard Boxes Likely Facilitating the Biting of a Patient by <i>Trypanosoma cruzi</i> -Infected Triatomine Bugs. <i>American Journal of Tropical Medicine and Hygiene</i> , 2016, 95, 1115-1117.	1.4	5
670	Changes in the immune response after treatment with benznidazole versus no treatment in patients with chronic indeterminate Chagas disease. <i>Acta Tropica</i> , 2016, 164, 117-124.	2.0	29
671	Effect of physical exercise training in patients with Chagas heart disease: study protocol for a randomized controlled trial (PEACH study). <i>Trials</i> , 2016, 17, 433.	1.6	11
672	<i>Trypanosoma cruzi</i> seroprevalence in pregnant women and screening by PCR and microhaematocrit in newborns from Guanajuato, Mexico. <i>Acta Tropica</i> , 2016, 164, 100-106.	2.0	19
673	ABO, Secretor and Lewis histo-blood group systems influence the digestive form of Chagas disease. <i>Infection, Genetics and Evolution</i> , 2016, 45, 170-175.	2.3	4
674	What is the β effect of <i>Trypanosoma rangeli</i> on its triatomine bug vector?. <i>Journal of Vector Ecology</i> , 2016, 41, 27-33.	1.0	10
675	Interactions between 4-aminoquinoline and heme: Promising mechanism against <i>Trypanosoma cruzi</i> . <i>International Journal for Parasitology: Drugs and Drug Resistance</i> , 2016, 6, 154-164.	3.4	17

#	ARTICLE	IF	CITATIONS
676	Putting Infection Dynamics at the Heart of Chagas Disease. <i>Trends in Parasitology</i> , 2016, 32, 899-911.	3.3	83
677	Sensitive detection and estimation of cell-derived peroxynitrite fluxes using fluorescein-boronate. <i>Free Radical Biology and Medicine</i> , 2016, 101, 284-295.	2.9	65
678	The detection of <i>Trypanosoma cruzi</i> by nested-PCR in elderly patients: relationship to the clinical and epidemiological profile. <i>Pathogens and Global Health</i> , 2016, 110, 228-232.	2.3	4
679	Identification of three cytochrome P450 genes in the Chagas' disease vector <i>Triatoma infestans</i> : Expression analysis in deltamethrin susceptible and resistant populations. <i>Infection, Genetics and Evolution</i> , 2016, 44, 459-470.	2.3	26
680	1,3,4-Thiadiazole derivatives of R-(+)-limonene benzaldehyde-thiosemicarbazones cause death in <i>Trypanosoma cruzi</i> through oxidative stress. <i>Microbes and Infection</i> , 2016, 18, 787-797.	1.9	15
681	Unlocking the in vitro anti- <i>Trypanosoma cruzi</i> activity of halophyte plants from the southern Portugal. <i>Asian Pacific Journal of Tropical Medicine</i> , 2016, 9, 735-741.	0.8	11
682	Host and parasite genetics shape a link between <i>Trypanosoma cruzi</i> infection dynamics and chronic cardiomyopathy. <i>Cellular Microbiology</i> , 2016, 18, 1429-1443.	2.1	78
683	Insect science – a vulnerable discipline?. <i>Entomologia Experimentalis Et Applicata</i> , 2016, 159, 121-134.	1.4	6
684	Ten years (2004–2014) of Chagas disease surveillance and vector control in Ecuador: successes and challenges. <i>Tropical Medicine and International Health</i> , 2016, 21, 84-92.	2.3	20
686	The role of CCR5 in Chagas disease - a systematic review. <i>Infection, Genetics and Evolution</i> , 2016, 45, 132-137.	2.3	17
687	The role of primary infection of Schwann cells in the aetiology of infective inflammatory neuropathies. <i>Journal of Infection</i> , 2016, 73, 402-418.	3.3	18
689	In Vitro and in Vivo Anti- <i>Trypanosoma cruzi</i> Activity of New Arylamine Mannich Base-Type Derivatives. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 10929-10945.	6.4	30
690	Parasites. <i>Microbiology Spectrum</i> , 2016, 4, .	3.0	29
691	An Aromatic Diamidine That Targets Kinetoplast DNA, Impairs the Cell Cycle in <i>Trypanosoma cruzi</i> , and Diminishes Trypomastigote Release from Infected Mammalian Host Cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5867-5877.	3.2	17
692	Direct identification of trypanosomatids by matrix-assisted laser desorption ionization-time of flight mass spectrometry (DIT MALDI-TOF MS). <i>Journal of Mass Spectrometry</i> , 2016, 51, 549-557.	1.6	13
693	Congenital and perinatally-acquired infections in resource-constrained settings. <i>Expert Review of Anti-Infective Therapy</i> , 2016, 14, 845-861.	4.4	13
694	What Do We Know About Chagas Disease in the United States?. <i>American Journal of Tropical Medicine and Hygiene</i> , 2016, 95, 1225-1227.	1.4	60
695	Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy. <i>The Cochrane Library</i> , 2016, 7, CD009077.	2.8	16

#	ARTICLE	IF	CITATIONS
696	Chagasâ€™ Disease: Update on Current Diagnosis. Current Cardiovascular Imaging Reports, 2016, 9, 1.	0.6	1
697	Trypanosoma. , 2016, , 157-194.		1
698	Evaluation of VDR gene polymorphisms in Trypanosoma cruzi infection and chronic Chagasic cardiomyopathy. Scientific Reports, 2016, 6, 31263.	3.3	13
699	The N-myristoylome of Trypanosoma cruzi. Scientific Reports, 2016, 6, 31078.	3.3	20
700	Pre-participation cardiovascular evaluation for athletic participants to prevent sudden death: Position paper from the EHRA and the EACPR, branches of the ESC. Endorsed by APHRS, HRS, and SOLAECE. Europace, 2017, 19, euw243.	1.7	86
701	Protozoa lectins and their role in hostâ€™pathogen interactions. Biotechnology Advances, 2016, 34, 1018-1029.	11.7	30
703	Dynamics of expression of two vitellogenin genes in the Chagasâ€™ disease vector Triatoma infestans: Analysis throughout pre-vitellogenesis and vitellogenesis. Acta Tropica, 2016, 156, 100-107.	2.0	8
704	Vector-borne transmission of Trypanosoma cruzi among captive Neotropical primates in a Brazilian zoo. Parasites and Vectors, 2016, 9, 39.	2.5	20
705	Targeting the Cytochrome <i>bc</i> ₁ Complex of Leishmania Parasites for Discovery of Novel Drugs. Antimicrobial Agents and Chemotherapy, 2016, 60, 4972-4982.	3.2	28
706	Chemotherapeutic Efficacy of Phosphodiesterase Inhibitors in Chagasic Cardiomyopathy. JACC Basic To Translational Science, 2016, 1, 235-250.	4.1	19
707	Chagas Disease in a Non-endemic Country: A Multidisciplinary Research, Bologna, Italy. Journal of Immigrant and Minority Health, 2016, 18, 616-623.	1.6	10
708	Identification of G protein coupled receptors for opsins and neurohormones in Rhodnius prolixus. Genomic and transcriptomic analysis. Insect Biochemistry and Molecular Biology, 2016, 69, 34-50.	2.7	72
709	A global systematic review of Chagas disease prevalence among migrants. Acta Tropica, 2016, 156, 68-78.	2.0	88
710	Synthesis and Evaluation of Oxyguanidine Analogues of the Cysteine Protease Inhibitor WRR-483 against Cruzain. ACS Medicinal Chemistry Letters, 2016, 7, 77-82.	2.8	26
711	Preventing pediatric cardiomyopathy: a 2015 outlook. Expert Review of Cardiovascular Therapy, 2016, 14, 321-339.	1.5	4
712	Trypanocidal and leishmanicidal activities of flavonoids isolated from <i>Stevia satureifolia</i> var. <i>satureifolia</i> . Pharmaceutical Biology, 2016, 54, 2188-2195.	2.9	38
713	Kdr mutations in Triatoma infestans from the Gran Chaco are distributed in two differentiated foci: Implications for pyrethroid resistance management. Acta Tropica, 2016, 158, 208-213.	2.0	33
714	Trypanosoma cruzi Polyamine Transporter: Its Role on Parasite Growth and Survival Under Stress Conditions. Journal of Membrane Biology, 2016, 249, 475-481.	2.1	24

#	ARTICLE	IF	CITATIONS
715	Curcumin Enhances the Anti-Trypanosoma cruzi Activity of Benznidazole-Based Chemotherapy in Acute Experimental Chagas Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3355-3364.	3.2	48
716	InÂvitro screening of 2-(1H-imidazol-1-yl)-1-phenylethanol derivatives as antiprotozoal agents and docking studies on Trypanosoma cruzi CYP51. <i>European Journal of Medicinal Chemistry</i> , 2016, 113, 28-33.	5.5	18
717	Chagas heart disease in professional athletes from endemic countries: A notorious case calls attention for its identification and stratification. <i>International Journal of Cardiology</i> , 2016, 207, 115-116.	1.7	2
718	Rapidly Progressing Chagas Cardiomyopathy. <i>American Journal of Tropical Medicine and Hygiene</i> , 2016, 94, 894-896.	1.4	2
719	A therapeutic nanoparticle vaccine against<i>Trypanosoma cruzi</i> in a BALB/c mouse model of Chagas disease. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 976-987.	3.3	52
720	Morpholino antisense oligo inhibits trans-splicing of pre-inositol 1,4,5-trisphosphate receptor mRNA of Trypanosoma cruzi and suppresses parasite growth and infectivity. <i>Parasitology International</i> , 2016, 65, 175-179.	1.3	7
721	Effect of secondary anchor amino acid substitutions on the immunogenic properties of an HLA-A*0201-restricted T cell epitope derived from the Trypanosoma cruzi KMP-11 protein. <i>Peptides</i> , 2016, 78, 68-76.	2.4	7
722	Putative Role of the Aldo-Keto Reductase from Trypanosoma cruzi in Benznidazole Metabolism. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2664-2670.	3.2	12
723	Total Artificial Heart as Bridge to Heart Transplantation in Chagas Cardiomyopathy: Case Report. <i>Transplantation Proceedings</i> , 2016, 48, 279-281.	0.6	11
724	Impact of vectorborne parasitic neglected tropical diseases on child health. <i>Archives of Disease in Childhood</i> , 2016, 101, 640-647.	1.9	9
725	<i>In Vitro</i> and <i>In Vivo</i> Trypanosomicidal Action of Novel Arylimidamides against Trypanosoma cruzi. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2425-2434.	3.2	21
726	Epidemiology and aetiology of heart failure. <i>Nature Reviews Cardiology</i> , 2016, 13, 368-378.	13.7	1,181
727	New approach towards the synthesis of selenosemicarbazones, useful compounds for Chagas' disease. <i>European Journal of Medicinal Chemistry</i> , 2016, 109, 107-113.	5.5	15
728	Synthesis of glycosylphosphatidylinositol (GPI)-anchor glycolipids bearing unsaturated lipids. <i>Chemical Communications</i> , 2016, 52, 1586-1589.	4.1	18
729	Interactions between RNA-binding proteins and P32 homologues in trypanosomes and human cells. <i>Current Genetics</i> , 2016, 62, 203-212.	1.7	2
730	Fluorine-containing benzothiazole as a novel trypanocidal agent: design, in silico study, synthesis and activity evaluation. <i>Medicinal Chemistry Research</i> , 2016, 25, 211-224.	2.4	18
731	Galectin-3 and Chagas Diseaseâ€™Associated Cardiomyopathy. <i>Journal of Infectious Diseases</i> , 2016, 213, 871.1-871.	4.0	1
732	Synthesis and trypanocidal activity of novel benzimidazole derivatives. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 4377-4381.	2.2	21

#	ARTICLE	IF	CITATIONS
733	Rhodnius prolixus supergene families of enzymes potentially associated with insecticide resistance. <i>Insect Biochemistry and Molecular Biology</i> , 2016, 69, 91-104.	2.7	68
734	Microbiological laboratory diagnostics of neglected zoonotic diseases (NZDs). <i>Acta Tropica</i> , 2017, 165, 40-65.	2.0	23
735	Comprehensive glycoprofiling of the epimastigote and trypomastigote stages of <i>Trypanosoma cruzi</i> . <i>Journal of Proteomics</i> , 2017, 151, 182-192.	2.4	52
736	Rhodnius prolixus intoxicated. <i>Journal of Insect Physiology</i> , 2017, 97, 93-113.	2.0	12
737	Structural analysis and molecular docking of trypanocidal aryloxy-quinones in trypanothione and glutathione reductases: a comparison with biochemical data. <i>Journal of Biomolecular Structure and Dynamics</i> , 2017, 35, 1785-1803.	3.5	15
738	The use of herbs against neglected diseases: Evaluation of in vitro leishmanicidal and trypanocidal activity of <i>Stryphnodendron rotundifolium</i> Mart. <i>Saudi Journal of Biological Sciences</i> , 2017, 24, 1136-1141.	3.8	14
739	Rhenium(I) tricarbonyl compounds of bioactive thiosemicarbazones: Synthesis, characterization and activity against <i>Trypanosoma cruzi</i> . <i>Journal of Inorganic Biochemistry</i> , 2017, 170, 125-133.	3.5	34
740	A systems approach to vaccine decision making. <i>Vaccine</i> , 2017, 35, A36-A42.	3.8	27
741	The molecular sensory machinery of a Chagas disease vector: expression changes through imaginal moult and sexually dimorphic features. <i>Scientific Reports</i> , 2017, 7, 40049.	3.3	44
742	Comparison of Trends in Mortality from Coronary Heart and Cerebrovascular Diseases in North and South America: 1980 to 2013. <i>American Journal of Cardiology</i> , 2017, 119, 862-871.	1.6	25
743	Eco-social processes influencing infectious disease emergence and spread. <i>Parasitology</i> , 2017, 144, 26-36.	1.5	28
744	Orcokinin neuropeptides regulate ecdysis in the hemimetabolous insect <i>Rhodnius prolixus</i> . <i>Insect Biochemistry and Molecular Biology</i> , 2017, 81, 91-102.	2.7	38
745	Overview and recent advances in the treatment of neuroblastoma. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 369-386.	2.4	286
746	Design and synthesis of a new series of 3,5-disubstituted isoxazoles active against <i>Trypanosoma cruzi</i> and <i>Leishmania amazonensis</i> . <i>European Journal of Medicinal Chemistry</i> , 2017, 128, 25-35.	5.5	47
747	Molecular modeling and structure-activity relationships studies of bioisoster hybrids of N-acylhydrazone and furoxan groups on cruzain. <i>Medicinal Chemistry Research</i> , 2017, 26, 760-769.	2.4	10
748	Engineering Oral and Parenteral Amorphous Amphotericin B Formulations against Experimental <i>Trypanosoma cruzi</i> Infections. <i>Molecular Pharmaceutics</i> , 2017, 14, 1095-1106.	4.6	21
749	Heart Transplantation for Chagas Cardiomyopathy. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 597-603.	0.6	44
750	Dissecting biochemical peculiarities of the ATPase activity of TcSub2, a component of the mRNA export pathway in <i>Trypanosoma cruzi</i> . <i>International Journal of Biological Macromolecules</i> , 2017, 98, 793-801.	7.5	2

#	ARTICLE	IF	CITATIONS
751	2017 ACC/AHA/HRS guideline for the evaluation and management of patients with syncope. <i>Heart Rhythm</i> , 2017, 14, e155-e217.	0.7	163
752	2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope. <i>Journal of the American College of Cardiology</i> , 2017, 70, e39-e110.	2.8	231
753	2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>Circulation</i> , 2017, 136, e60-e122.	1.6	189
754	Comparison and validation of two computational models of Chagas disease: A thirty year perspective from Venezuela. <i>Epidemics</i> , 2017, 18, 81-91.	3.0	14
755	Right Ventricular Systolic Dysfunction in Chagas Disease Defined by Speckle-Tracking Echocardiography: A Comparative Study with Cardiac Magnetic Resonance Imaging. <i>Journal of the American Society of Echocardiography</i> , 2017, 30, 493-502.	2.8	20
756	Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T.ÂCruzi Carriers. <i>Journal of the American College of Cardiology</i> , 2017, 69, 939-947.	2.8	231
757	Cost-effectiveness of Chagas disease screening in Latin American migrants at primary health-care centres in Europe: a Markov model analysis. <i>The Lancet Global Health</i> , 2017, 5, e439-e447.	6.3	84
758	Chagas disease in non-endemic countries. <i>The Lancet Global Health</i> , 2017, 5, e379-e380.	6.3	17
759	Animals and Mechanisms of Disease Transmission. , 2017, , 15-38.		14
760	Synthesis and trypanocidal activity of a library of 4-substituted 2-(1H-pyrrolo[3,2-c]pyridin-2-yl)propan-2-ols. <i>European Journal of Medicinal Chemistry</i> , 2017, 128, 202-212.	5.5	6
761	The contemporary distribution of <i>Trypanosoma cruzi</i> infection in humans, alternative hosts and vectors. <i>Scientific Data</i> , 2017, 4, 170050.	5.3	39
762	Comparison of four PCR methods for efficient detection of <i>Trypanosoma cruzi</i> in routine diagnostics. <i>Diagnostic Microbiology and Infectious Disease</i> , 2017, 88, 225-232.	1.8	34
763	Challenges in the management of Chagas disease in Latin-American migrants in Europe. <i>Clinical Microbiology and Infection</i> , 2017, 23, 290-295.	6.0	61
764	Use of two-photon microscopy to study <i>Leishmania major</i> infection of the skin. <i>Methods</i> , 2017, 127, 45-52.	3.8	16
765	Chagas disease in Europe: A review for the internist in the globalized world. <i>European Journal of Internal Medicine</i> , 2017, 43, 6-15.	2.2	148
766	Identification of novel mammalian hosts and Brazilian biome geographic distribution of <i>Trypanosoma cruzi</i> TcIII and TcIV. <i>Acta Tropica</i> , 2017, 172, 173-179.	2.0	21
767	Identification of Specific Inhibitors of <i>Trypanosoma cruzi</i> Malic Enzyme Isoforms by Target-Based HTS. <i>SLAS Discovery</i> , 2017, 22, 1150-1161.	2.7	13
768	Physician Knowledge of Chagas Disease in Hispanic Immigrants Living in Appalachian Ohio. <i>Journal of Racial and Ethnic Health Disparities</i> , 2017, 4, 523-528.	3.2	13

#	ARTICLE	IF	CITATIONS
769	Modeling Chagas disease in Chile: From vector to congenital transmission. <i>BioSystems</i> , 2017, 156-157, 63-71.	2.0	13
770	Susceptibility Testing of Medically Important Parasites. <i>Clinical Microbiology Reviews</i> , 2017, 30, 647-669.	13.6	9
771	TcI, TcII and TcVI <i>Trypanosoma cruzi</i> samples from Chagas disease patients with distinct clinical forms and critical analysis of in vitro and in vivo behavior, response to treatment and infection evolution in murine model. <i>Acta Tropica</i> , 2017, 167, 108-120.	2.0	33
772	A comparison of toxicity and toxicokinetics in rats and dogs following twenty-eight-day, repeat-dose oral administration of nifurtimox. <i>Toxicology Research</i> , 2017, 6, 544-553.	2.1	3
773	Myenteric neuroprotective role of aspirin in acute and chronic experimental infections with <i>Trypanosoma cruzi</i> . <i>Neurogastroenterology and Motility</i> , 2017, 29, 1-13.	3.0	13
774	Treatment of Infected Women of Childbearing Age Prevents Congenital <i>Trypanosoma cruzi</i> Infection by Eliminating the Parasitemia Detected by PCR. <i>Journal of Infectious Diseases</i> , 2017, 215, 1452-1458.	4.0	78
776	Repurposing of Human Kinase Inhibitors in Neglected Protozoan Diseases. <i>ChemMedChem</i> , 2017, 12, 1235-1253.	3.2	26
777	Cross-sectional, descriptive study of Chagas disease among citizens of Bolivian origin living in Munich, Germany. <i>BMJ Open</i> , 2017, 7, e013960.	1.9	31
778	Omega-3 supplementation on inflammatory markers in patients with chronic Chagas cardiomyopathy: a randomized clinical study. <i>Nutrition Journal</i> , 2017, 16, 36.	3.4	12
779	Synthesis and biological evaluation of 2-methyl-1H-benzimidazole-5-carbohydrazides derivatives as modifiers of redox homeostasis of <i>Trypanosoma cruzi</i> . <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 3403-3407.	2.2	13
780	Biodegradable Polymeric Nanocapsules Prevent Cardiotoxicity of Anti- <i>Trypanosomal</i> Lychnopholide. <i>Scientific Reports</i> , 2017, 7, 44998.	3.3	32
781	Sudden death circadian rhythm in Chagasic patients compared to non-Chagasic patients. <i>Chronobiology International</i> , 2017, 34, 659-665.	2.0	1
782	Epithelial cell types and their proposed roles in maintaining the mucosal barrier in human chagasic megacolon. <i>Histochemistry and Cell Biology</i> , 2017, 148, 207-216.	1.7	3
783	Chagas Disease: An Important Cause of Megaesophagus in Latin America. <i>Archivos De Bronconeumologia</i> , 2017, 53, 450.	0.8	1
784	Aryl- or heteroaryl-based hydrazinylphthalazine derivatives as new potential antitrypanosomal agents. <i>Bioorganic Chemistry</i> , 2017, 72, 51-56.	4.1	16
785	Mechanistic Insights into the Anti-angiogenic Activity of <i>Trypanosoma cruzi</i> Protein 21 and its Potential Impact on the Onset of Chagasic Cardiomyopathy. <i>Scientific Reports</i> , 2017, 7, 44978.	3.3	21
786	Evaluation of Right Ventricular Systolic Function in Chagas Disease Using Cardiac Magnetic Resonance Imaging. <i>Circulation: Cardiovascular Imaging</i> , 2017, 10, .	2.6	22
787	Blood Gene Signatures of Chagas Cardiomyopathy With or Without Ventricular Dysfunction. <i>Journal of Infectious Diseases</i> , 2017, 215, 387-395.	4.0	32

#	ARTICLE	IF	CITATIONS
788	Simvastatin Attenuates Endothelial Activation through 15-Epi-Lipoxin A4 Production in Murine Chronic Chagas Cardiomyopathy. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	27
789	Characterization and Diagnostic Application of <i>Trypanosoma cruzi</i> Trypomastigote Excreted-Secreted Antigens Shed in Extracellular Vesicles Released from Infected Mammalian Cells. <i>Journal of Clinical Microbiology</i> , 2017, 55, 744-758.	3.9	45
790	Novel DNA coding regions and protein arginylation reveal unexplored <i>T. cruzi</i> proteome and PTMs. <i>International Journal of Mass Spectrometry</i> , 2017, 418, 51-66.	1.5	4
791	Identification of <i>Trypanosoma cruzi</i> Discrete Typing Units (DTUs) in Latin-American migrants in Barcelona (Spain). <i>Parasitology International</i> , 2017, 66, 83-88.	1.3	20
792	How universal is coverage and access to diagnosis and treatment for Chagas disease in Colombia? A health systems analysis. <i>Social Science and Medicine</i> , 2017, 175, 187-198.	3.8	40
793	Prevalence of <i>Trypanosoma cruzi</i> /HIV coinfection in southern Brazil. <i>Brazilian Journal of Infectious Diseases</i> , 2017, 21, 180-184.	0.6	21
794	Soluble N-ethylmaleimide-sensitive factor attachment protein receptors required during <i>Trypanosoma cruzi</i> parasitophorous vacuole development. <i>Cellular Microbiology</i> , 2017, 19, e12713.	2.1	15
795	Rapid Chagas Disease Drug Target Discovery Using Directed Evolution in Drug-Sensitive Yeast. <i>ACS Chemical Biology</i> , 2017, 12, 422-434.	3.4	26
796	Characterization of <i>Trypanosoma cruzi</i> MutY DNA glycosylase ortholog and its role in oxidative stress response. <i>Infection, Genetics and Evolution</i> , 2017, 55, 332-342.	2.3	6
797	Development and <i>in vitro/in vivo</i> evaluation of a novel benznidazole liquid dosage form using a quality-by-design approach. <i>Tropical Medicine and International Health</i> , 2017, 22, 1514-1522.	2.3	14
798	Chagas disease among pregnant Latin American women in the United Kingdom: time for action. <i>BMJ Global Health</i> , 2017, 2, e000478.	4.7	6
799	Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against <i>Trypanosoma cruzi</i> . <i>Journal of Medicinal Chemistry</i> , 2017, 60, 7284-7299.	6.4	31
800	Cell therapies for Chagas disease. <i>Cytotherapy</i> , 2017, 19, 1339-1349.	0.7	10
801	Mass Spectrometry-Based Chemical Cartography of a Cardiac Parasitic Infection. <i>Analytical Chemistry</i> , 2017, 89, 10414-10421.	6.5	35
802	Novel scaffolds for inhibition of Cruzipain identified from high-throughput screening of anti-kinetoplastid chemical boxes. <i>Scientific Reports</i> , 2017, 7, 12073.	3.3	27
803	Pharmacist intervention in patients receiving treatment for Chagas disease: An emerging challenge for non-endemic countries. <i>Infection, Disease and Health</i> , 2017, 22, 219-226.	1.1	2
804	MD Simulations of Viruslike Particles with Supra CG Solvation Affordable to Desktop Computers. <i>Journal of Chemical Theory and Computation</i> , 2017, 13, 5106-5116.	5.3	29
805	Drug repurposing strategy against <i>Trypanosoma cruzi</i> infection: In vitro and in vivo assessment of the activity of metronidazole in mono- and combined therapy. <i>Biochemical Pharmacology</i> , 2017, 145, 46-53.	4.4	25

#	ARTICLE	IF	CITATIONS
806	Addressing the Challenges of Chagas Disease. <i>Infectious Diseases in Clinical Practice</i> , 2017, 25, 118-125.	0.3	14
807	Heteroleptic oxidovanadium(IV) complexes of 2-hydroxynaphthylaldimine and polypyridyl ligands against <i>Trypanosoma cruzi</i> and prostate cancer cells. <i>Journal of Inorganic Biochemistry</i> , 2017, 175, 154-166.	3.5	30
808	The immunomodulatory effects of the Enalapril in combination with Benznidazole during acute and chronic phases of the experimental infection with <i>Trypanosoma cruzi</i> . <i>Acta Tropica</i> , 2017, 174, 136-145.	2.0	15
809	In silico molecular docking studies of new potential 4-phthalazinyl-hydrazones on selected <i>Trypanosoma cruzi</i> and <i>Leishmania</i> enzyme targets. <i>Journal of Molecular Graphics and Modelling</i> , 2017, 76, 313-329.	2.4	22
810	Identification and preliminary characterization of a putative C-type lectin receptor-like protein in the <i>T. cruzi</i> tomato lectin endocytic-enriched proteome. <i>Microbiological Research</i> , 2017, 205, 73-79.	5.3	3
811	Microvesicles released during the interaction between <i>Trypanosoma cruzi</i> TcI and TcII strains and host blood cells inhibit complement system and increase the infectivity of metacyclic forms of host cells in a strain-independent process. <i>Pathogens and Disease</i> , 2017, 75, .	2.0	35
812	Extracorporeal Membrane Oxygenation in Dengue, Malaria, and Acute Chagas Disease. <i>ASAIO Journal</i> , 2017, 63, e71-e76.	1.6	5
813	Therapeutic effects of sphingosine kinase inhibitor N,N-dimethylsphingosine (DMS) in experimental chronic Chagas disease cardiomyopathy. <i>Scientific Reports</i> , 2017, 7, 6171.	3.3	10
814	Chagas Disease: An Important Cause of Megaesophagus in Latin America. <i>Archivos De Bronconeumologia</i> , 2017, 53, 450.	0.8	0
815	A Community-Based Screening Program for Chagas Disease in the USA. <i>Trends in Parasitology</i> , 2017, 33, 828-831.	3.3	17
816	Hunting hidden parasites: <i>Trypanosoma cruzi</i> . <i>Lancet, The</i> , 2017, 390, 724-726.	13.7	16
817	Development of a pharmacophore for cruzain using oxadiazoles as virtual molecular probes: quantitative structure-activity relationship studies. <i>Journal of Computer-Aided Molecular Design</i> , 2017, 31, 801-816.	2.9	9
818	Heart transplantation for Chagas cardiomyopathy. <i>Revista Portuguesa De Cardiologia</i> , 2017, 36, 871.e1-871.e4.	0.5	7
819	Endocardial Unipolar Voltage Maps to Identify Epicardial Circuits During Ventricular Tachycardia Ablation in Chagasic Cardiomyopathy. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2017, 10, .	4.8	0
820	Cardiac autonomic denervation and expression of neurotrophins (NGF and BDNF) and their receptors during experimental Chagas disease. <i>Growth Factors</i> , 2017, 35, 161-170.	1.7	9
822	In focus in HCB. <i>Histochemistry and Cell Biology</i> , 2017, 148, 103-104.	1.7	0
823	Avian antibodies (IgY) against <i>Trypanosoma cruzi</i> : Purification and characterization studies. <i>Journal of Immunological Methods</i> , 2017, 449, 56-61.	1.4	15
824	Genetic Adjuvantation of a Cell-Based Therapeutic Vaccine for Amelioration of Chagasic Cardiomyopathy. <i>Infection and Immunity</i> , 2017, 85, .	2.2	16

#	ARTICLE	IF	CITATIONS
825	Participation of <sc>TLR</sc>2 and <sc>TLR</sc>4 in Cytokines Production by Patients with Symptomatic and Asymptomatic Chronic Chagas Disease. Scandinavian Journal of Immunology, 2017, 85, 58-65.	2.7	13
826	Cysteine mutagenesis improves the production without abrogating antigenicity of a recombinant protein vaccine candidate for human chagas disease. Human Vaccines and Immunotherapeutics, 2017, 13, 621-633.	3.3	39
827	Evaluation of Parameters Impacting Drug Susceptibility in Intracellular Trypanosoma cruzi Assay Protocols. SLAS Discovery, 2017, 22, 125-134.	2.7	15
828	Chagas Disease (American Trypanosomiasis). , 2017, , 1065-1072.e1.		2
829	Blood and Tissue Protozoa. , 2017, , 1751-1762.e1.		0
830	Pre-participation cardiovascular evaluation for athletic participants to prevent sudden death: Position paper from the EHRA and the EACPR, branches of the ESC. Endorsed by APHRS, HRS, and SOLAECE. European Journal of Preventive Cardiology, 2017, 24, 41-69.	1.8	181
831	Molecular mechanisms of cardiac electromechanical remodeling during Chagas disease: Role of TNF and TGF- β 2. Trends in Cardiovascular Medicine, 2017, 27, 81-91.	4.9	22
832	Antiparasitic Activity of Diterpenoids Against Trypanosoma cruzi. Planta Medica, 2017, 83, 306-311.	1.3	11
833	The Phosphatidylinositol 3-kinase Class III Complex Containing TcVps15 and TcVps34 Participates in Autophagy in <i>Trypanosoma cruzi</i>. Journal of Eukaryotic Microbiology, 2017, 64, 308-321.	1.7	16
834	Global properties of vector-host disease models with time delays. Journal of Mathematical Biology, 2017, 74, 1397-1423.	1.9	32
835	Novel 2-arylazoimidazole derivatives as inhibitors of Trypanosoma cruzi proliferation: Synthesis and evaluation of their biological activity. European Journal of Medicinal Chemistry, 2017, 125, 327-334.	5.5	7
836	Heart transplantation for Chagas cardiomyopathy. Revista Portuguesa De Cardiologia (English) Tj ETQq1 1 0.784314,rgBT /Oerlock 10	0.2	0
837	PP107 Amiodarone For Arrhythmia In Chagas Patients: A Systematic Review. International Journal of Technology Assessment in Health Care, 2017, 33, 121-122.	0.5	0
838	Valor adicional do limiar anaer3bio em um modelo de predi3o de morte geral em uma coorte urbana de pacientes com cardiopatia chag3sica. Revista Portuguesa De Cardiologia, 2017, 36, 927-934.	0.5	6
839	Additional value of anaerobic threshold in a general mortality prediction model in a urban patient cohort with Chagas cardiomyopathy. Revista Portuguesa De Cardiologia (English Edition), 2017, 36, 927-934.	0.2	4
841	Utility of Cardiac Implantable Electronic Devices in Patients with Chagas Disease and Systolic Heart Failure. , 2017, , .		0
842	Lysosomes: How Plasma Membrane Repair Route Can Be Hijacked by Parasites?. , 2017, , .		0
843	Novel Insights into the Pathophysiology of Chagas' Cardiomyopathy. , 2017, , .		1

#	ARTICLE	IF	CITATIONS
844	Increasing access to comprehensive care for Chagas disease: development of a patient-centered model in Colombia. <i>Revista Panamericana De Salud Publica/Pan American Journal of Public Health</i> , 2017, 41, 1-9.	1.1	12
845	Subverting Host Cell P21-Activated Kinase: A Case of Convergent Evolution across Pathogens. <i>Pathogens</i> , 2017, 6, 17.	2.8	10
846	Biosensors to Diagnose Chagas Disease: A Brief Review. <i>Sensors</i> , 2017, 17, 2629.	3.8	11
847	Clinical phases and forms of Chagas disease. , 2017, , 653-686.		9
848	Nanoarchitectures for Neglected Tropical Protozoal Diseases: Challenges and State of the Art. , 2017, , 439-480.		23
849	Protozoan Diseases: Chagas Disease. , 2017, , 70-78.		0
850	Chagas disease in pre-Colombian civilizations**In memoriam to Arthur Aufderheide who opened a new research field in ancient medicine and parasitology.. , 2017, , 23-46.		2
851	Chagas Disease Diagnostic Applications. <i>Advances in Parasitology</i> , 2017, 97, 1-45.	3.2	87
852	Inactive trans-Sialidase Expression in iTS-null <i>Trypanosoma cruzi</i> Generates Virulent Trypomastigotes. <i>Frontiers in Cellular and Infection Microbiology</i> , 2017, 7, 430.	3.9	11
853	The Roles of Mast Cells in Parasitic Protozoan Infections. <i>Frontiers in Immunology</i> , 2017, 8, 363.	4.8	41
854	Canine Macrophage DH82 Cell Line As a Model to Study Susceptibility to <i>Trypanosoma cruzi</i> Infection. <i>Frontiers in Immunology</i> , 2017, 8, 604.	4.8	15
855	Camelid Single-Domain Antibodies As an Alternative to Overcome Challenges Related to the Prevention, Detection, and Control of Neglected Tropical Diseases. <i>Frontiers in Immunology</i> , 2017, 8, 653.	4.8	28
856	The Complement System: A Prey of <i>Trypanosoma cruzi</i> . <i>Frontiers in Microbiology</i> , 2017, 8, 607.	3.5	48
857	Effects of (1 <i>E</i> ,4 <i>E</i>)-2-Methyl-1,5-bis(4-nitrophenyl)penta-1,4-dien-3-one on <i>Trypanosoma cruzi</i> and Its Combinational Effect with Benznidazole, Ketoconazole, or Fluconazole. <i>BioMed Research International</i> , 2017, 2017, 1-11.	1.9	9
858	Chagas Cardiomyopathy Presenting as Symptomatic Bradycardia: An Underappreciated Emerging Public Health Problem in the United States. <i>Case Reports in Cardiology</i> , 2017, 2017, 1-5.	0.2	2
859	Imaging Diagnosis of Right Ventricle Involvement in Chagas Cardiomyopathy. <i>BioMed Research International</i> , 2017, 2017, 1-14.	1.9	9
860	Chronic Chagas cardiomyopathy: a review of the main pathogenic mechanisms and the efficacy of aetiological treatment following the BENznidazole Evaluation for Interrupting Trypanosomiasis (BENEFIT) trial. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2017, 112, 224-235.	1.6	152
861	Association of caspase-1 polymorphisms with Chagas cardiomyopathy among individuals in Santa Cruz, Bolivia. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2017, 50, 516-523.	0.9	6

#	ARTICLE	IF	CITATIONS
862	Experimental and Clinical Treatment of Chagas Disease: A Review. American Journal of Tropical Medicine and Hygiene, 2017, 97, 1289-1303.	1.4	212
863	Nitric Oxide Donors for Treating Neglected Diseases. , 2017, , 25-53.		5
864	Bone marrow cell migration to the heart in a chimeric mouse model of acute chagasic disease. Memorias Do Instituto Oswaldo Cruz, 2017, 112, 551-560.	1.6	2
865	Evidence of neurofibromatosis type 1 in a multi-morbid Inca child mummy: A paleoradiological investigation using computed tomography. PLoS ONE, 2017, 12, e0175000.	2.5	13
866	Risk factors for treatment interruption and severe adverse effects to benznidazole in adult patients with Chagas disease. PLoS ONE, 2017, 12, e0185033.	2.5	44
867	Improving access to Chagas disease diagnosis and etiologic treatment in remote rural communities of the Argentine Chaco through strengthened primary health care and broad social participation. PLoS Neglected Tropical Diseases, 2017, 11, e0005336.	3.0	37
868	"I Cannot Be Worried": Living with Chagas Disease in Tropical Bolivia. PLoS Neglected Tropical Diseases, 2017, 11, e0005251.	3.0	18
869	Comparative and functional triatomine genomics reveals reductions and expansions in insecticide resistance-related gene families. PLoS Neglected Tropical Diseases, 2017, 11, e0005313.	3.0	49
870	Unraveling Chagas disease transmission through the oral route: Gateways to Trypanosoma cruzi infection and target tissues. PLoS Neglected Tropical Diseases, 2017, 11, e0005507.	3.0	61
871	The superfamily keeps growing: Identification in trypanosomatids of RibJ, the first riboflavin transporter family in protists. PLoS Neglected Tropical Diseases, 2017, 11, e0005513.	3.0	11
872	An ImmunoSignature test distinguishes Trypanosoma cruzi, hepatitis B, hepatitis C and West Nile virus seropositivity among asymptomatic blood donors. PLoS Neglected Tropical Diseases, 2017, 11, e0005882.	3.0	12
873	Systemic insecticide treatment of the canine reservoir of Trypanosoma cruzi induces high levels of lethality in Triatoma infestans, a principal vector of Chagas disease. Parasites and Vectors, 2017, 10, 344.	2.5	40
874	Seropositivity for Trypanosoma cruzi in domestic dogs from Sonora, Mexico. Infectious Diseases of Poverty, 2017, 6, 120.	3.7	27
875	Combined parasitological and molecular-based diagnostic tools improve the detection of Trypanosoma cruzi in single peripheral blood samples from patients with Chagas disease. Revista Da Sociedade Brasileira De Medicina Tropical, 2017, 50, 506-515.	0.9	8
877	Diet Quality of patients with chronic Chagas disease in a tertiary hospital: a case-control study. Revista Da Sociedade Brasileira De Medicina Tropical, 2017, 50, 795-804.	0.9	7
878	Therapeutic drug monitoring of benznidazole and nifurtimox: a systematic review and quality assessment of published clinical practice guidelines. Revista Da Sociedade Brasileira De Medicina Tropical, 2017, 50, 748-755.	0.9	20
879	Genetic Polymorphisms of IL17 and Chagas Disease in the South and Southeast of Brazil. Journal of Immunology Research, 2017, 2017, 1-7.	2.2	23
880	Chagas Cardiomyopathy. , 2017, , 553-574.		1

#	ARTICLE	IF	CITATIONS
881	Chagas Disease. , 2017, , 371-381.		1
883	Analysis of the seroprevalence of and factors associated with Chagas disease in an endemic area in Northeastern Brazil. Revista Da Sociedade Brasileira De Medicina Tropical, 2017, 50, 44-51.	0.9	7
884	Translation of Saliva Proteins Into Tools to Prevent Vector-Borne Disease Transmission. , 2017, , 249-300.		3
885	Reassessment of quality of life domains in patients with compensated Chagas heart failure after participating in a cardiac rehabilitation program. Revista Da Sociedade Brasileira De Medicina Tropical, 2017, 50, 404-407.	0.9	15
886	Development of Diagnostics for Chagas Disease: Where Should We Put Our Limited Resources?. PLoS Neglected Tropical Diseases, 2017, 11, e0005148.	3.0	19
887	Detection of Trypanosoma cruzi antibodies in multitransfused patients in Colombia. Biomedica, 2017, 37, 361.	0.7	0
888	Chronic Chagas cardiomyopathy: a therapeutic challenge and future strategies. Emerging Topics in Life Sciences, 2017, 1, 579-584.	2.6	0
889	Trypanocidal Effects of Essential Oils from Selected Medicinal Plants. Synergy among the Main Components. Natural Product Communications, 2017, 12, 1934578X1701200.	0.5	7
890	Antiparasitic Agents. , 2017, , 717-750.		0
891	Immigrant Populations: Global Health in our Backyard. Annals of Global Health, 2018, 80, 429.	2.0	6
892	A cohort study of cardiac resynchronization therapy in patients with chronic Chagas cardiomyopathy. Europace, 2018, 20, 1813-1818.	1.7	8
893	The Trypanosoma cruzi RNA-binding protein RBP42 is expressed in the cytoplasm throughout the life cycle of the parasite. Parasitology Research, 2018, 117, 1095-1104.	1.6	11
894	Molecular diagnosis of Trypanosoma cruzi. Acta Tropica, 2018, 184, 59-66.	2.0	76
895	A mathematical model of Chagas disease transmission. AIP Conference Proceedings, 2018, , .	0.4	1
896	Temporal trends in the contribution of Chagas cardiomyopathy to mortality among patients with heart failure. Heart, 2018, 104, 1522-1528.	2.9	17
897	Medicinal Attributes of Lignans Extracted from <i>Piper Cubeba</i>: Current Developments. ChemistryOpen, 2018, 7, 180-191.	1.9	11
898	A cohort study of cardiac resynchronization therapy in patients with chronic Chagas cardiomyopathy. Europace, 2018, 20, 1717-1718.	1.7	2
899	Synthesis of aminophenylhydroxamate and aminobenzylhydroxamate derivatives and in vitro screening for antiparasitic and histone deacetylase inhibitory activity. International Journal for Parasitology: Drugs and Drug Resistance, 2018, 8, 59-66.	3.4	11

#	ARTICLE	IF	CITATIONS
900	Trypanosoma cruzi discrete typing unit TcIV implicated in a case of acute disseminated canine Chagas disease. <i>Veterinary Parasitology: Regional Studies and Reports</i> , 2018, 12, 85-88.	0.5	5
901	Identification and heterologous expression of the actinoallolide biosynthetic gene cluster. <i>Journal of Antibiotics</i> , 2018, 71, 749-752.	2.0	12
902	Usefulness of the ARCHITECT Chagas [®] assay as a single test for the diagnosis of chronic Chagas disease. <i>Tropical Medicine and International Health</i> , 2018, 23, 634-640.	2.3	11
903	Synthesis of potential anti- Trypanosoma cruzi azole-naftifine analogues by azide-alkyne click reaction. <i>Mendeleev Communications</i> , 2018, 28, 195-197.	1.6	2
904	Long-term follow-up of Chagas heart disease patients receiving an implantable cardioverter-defibrillator for secondary prevention. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2018, 41, 583-588.	1.2	9
905	Chronic Infections and the Hypothalamus-Pituitary-Adrenal Axis in the Context of Immune-Mediated Inflammation. <i>Advances in Neuroimmune Biology</i> , 2018, 7, 79-89.	0.7	2
906	Crystal structures of FMN bound and FMN free forms of dihydroorotate dehydrogenase from Trypanosoma brucei. <i>FEBS Open Bio</i> , 2018, 8, 680-691.	2.3	7
907	Nanoencapsulation of benznidazole in calcium carbonate increases its selectivity to Trypanosoma cruzi. <i>Parasitology</i> , 2018, 145, 1191-1198.	1.5	24
908	Parasitische Protozoen. , 2018, , 99-247.		0
909	Could age and aging change the host response to systemic parasitic infections? A systematic review of preclinical evidence. <i>Experimental Gerontology</i> , 2018, 104, 17-27.	2.8	17
910	Nucleotide and nucleoside involvement in immunomodulation in experimental Chagas disease. <i>Molecular and Cellular Biochemistry</i> , 2018, 447, 203-208.	3.1	1
911	Trypanosoma Species (Trypanosomiasis). , 2018, , 1366-1373.e2.		0
912	The role of HLA in parasitic diseases. <i>Hla</i> , 2018, 91, 255-270.	0.6	20
913	Chagas Disease Recommendations for Solid-Organ Transplant Recipients and Donors. <i>Transplantation</i> , 2018, 102, S1-S7.	1.0	41
914	Parasitic and Protozoal Infections. , 2018, , 271-294.		0
915	Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 419-430.	9.1	214
916	What to expect and when: benznidazole toxicity in chronic Chagas [™] disease treatment. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1060-1067.	3.0	57
917	Neuropathies of Infectious Origin. , 2018, , 357-368.		0

#	ARTICLE	IF	CITATIONS
918	Tropical medicine and anaesthesia 1. BJA Education, 2018, 18, 35-40.	1.4	1
919	Recommendations for Multimodality Cardiac Imaging in Patients with Chagas Disease: A Report from the American Society of Echocardiography in Collaboration With the InterAmerican Association of Echocardiography (ECOSIAC) and the Cardiovascular Imaging Department of the Brazilian Society of Cardiology (DIC-SBC). Journal of the American Society of Echocardiography, 2018, 31, 3-25.	2.8	50
920	Adaptations in energy metabolism and gene family expansions revealed by comparative transcriptomics of three Chagas disease triatomine vectors. BMC Genomics, 2018, 19, 296.	2.8	12
921	Detection and genotyping of Trypanosoma cruzi from aÃ§ai products commercialized in Rio de Janeiro and ParÃ¡, Brazil. Parasites and Vectors, 2018, 11, 233.	2.5	22
922	Miscellaneous Vector-Borne Diseases. , 2018, , 173-195.		0
923	Leveraging the cruzain S3 subsite to increase affinity for reversible covalent inhibitors. Bioorganic Chemistry, 2018, 79, 285-292.	4.1	20
924	Multi-kinetic release of benzimidazole-loaded multiparticulate drug delivery systems based on polymethacrylate interpolyelectrolyte complexes. European Journal of Pharmaceutical Sciences, 2018, 120, 107-122.	4.0	20
925	Infectious myocarditis: the role of the cardiac vasculature. Heart Failure Reviews, 2018, 23, 583-595.	3.9	31
926	Mast Cells and Serotonin Synthesis Modulate Chagas Disease in the Colon: Clinical and Experimental Evidence. Digestive Diseases and Sciences, 2018, 63, 1473-1484.	2.3	10
927	Enolase from Trypanosoma cruzi is inhibited by its interaction with metalloprotease-1 and a putative acireductone dioxygenase. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2018, 1866, 651-660.	2.3	4
928	The severity of ventricular arrhythmia correlates with the extent of myocardial sympathetic denervation, but not with myocardial fibrosis extent in chronic Chagas cardiomyopathy. Journal of Nuclear Cardiology, 2018, 25, 75-83.	2.1	28
929	Rapidly progressive course of Trypanosoma cruzi infection in mice heterozygous for hexamethylene bis-acetamide inducible 1 (Hexim1) gene. Microbes and Infection, 2018, 20, 25-36.	1.9	3
930	Identification of Structure-Stabilizing Interactions in Enzymes: A Novel Mechanism to Impact Enzyme Activity. Cell Biochemistry and Biophysics, 2018, 76, 59-71.	1.8	1
931	From Lemongrass to Ivermectin: Ethnomedical Management of Chagas Disease in Tropical Bolivia. Medical Anthropology: Cross Cultural Studies in Health and Illness, 2018, 37, 236-252.	1.2	15
932	Design of prospective antiparasitic metal-based compounds including selected organometallic cores. Inorganica Chimica Acta, 2018, 472, 58-75.	2.4	52
933	Survey of Pediatric Infectious Diseases Society Members About Congenital Chagas Disease. Pediatric Infectious Disease Journal, 2018, 37, e24-e27.	2.0	25
934	Trypanosoma cruzi Infection Does Not Decrease Survival or Reproduction of the Common Bed Bug, Cimex lectularius. American Journal of Tropical Medicine and Hygiene, 2018, 98, 724-734.	1.4	4
935	Congenital and Blood Transfusion Transmission of Chagas Disease: A Framework Using Mathematical Modeling. Complexity, 2018, 2018, 1-10.	1.6	1

#	ARTICLE	IF	CITATIONS
936	Chagas Disease Cardiomyopathy. International Journal of Cardiovascular Sciences, 2018, , .	0.1	15
937	PIK3CA mutations are frequent in esophageal squamous cell carcinoma associated with chagasic megaesophagus and are associated with a worse patient outcome. Infectious Agents and Cancer, 2018, 13, 43.	2.6	16
938	Ruthenium-catalyzed C=C oxygenation of quinones by weak O-coordination for potent trypanocidal agents. Chemical Communications, 2018, 54, 12840-12843.	4.1	48
939	Sudden Death Circadian Rhythm in Chagasic Patients Compared to Non-Chagasic Patients. , 0, , .		0
940	Coinfection of and Leishmania spp. in Synanthropic Reservoirs (Canis familiaris) in an Endemic Area of The State of Quer�taro, Use of FeSODe as an Antigenic Tool. Journal of Preventive Medicine, 2018, 03, .	0.4	1
941	Transmitter Insect of Chagas Disease in Northwest Mexico: A Comparative Study of the Cuticular Hydrocarbons Profile of Three Populations of Triatoma rubida: Peridomestic, Domestic and Sylvatic. , 0, , .		0
942	Efficacy and Safety of Chagas Disease Drug Therapy and Treatment Perspectives. , 0, , .		6
943	Early Detection of Chronic Asymptomatic Chagas Infection. Medical Science Monitor, 2018, 24, 4567-4571.	1.1	6
944	Cardiac Evaluation in the Acute Phase of Chagas' Disease with Post-Treatment Evolution in Patients Attended in the State of Amazonas, Brazil. Arquivos Brasileiros De Cardiologia, 2018, 112, 240-246.	0.8	12
945	A decade of vector control activities: Progress and limitations of Chagas disease prevention in a region of Guatemala with persistent Triatoma dimidiata infestation. PLoS Neglected Tropical Diseases, 2018, 12, e0006896.	3.0	12
946	Left Ventricular Scar and Prognosis in Chronic Chagas Cardiomyopathy. Journal of the American College of Cardiology, 2018, 72, 2567-2576.	2.8	46
947	Discovery of Non-Peptidic Compounds against Chagas Disease Applying Pharmacophore Guided Molecular Modelling Approaches. Molecules, 2018, 23, 3054.	3.8	3
948	Host-Directed Drug Therapies for Neglected Tropical Diseases Caused by Protozoan Parasites. Frontiers in Microbiology, 2018, 9, 2655.	3.5	45
949	Renal dysfunction in Leishmaniasis and Chagas disease coinfection: a case report. Revista Do Instituto De Medicina Tropical De Sao Paulo, 2018, 60, e73.	1.1	5
950	Triatomines: Trypanosomatids, Bacteria, and Viruses Potential Vectors?. Frontiers in Cellular and Infection Microbiology, 2018, 8, 405.	3.9	31
951	Exploring the parasite load and molecular diversity of Trypanosoma cruzi in patients with chronic Chagas disease from different regions of Brazil. PLoS Neglected Tropical Diseases, 2018, 12, e0006939.	3.0	44
952	The economic value of identifying and treating Chagas disease patients earlier and the impact on Trypanosoma cruzi transmission. PLoS Neglected Tropical Diseases, 2018, 12, e0006809.	3.0	32
953	Chagas disease. JAAPA: Official Journal of the American Academy of Physician Assistants, 2018, 31, 30-33.	0.3	14

#	ARTICLE	IF	CITATIONS
954	Canine Trypanosoma cruzi infection in the Bolivian Chaco. Parasites and Vectors, 2018, 11, 632.	2.5	8
955	Implementation science: Epidemiology and feeding profiles of the Chagas vector Triatoma dimidiata prior to Ecohealth intervention for three locations in Central America. PLoS Neglected Tropical Diseases, 2018, 12, e0006952.	3.0	18
956	Detecting the Prevalence of Chagas Disease among People Living with HIV/AIDS in Los Angeles County, California. Journal of Tropical Diseases, 2018, 06, .	0.1	1
957	Integrating evidence, models and maps to enhance Chagas disease vector surveillance. PLoS Neglected Tropical Diseases, 2018, 12, e0006883.	3.0	12
958	Trypanosoma cruzi infection in naturally infected dogs from an endemic region of Cundinamarca, Colombia. Veterinary Parasitology: Regional Studies and Reports, 2018, 14, 212-216.	0.5	5
959	Health Research Priority Setting: The Duties of Individual Funders. American Journal of Bioethics, 2018, 18, 6-17.	0.9	29
960	Dysregulated Network of Immune, Endocrine and Metabolic Markers is Associated to More Severe Human Chronic Chagas Cardiomyopathy. NeuroImmunoModulation, 2018, 25, 119-128.	1.8	23
961	Effect of a new anti-T. cruzi metallic compound based on palladium. BioMetals, 2018, 31, 961-974.	4.1	15
962	Autoimmunity in Chronic Chagas Disease: A Road of Multiple Pathways to Cardiomyopathy?. Frontiers in Immunology, 2018, 9, 1842.	4.8	44
963	Isosorbide and nifedipine for Chagas' megaesophagus: A systematic review and meta-analysis. PLoS Neglected Tropical Diseases, 2018, 12, e0006836.	3.0	8
964	Congenital Chagas disease: current diagnostics, limitations and future perspectives. Current Opinion in Infectious Diseases, 2018, 31, 415-421.	3.1	52
965	Involvement of neutrophils in Chagas disease pathology. Parasite Immunology, 2018, 40, e12593.	1.5	11
966	Conserved epitopes in variants of amastin protein of Trypanosoma cruzi for vaccine design: A bioinformatics approach. Microbial Pathogenesis, 2018, 125, 423-430.	2.9	5
967	Novel Therapies for Relapsed and Refractory Neuroblastoma. Children, 2018, 5, 148.	1.5	34
968	Relevance of Trypanothione Reductase Inhibitors on <i>Trypanosoma cruzi</i> Infection: A Systematic Review, Meta-Analysis, and In Silico Integrated Approach. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-20.	4.0	16
969	Diagnosis and Management of Chagas Cardiomyopathy in the United States. Current Cardiology Reports, 2018, 20, 131.	2.9	13
970	Purinergic Antagonist Suramin Aggravates Myocarditis and Increases Mortality by Enhancing Parasitism, Inflammation, and Reactive Tissue Damage in <i>Trypanosoma cruzi</i> -Infected Mice. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-11.	4.0	9
971	Spatial prediction of risk areas for vector transmission of Trypanosoma cruzi in the State of Paraná, southern Brazil. PLoS Neglected Tropical Diseases, 2018, 12, e0006907.	3.0	15

#	ARTICLE	IF	CITATIONS
972	Trypanocidal Activity of Natural Sesquiterpenoids Involves Mitochondrial Dysfunction, ROS Production and Autophagic Phenotype in <i>Trypanosoma cruzi</i> . <i>Molecules</i> , 2018, 23, 2800.	3.8	21
973	Cardiac surgery for Chagas disease. <i>Journal of Cardiac Surgery</i> , 2018, 33, 597-602.	0.7	3
974	Current Screening Methodologies in Drug Discovery for Selected Human Diseases. <i>Marine Drugs</i> , 2018, 16, 279.	4.6	73
975	WATER INGESTION DYNAMICS IN PATIENTS WITH ACHALASIA: INFLUENCE OF SEX AND AGE. <i>Arquivos De Gastroenterologia</i> , 2018, 55, 25-29.	0.8	2
976	New heteroleptic oxidovanadium(V) complexes: synthesis, characterization and biological evaluation as potential agents against <i>Trypanosoma cruzi</i> . <i>Journal of Biological Inorganic Chemistry</i> , 2018, 23, 1265-1281.	2.6	17
977	Phospho-proteomic analysis of primary human colon epithelial cells during the early <i>Trypanosoma cruzi</i> infection phase. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006792.	3.0	17
978	Experimental models in Chagas disease: a review of the methodologies applied for screening compounds against <i>Trypanosoma cruzi</i> . <i>Parasitology Research</i> , 2018, 117, 3367-3380.	1.6	16
979	Assessment of genetic mutation frequency induced by oxidative stress in <i>Trypanosoma cruzi</i> . <i>Genetics and Molecular Biology</i> , 2018, 41, 466-474.	1.3	18
980	Early <i>Trypanosoma cruzi</i> Infection Triggers mTORC1-Mediated Respiration Increase and Mitochondrial Biogenesis in Human Primary Cardiomyocytes. <i>Frontiers in Microbiology</i> , 2018, 9, 1889.	3.5	27
981	Oral Versus Intra-gastric Inoculation: Similar Pathways of <i>Trypanosoma cruzi</i> Experimental Infection? From Target Tissues, Parasite Evasion, and Immune Response. <i>Frontiers in Immunology</i> , 2018, 9, 1734.	4.8	10
982	Cardiac Autonomic modulation and long-term use of amiodarone in patients with chronic Chagasic cardiopathy. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2018, 41, 788-798.	1.2	4
983	Genetic Polymorphisms of Manganese-Dependent Superoxide Dismutase in Chagas Disease. <i>Infectious Diseases in Clinical Practice</i> , 2018, 26, 159-164.	0.3	1
984	Chagas Cardiomyopathy: A Comprehensive Perioperative Review. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2018, 32, 2780-2788.	1.3	3
985	Introducing automation to the molecular diagnosis of <i>Trypanosoma cruzi</i> infection: A comparative study of sample treatments, DNA extraction methods and real-time PCR assays. <i>PLoS ONE</i> , 2018, 13, e0195738.	2.5	28
986	Chagas Cardiomyopathy: Evidence in Medical and Nutritional Management. <i>Current Tropical Medicine Reports</i> , 2018, 5, 193-203.	3.7	0
987	Treatment of Chagas Disease in the United States. <i>Current Treatment Options in Infectious Diseases</i> , 2018, 10, 373-388.	1.9	74
988	Barriers to Diagnosis Access for Chagas Disease in Colombia. <i>Journal of Parasitology Research</i> , 2018, 1-14.	1.2	26
989	Autoimmunity and the Paradox of Chagas Disease. , 2018, , 139-147.		1

#	ARTICLE	IF	CITATIONS
990	Chagas Disease. , 2018, , 75-82.		0
991	Scientometrics analysis of research activity and collaboration patterns in Chagas cardiomyopathy. PLoS Neglected Tropical Diseases, 2018, 12, e0006602.	3.0	24
992	A novel nanoluciferase-based system to monitor Trypanosoma cruzi infection in mice by bioluminescence imaging. PLoS ONE, 2018, 13, e0195879.	2.5	30
993	Insect vectors of Chagas disease (Trypanosoma cruzi) in Northeastern Brazil. Revista Da Sociedade Brasileira De Medicina Tropical, 2018, 51, 174-182.	0.9	14
994	2,4-Diamino-6-methylpyrimidines for the potential treatment of Chagasâ€™ disease. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 3025-3030.	2.2	5
995	Development of a Trypanosoma cruzi strain typing assay using MS2 peptide spectral libraries (Tc-STAMS2). PLoS Neglected Tropical Diseases, 2018, 12, e0006351.	3.0	12
996	Imaging the development of chronic Chagas disease after oral transmission. Scientific Reports, 2018, 8, 11292.	3.3	36
997	Impact of benznidazole treatment on the functional response of Trypanosoma cruzi antigen-specific CD4+CD8+ T cells in chronic Chagas disease patients. PLoS Neglected Tropical Diseases, 2018, 12, e0006480.	3.0	20
998	Innate immune receptors over expression correlate with chronic chagasic cardiomyopathy and digestive damage in patients. PLoS Neglected Tropical Diseases, 2018, 12, e0006589.	3.0	19
999	MyD88 activation in cardiomyocytes contributes to the heart immune response to acute Trypanosoma cruzi infection with no effect on local parasite control. PLoS Neglected Tropical Diseases, 2018, 12, e0006617.	3.0	1
1000	Cascade Ligand- and Structure-Based Virtual Screening to Identify New Trypanocidal Compounds Inhibiting Putrescine Uptake. Frontiers in Cellular and Infection Microbiology, 2018, 8, 173.	3.9	22
1001	Extracellular Vesicles Shed By Trypanosoma cruzi Potentiate Infection and Elicit Lipid Body Formation and PGE2 Production in Murine Macrophages. Frontiers in Immunology, 2018, 9, 896.	4.8	38
1002	Circulating Plasma MicroRNA-208a as Potential Biomarker of Chronic Indeterminate Phase of Chagas Disease. Frontiers in Microbiology, 2018, 9, 269.	3.5	31
1003	Regulatory Lymphoid and Myeloid Cells Determine the Cardiac Immunopathogenesis of Trypanosoma cruzi Infection. Frontiers in Microbiology, 2018, 9, 351.	3.5	13
1004	BALB/c and C57BL/6 Mice Cytokine Responses to Trypanosoma cruzi Infection Are Independent of Parasite Strain Infectivity. Frontiers in Microbiology, 2018, 9, 553.	3.5	25
1005	Extracellular Vesicles in Chagas Disease: A New Passenger for an Old Disease. Frontiers in Microbiology, 2018, 9, 1190.	3.5	38
1006	Preclinical pharmacokinetics of benznidazole-loaded interpolyelectrolyte complex-based delivery systems. European Journal of Pharmaceutical Sciences, 2018, 122, 281-291.	4.0	9
1007	Trypanosomatid parasites in Austrian mosquitoes. PLoS ONE, 2018, 13, e0196052.	2.5	18

#	ARTICLE	IF	CITATIONS
1008	Precision Organisms. , 2018, , 181-228.		0
1009	Development of <i>Trypanosoma cruzi</i> in vitro assays to identify compounds suitable for progression in Chagasâ€™ disease drug discovery. PLoS Neglected Tropical Diseases, 2018, 12, e0006612.	3.0	76
1010	Polysaccharides-based multiparticulated interpolyelectrolyte complexes for controlled benznidazole release. International Journal of Pharmaceutics, 2018, 545, 366-377.	5.2	9
1011	Comparative genomics analysis of triatomines reveals common first line and inducible immunity-related genes and the absence of Imd canonical components among hemimetabolous arthropods. Parasites and Vectors, 2018, 11, 48.	2.5	53
1012	<i>Trypanosoma cruzi</i> activates mouse cardiac fibroblasts in vitro leading to fibroblast-myofibroblast transition and increase in expression of extracellular matrix proteins. Parasites and Vectors, 2018, 11, 72.	2.5	14
1013	Assemblages A and B of <i>Giardia duodenalis</i> reduce enteric glial cells in the small intestine in mice. Parasitology Research, 2018, 117, 2025-2033.	1.6	6
1014	Arthropods and Health. , 2018, , 3-26.		1
1015	<i>Trypanosoma cruzi</i> biochemical changes and cell death induced by an organometallic platinum-based compound. Chemical Biology and Drug Design, 2018, 92, 1657-1669.	3.2	21
1016	Chagas Cardiomyopathy: An Update of Current Clinical Knowledge and Management: A Scientific Statement From the American Heart Association. Circulation, 2018, 138, e169-e209.	1.6	315
1017	Synthesis and Biological in vitro and in vivo Evaluation of 2-(5-Nitroindazol-1-yl)ethylamines and Related Compounds as Potential Therapeutic Alternatives for Chagas Disease. ChemMedChem, 2018, 13, 2104-2118.	3.2	14
1018	Anti-serum validation for use in immunohistochemistry for <i>Trypanosoma cruzi</i> detection. Revista Da Sociedade Brasileira De Medicina Tropical, 2018, 51, 467-474.	0.9	5
1019	Bundle branch reentry: A novel mechanism for sustained ventricular tachycardia in Chagas heart disease. HeartRhythm Case Reports, 2018, 4, 293-297.	0.4	7
1020	The effect of temperature increase on the development of <i>Rhodnius prolixus</i> and the course of <i>Trypanosoma cruzi</i> metacyclogenesis. PLoS Neglected Tropical Diseases, 2018, 12, e0006735.	3.0	29
1021	Assessing the partners of the RBP9-mRNP complex in <i>Trypanosoma cruzi</i> using shotgun proteomics and RNA-seq. RNA Biology, 2018, 15, 1-13.	3.1	10
1022	The role of animal grazing in the spread of Chagas disease. Journal of Theoretical Biology, 2018, 457, 19-28.	1.7	16
1023	Proteome-Wide Analysis of <i>Trypanosoma cruzi</i> Exponential and Stationary Growth Phases Reveals a Subcellular Compartment-Specific Regulation. Genes, 2018, 9, 413.	2.4	32
1024	Ecological multiplex interactions determine the role of species for parasite spread amplification. ELife, 2018, 7, .	6.0	10
1025	Chagas disease cardiomyopathy treatment remains a challenge – Authors' reply. Lancet, The, 2018, 391, 2209-2210.	13.7	19

#	ARTICLE	IF	CITATIONS
1026	Beyond O&P Times Three. American Journal of Gastroenterology, 2018, 113, 805-818.	0.4	15
1027	Climate Change and the Neglected Tropical Diseases. Advances in Parasitology, 2018, 100, 39-126.	3.2	65
1028	Second Generation of Mannich Base-Type Derivatives with <i>in Vivo</i> Activity against <i>Trypanosoma cruzi</i> . Journal of Medicinal Chemistry, 2018, 61, 5643-5663.	6.4	32
1029	L-arginine supplementation reduces mortality and improves disease outcome in mice infected with <i>Trypanosoma cruzi</i> . PLoS Neglected Tropical Diseases, 2018, 12, e0006179.	3.0	28
1030	Inhibitors of <i>Trypanosoma cruzi</i> Sir2 related protein 1 as potential drugs against Chagas disease. PLoS Neglected Tropical Diseases, 2018, 12, e0006180.	3.0	10
1031	Evolution, Systematics, and Biogeography of the Triatominae, Vectors of Chagas Disease. Advances in Parasitology, 2018, 99, 265-344.	3.2	112
1032	The protein family TcTASV-C is a novel <i>Trypanosoma cruzi</i> virulence factor secreted in extracellular vesicles by trypomastigotes and highly expressed in bloodstream forms. PLoS Neglected Tropical Diseases, 2018, 12, e0006475.	3.0	19
1033	Haematological alterations in non-human hosts infected with <i>Trypanosoma cruzi</i> : a systematic review. Parasitology, 2019, 146, 142-160.	1.5	5
1034	Inflammation of the Myocardium, Endocardium and Aorta. , 2019, , 187-202.		0
1035	Chagas disease: comments on the 2018 PAHO Guidelines for diagnosis and management. Journal of Travel Medicine, 2019, 26, .	3.0	11
1036	A Parasite Biomarker Set for Evaluating Benznidazole Treatment Efficacy in Patients with Chronic Asymptomatic <i>Trypanosoma cruzi</i> Infection. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	10
1037	Exploring oxidovanadium(<i>scp</i>) homoleptic complexes with 8-hydroxyquinoline derivatives as prospective antitrypanosomal agents. New Journal of Chemistry, 2019, 43, 17756-17773.	2.8	17
1038	Novel [1,2,3]triazolo[1,5-a]pyridine derivatives are trypanocidal by sterol biosynthesis pathway alteration. Future Medicinal Chemistry, 2019, 11, 1137-1155.	2.3	6
1039	Identification of Phenylpyrazolone Dimers as a New Class of Anti- <i>Trypanosoma cruzi</i> Agents. ChemMedChem, 2019, 14, 1662-1668.	3.2	2
1040	Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation. Bioorganic and Medicinal Chemistry, 2019, 27, 3902-3917.	3.0	17
1041	Unveiling the partners of the DRBD2-mRNP complex, an RBP in <i>Trypanosoma cruzi</i> and ortholog to the yeast SR-protein Gbp2. BMC Microbiology, 2019, 19, 128.	3.3	17
1042	Nanocarriers for effective delivery of benznidazole and nifurtimox in the treatment of chagas disease: A review. Acta Tropica, 2019, 198, 105080.	2.0	28
1043	Chagas Disease: From Discovery to a Worldwide Health Problem. Frontiers in Public Health, 2019, 7, 166.	2.7	309

#	ARTICLE	IF	CITATIONS
1044	B-1 Cells May Drive Macrophages Susceptibility to <i>Trypanosoma cruzi</i> Infection. <i>Frontiers in Microbiology</i> , 2019, 10, 1598.	3.5	6
1045	Copper complexes and carbon nanotube-copper ferrite-catalyzed benzenoid A-ring selenation of quinones: an efficient method for the synthesis of trypanocidal agents. <i>New Journal of Chemistry</i> , 2019, 43, 13751-13763.	2.8	27
1046	<i>Trypanosoma cruzi</i> infection in a zoo-housed red panda in Kansas. <i>Journal of Veterinary Diagnostic Investigation</i> , 2019, 31, 752-755.	1.1	8
1047	Carbonic anhydrases from pathogens. , 2019, , 449-475.		3
1048	Could pre-infection exercise training improve the efficacy of specific antiparasitic chemotherapy for Chagas disease?. <i>Parasitology</i> , 2019, 146, 1655-1664.	1.5	2
1049	Betulinic Acid Derivative BA5, Attenuates Inflammation and Fibrosis in Experimental Chronic Chagas Disease Cardiomyopathy by Inducing IL-10 and M2 Polarization. <i>Frontiers in Immunology</i> , 2019, 10, 1257.	4.8	10
1050	Nifurtimox Inhibits the Progression of Neuroblastoma <i>in vivo</i> . <i>Journal of Cancer</i> , 2019, 10, 2194-2204.	2.5	6
1051	Physical training improves exercise tolerance, cardiac function and promotes changes in neurotrophins levels in chagasic mice. <i>Life Sciences</i> , 2019, 232, 116629.	4.3	12
1052	Lineage-specific rapid diagnostic tests can resolve <i>Trypanosoma cruzi</i> TcII/VI ecological and epidemiological associations in the Argentine Chaco. <i>Parasites and Vectors</i> , 2019, 12, 424.	2.5	15
1053	Nitroheterocyclic derivatives: privileged scaffold for drug development against Chagas disease. <i>Medicinal Chemistry Research</i> , 2019, 28, 2099-2108.	2.4	14
1055	Ventricular arrhythmias in the Chagas disease are not random phenomena: Long-term monitoring in Chagas arrhythmias. <i>Journal of Cardiovascular Electrophysiology</i> , 2019, 30, 2370-2376.	1.7	4
1056	Orthotopic cardiac transplantation for Chagas cardiomyopathy in Australia. <i>Internal Medicine Journal</i> , 2019, 49, 1194-1195.	0.8	0
1057	Parasitic Diseases Within the Spinal Cord and Nerve Roots. <i>SN Comprehensive Clinical Medicine</i> , 2019, 1, 869-881.	0.6	0
1058	<i>Trypanosoma cruzi</i> infection associated with atypical clinical manifestation during the acute phase of the Chagas disease. <i>Parasites and Vectors</i> , 2019, 12, 506.	2.5	12
1059	Genetic structure of the Chagas disease vector <i>Triatoma infestans</i> (Hemiptera: Reduviidae) based on nuclear and mitochondrial DNA sequences. <i>Zoological Journal of the Linnean Society</i> , 0, , .	2.3	3
1060	Chagas Disease Drug Discovery: Multiparametric Lead Optimization against <i>Trypanosoma cruzi</i> in Acylaminobenzothiazole Series. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 10362-10375.	6.4	11
1061	Chagasic Megaesophagus-Associated Carcinoma: Clinical Pattern and Outcomes. <i>Journal of Global Oncology</i> , 2019, 5, 1-5.	0.5	4
1062	Chagas Disease. <i>Birkhauser Advances in Infectious Diseases</i> , 2019, , .	0.3	7

#	ARTICLE	IF	CITATIONS
1063	Diminished Prolinemia in Chronic Chagasic Patients: A New Clue for Disease Pathology?. <i>Molecules</i> , 2019, 24, 3167.	3.8	1
1064	The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by <i>Trypanosoma cruzi</i> . <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007226.	3.0	6
1065	Condensation and substitution products obtained in reactions of isomeric bromo-nitrofurals with ferrocenylamine: Electrochemistry and anti-parasitic evaluation. <i>Journal of Organometallic Chemistry</i> , 2019, 901, 120946.	1.8	8
1066	Comparative evaluation of immunoassays to improve access to diagnosis for Chagas disease in Colombia. <i>International Journal of Infectious Diseases</i> , 2019, 87, 100-108.	3.3	13
1067	Nanomedicine strategies for addressing major needs in neglected tropical diseases. <i>Annual Reviews in Control</i> , 2019, 48, 423-441.	7.9	10
1068	In vitro activities of adamantylidene-substituted alkylphosphocholine TCAN26 against <i>Trypanosoma cruzi</i> : Antiproliferative and ultrastructural effects. <i>Experimental Parasitology</i> , 2019, 206, 107730.	1.2	4
1069	IL-17A, a possible biomarker for the evaluation of treatment response in <i>Trypanosoma cruzi</i> infected children: A 12-months follow-up study in Bolivia. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007715.	3.0	6
1070	Proposed multidimensional framework for understanding Chagas disease healthcare barriers in the United States. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007447.	3.0	33
1071	Echocardiographic Measurements in a Preclinical Model of Chronic Chagasic Cardiomyopathy in Dogs: Validation and Reproducibility. <i>Frontiers in Cellular and Infection Microbiology</i> , 2019, 9, 332.	3.9	12
1072	Insights into Ergosterol Peroxide's Trypanocidal Activity. <i>Biomolecules</i> , 2019, 9, 484.	4.0	9
1073	Neuroimaging of Emergent and Reemergent Infections. <i>Radiographics</i> , 2019, 39, 1649-1671.	3.3	29
1074	Trypanocidal Trikingolides From <i>Trixis Vauthieri</i> . <i>Natural Product Research</i> , 2019, 35, 1-9.	1.8	2
1075	American Trypanosomiasis (Chagas Disease). <i>Infectious Disease Clinics of North America</i> , 2019, 33, 119-134.	5.1	145
1077	Characterization of Evolutionarily Conserved <i>Trypanosoma cruzi</i> NatC and NatA-N-Terminal Acetyltransferase Complexes. <i>Journal of Parasitology Research</i> , 2019, 2019, 1-11.	1.2	3
1078	Heterogeneity of <i>Trypanosoma cruzi</i> infection rates in vectors and animal reservoirs in Colombia: a systematic review and meta-analysis. <i>Parasites and Vectors</i> , 2019, 12, 308.	2.5	13
1079	Nanopore Sequencing Significantly Improves Genome Assembly of the Protozoan Parasite <i>Trypanosoma cruzi</i> . <i>Genome Biology and Evolution</i> , 2019, 11, 1952-1957.	2.5	38
1080	ACAT-1 gene rs1044925 SNP and its relation with different clinical forms of chronic Chagas disease. <i>Parasitology Research</i> , 2019, 118, 2343-2351.	1.6	5
1081	Drug-induced Injury, Infections, and Congenital and Miscellaneous Disorders. , 2019, , 81-118.		0

#	ARTICLE	IF	CITATIONS
1082	Eukaryotes. , 2019, , 121-168.		0
1083	Drug transporter and oxidative stress gene expression in human macrophages infected with benznidazole-sensitive and naturally benznidazole-resistant <i>Trypanosoma cruzi</i> parasites treated with benznidazole. <i>Parasites and Vectors</i> , 2019, 12, 262.	2.5	7
1084	A therapeutic vaccine prototype induces protective immunity and reduces cardiac fibrosis in a mouse model of chronic <i>Trypanosoma cruzi</i> infection. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007413.	3.0	40
1085	Oral Route Driven Acute <i>Trypanosoma cruzi</i> Infection Unravels an IL-6 Dependent Hemostatic Derangement. <i>Frontiers in Immunology</i> , 2019, 10, 1073.	4.8	14
1086	Comparison of the amount and patterns of late enhancement in Chagas disease according to the presence and type of ventricular tachycardia. <i>Journal of Cardiovascular Electrophysiology</i> , 2019, 30, 1517-1525.	1.7	5
1087	Cultural perception of triatomine bugs and Chagas disease in Bolivia: a cross-sectional field study. <i>Parasites and Vectors</i> , 2019, 12, 291.	2.5	24
1088	Mitochondrial genomes of three kissing bugs (Reduviidae: Triatominae) and their phylogenetic implications. <i>International Journal of Biological Macromolecules</i> , 2019, 134, 36-42.	7.5	19
1089	The neuropeptide CCHamide 2 regulates diuresis in the Chagasâ€™ disease vector <i>Rhodnius prolixus</i> . <i>Journal of Experimental Biology</i> , 2019, 222, .	1.7	14
1090	Economic value of a therapeutic Chagas vaccine for indeterminate and Chagasic cardiomyopathy patients. <i>Vaccine</i> , 2019, 37, 3704-3714.	3.8	12
1091	T-Cell Immunophenotyping and Cytokine Production Analysis in Patients with Chagas Disease 4 Years after Benznidazole Treatment. <i>Infection and Immunity</i> , 2019, 87, .	2.2	10
1092	Human collectin-11 (COLEC11) and its synergic genetic interaction with MASP2 are associated with the pathophysiology of Chagas Disease. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007324.	3.0	7
1093	Systematic Review of the Epidemiology of Chagas Disease in the Americas: a Call for Standardized Reporting of Chagas Disease Prevalence. <i>Current Tropical Medicine Reports</i> , 2019, 6, 23-34.	3.7	8
1094	Plant-derived compounds against protozoan neglected diseases: toward sustainable drug development. , 2019, , 241-292.		3
1095	Impact of levamisole in co-administration with benznidazole on experimental Chagas disease. <i>Parasitology</i> , 2019, 146, 1055-1062.	1.5	7
1096	Natural and synthetic quinoline molecules against tropical parasitic pathologies: an analysis of activity and structural evolution for developing new quinoline-based antiprotozoal agents. , 2019, , 87-164.		6
1097	Evaluation and Management of Congenital Chagas Disease in the United States. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2019, 8, 461-469.	1.3	29
1098	<i>Trypanosoma cruzi</i> : A review of biological and methodological factors in Mexican strains. <i>Acta Tropica</i> , 2019, 195, 51-57.	2.0	18
1099	Medical Proof of Evolution. , 2019, , 307-327.		0

#	ARTICLE	IF	CITATIONS
1100	Tissue and blood protozoa including toxoplasmosis, Chagas disease, leishmaniasis, <i>Babesia</i>, <i>Acanthamoeba</i>, <i>Balamuthia</i>, and <i>Naegleria</i> in solid organ transplant recipientsâ€™ Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clinical Transplantation</i> , 2019, 33, e13546.	1.6	79
1101	Isolation and Phenotypic Characterization of Inflammatory Cells from Clinical Samples: Purification of Macrophages from <i>Trypanosoma cruzi</i> -Infected Hearts. <i>Methods in Molecular Biology</i> , 2019, 1955, 381-395.	0.9	3
1103	Drug Repurposing in Search of Anti-Infectives: Need of the Hour in the Multidrug Resistance Era!. , 2019, , 399-426.		3
1104	Development of a motion-based cell-counting system for <i>Trypanosoma</i> parasite using a pattern recognition approach. <i>BioTechniques</i> , 2019, 66, 179-185.	1.8	3
1105	Predictors of mortality and heart transplantation in patients with Chagasâ€™ cardiomyopathy and ventricular tachycardia treated with implantable cardioverter-defibrillators. <i>Europace</i> , 2019, 21, 1070-1078.	1.7	7
1106	A prophylactic Î±-Gal-based glycovaccine effectively protects against murine acute Chagas disease. <i>Npj Vaccines</i> , 2019, 4, 13.	6.0	40
1107	The Esophageal Microbiome. , 2019, , 1-16.		0
1108	Characterization of digestive disorders of patients with chronic Chagas disease in Cochabamba, Bolivia. <i>Heliyon</i> , 2019, 5, e01206.	3.2	11
1109	Repurposing strategies for Chagas disease therapy: the effect of imatinib and derivatives against <i>Trypanosoma cruzi</i>. <i>Parasitology</i> , 2019, 146, 1006-1012.	1.5	25
1110	The fecal, oral, and skin microbiota of children with Chagas disease treated with benznidazole. <i>PLoS ONE</i> , 2019, 14, e0212593.	2.5	21
1111	Chagas screening and treatment among Bolivians living in Madrid, Spain: The need for an official protocol. <i>PLoS ONE</i> , 2019, 14, e0213577.	2.5	22
1112	Infection by <i>Trypanosoma cruzi</i> in the central nervous system in non-human mammals: a systematic review. <i>Parasitology</i> , 2019, 146, 983-1005.	1.5	3
1113	MicroRNA Transcriptome Profiling in Heart of <i>Trypanosoma cruzi</i> -Infected Mice. <i>Methods in Molecular Biology</i> , 2019, 1955, 203-214.	0.9	4
1114	A new level of complexity in parasite-host interaction: The role of extracellular vesicles. <i>Advances in Parasitology</i> , 2019, 104, 39-112.	3.2	25
1115	Estimating the current burden of Chagas disease in Mexico: A systematic review and meta-analysis of epidemiological surveys from 2006 to 2017. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0006859.	3.0	46
1116	A review on the occurrence of companion vector-borne diseases in pet animals in Latin America. <i>Parasites and Vectors</i> , 2019, 12, 145.	2.5	80
1117	Low-Level Parasite Persistence Drives Vasculitis and Myositis in Skeletal Muscle of Mice Chronically Infected with <i>Trypanosoma cruzi</i> . <i>Infection and Immunity</i> , 2019, 87, .	2.2	13
1119	Rassi Score. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1734-1735.	2.8	4

#	ARTICLE	IF	CITATIONS
1120	Reactive species and pathogen antioxidant networks during phagocytosis. <i>Journal of Experimental Medicine</i> , 2019, 216, 501-516.	8.5	67
1121	Progression of Baseline Electrocardiogram Abnormalities in Chagas Patients Undergoing Antitrypanosomal Treatment. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz012.	0.9	8
1122	Nanoparticulate drug delivery systems for the treatment of neglected tropical protozoan diseases. <i>Journal of Venomous Animals and Toxins Including Tropical Diseases</i> , 2019, 25, e144118.	1.4	33
1124	First report of family clusters of Chagas disease seropositive blood donors in Mexico City and their epidemiological relevance. <i>Acta Tropica</i> , 2019, 193, 23-30.	2.0	3
1125	Spatio-temporal characterization of <i>Trypanosoma cruzi</i> infection and discrete typing units infecting hosts and vectors from non-domestic foci of Chile. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007170.	3.0	20
1126	Chagas Cardiomyopathy in Latin America Review. <i>Current Cardiology Reports</i> , 2019, 21, 8.	2.9	28
1127	<i>Trypanosoma cruzi</i> Infection: Mechanisms of Evasion of Immune Response. , 2019, , .		1
1128	Duration and determinants of Chagas latency. <i>JB I Database of Systematic Reviews and Implementation Reports</i> , 2019, 17, 2122-2128.	1.7	3
1129	13. Metal Compounds in the Development of Antiparasitic Agents: Rational Design from Basic Chemistry to the Clinic. , 2019, 19, 331-358.		5
1130	Life Cycle of <i>Trypanosoma cruzi</i> in the Invertebrate and the Vertebrate Hosts. , 0, , .		7
1131	MOLECULAR FRACTIONATION WITH CONJUGATE CAPS STUDY OF THE INTERACTION OF THE ANACARDIC ACID WITH THE ACTIVE SITE OF <i>TRYPANOSOMA CRUZI</i> GAPDH ENZYME: A QUANTUM INVESTIGATION. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 2019, , 183-189.	0.3	1
1132	Alteration of the aggregation and spatial organization of the vector of Chagas disease, <i>Triatoma infestans</i> , by the parasite <i>Trypanosoma cruzi</i> . <i>Scientific Reports</i> , 2019, 9, 17432.	3.3	9
1133	Exoproteome profiling of <i>Trypanosoma cruzi</i> during amastigogenesis early stages. <i>PLoS ONE</i> , 2019, 14, e0225386.	2.5	6
1134	Possible Role of Gap Junction Channels and Non-Junctional Channels in the Infection Caused by <i>Trypanosoma cruzi</i> . , 0, , .		0
1135	The senseless orphanage of Chagas disease. <i>Expert Opinion on Orphan Drugs</i> , 2019, 7, 535-545.	0.8	6
1136	Cardiac Chagas Disease: MMPs, TIMPs, Galectins, and TGF- β as Tissue Remodelling Players. <i>Disease Markers</i> , 2019, 2019, 1-10.	1.3	12
1137	Using evidence from hair and other soft tissues to infer the need for and receipt of health-related care provision. <i>International Journal of Paleopathology</i> , 2019, 25, 91-98.	1.4	1
1138	The Skiles Mummy: Care of a debilitated hunter-gatherer evidenced by coprolite studies and stable isotopic analysis of hair. <i>International Journal of Paleopathology</i> , 2019, 25, 82-90.	1.4	11

#	ARTICLE	IF	CITATIONS
1139	A systematic review of the <i>Trypanosoma cruzi</i> genetic heterogeneity, host immune response and genetic factors as plausible drivers of chronic chagasic cardiomyopathy. <i>Parasitology</i> , 2019, 146, 269-283.	1.5	20
1140	High Throughput and Computational Repurposing for Neglected Diseases. <i>Pharmaceutical Research</i> , 2019, 36, 27.	3.5	37
1141	New polyamine drugs as more effective antichagas agents than benznidazole in both the acute and chronic phases. <i>European Journal of Medicinal Chemistry</i> , 2019, 164, 27-46.	5.5	14
1142	Drug Target Selection for <i>Trypanosoma cruzi</i> Metabolism by Metabolic Control Analysis and Kinetic Modeling. <i>Current Medicinal Chemistry</i> , 2019, 26, 6652-6671.	2.4	11
1143	The role of myeloid-derived suppressor cells in chronic infectious diseases and the current methodology available for their study. <i>Journal of Leukocyte Biology</i> , 2019, 105, 857-872.	3.3	22
1144	Thiazole, thio and semicarbazone derivatives against tropical infective diseases: Chagas disease, human African trypanosomiasis (HAT), leishmaniasis, and malaria. <i>European Journal of Medicinal Chemistry</i> , 2019, 162, 378-395.	5.5	48
1145	Mitochondrial dysfunction and ROS production are essential for anti- <i>Trypanosoma cruzi</i> activity of β -lapachone-derived naphthoimidazoles. <i>Free Radical Biology and Medicine</i> , 2019, 130, 408-418.	2.9	32
1146	Effects of Trypanocidal Treatment on Echocardiographic Parameters in Chagas Cardiomyopathy and Prognostic Value of Wall Motion Score Index: A BENEFIT Trial Echocardiographic Substudy. <i>Journal of the American Society of Echocardiography</i> , 2019, 32, 286-295.e3.	2.8	21
1147	Ruthenium(II)-Catalyzed C-H Alkenylation of Quinones: Diversity-Oriented Strategy for Trypanocidal Compounds. <i>European Journal of Organic Chemistry</i> , 2019, 2019, 2344-2353.	2.4	25
1148	Prevalence of Chagas disease in Colombia: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2019, 14, e0210156.	2.5	37
1149	Pathogenesis of Chagas Disease: an Emphasis for Transplant Patient Populations. <i>Current Tropical Medicine Reports</i> , 2019, 6, 1-7.	3.7	2
1150	<i>Trypanosoma cruzi</i> Neurotrophic Factor Facilitates Cardiac Repair in a Mouse Model of Chronic Chagas Disease. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 368, 11-20.	2.5	2
1151	<i>Trypanosoma cruzi</i> in a Mexican Free-Tailed Bat (<i>Tadarida brasiliensis</i>) in Oklahoma, USA. <i>Journal of Wildlife Diseases</i> , 2019, 55, 444.	0.8	7
1152	A step towards development of promising trypanocidal agents: Synthesis, characterization and <i>in vitro</i> biological evaluation of ferrocenyl Mannich base-type derivatives. <i>European Journal of Medicinal Chemistry</i> , 2019, 163, 569-582.	5.5	11
1153	Seroprevalence and geographical distribution of sero-positive blood donors to <i>Trypanosoma cruzi</i> at the central blood bank of the National Medical Center "La Raza". <i>Transfusion</i> , 2019, 59, 639-647.	1.6	4
1154	Seroprevalence of <i>Trypanosoma cruzi</i> infection among at-risk blood donors in Japan. <i>Transfusion</i> , 2019, 59, 287-294.	1.6	9
1155	Spatial analysis of dengue, cysticercosis and Chagas disease mortality in Ecuador, 2011-2016. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2019, 113, 44-47.	1.8	5
1156	Trypomastigote Excretory Secretory Antigen Blot Is Associated With <i>Trypanosoma cruzi</i> Load and Detects Congenital <i>T. cruzi</i> Infection in Neonates, Using Anti-Shed Acute Phase Antigen Immunoglobulin M. <i>Journal of Infectious Diseases</i> , 2019, 219, 609-618.	4.0	13

#	ARTICLE	IF	CITATIONS
1157	Trypanosomes. , 2019, , .		0
1158	The Burden of Pulmonary Hypertension in Resource-Limited Settings. <i>Global Heart</i> , 2014, 9, 297.	2.3	17
1159	Relationship between microvascular changes, autonomic denervation, and myocardial fibrosis in Chagas cardiomyopathy: Evaluation by MRI and SPECT imaging. <i>Journal of Nuclear Cardiology</i> , 2020, 27, 434-444.	2.1	16
1160	American Trypanosomiasis (Chagas Disease). , 2020, , 762-775.		10
1161	O-geranylchalcones: synthesis and metabolic inhibition against <i>Leishmania mexicana</i> and <i>Trypanosoma cruzi</i> . <i>Medicinal Chemistry Research</i> , 2020, 29, 156-165.	2.4	2
1162	In vitro models for investigation of the host-parasite interface - possible applications in acute Chagas disease. <i>Acta Tropica</i> , 2020, 202, 105262.	2.0	11
1163	A Latin American Patient With a Left Ventricular Pseudoaneurysm Presenting With Progressive Dyspnea and Palpitations. <i>American Journal of Medicine</i> , 2020, 133, e180-e182.	1.5	0
1164	($\hat{\pm}$)-Licarin A and its semi-synthetic derivatives: In vitro and in silico evaluation of trypanocidal and schistosomicidal activities. <i>Acta Tropica</i> , 2020, 202, 105248.	2.0	16
1165	Structure-activity relationship of 4-azaindole-2-piperidine derivatives as agents against <i>Trypanosoma cruzi</i> . <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 126779.	2.2	6
1166	<i>Trypanosoma cruzi</i> cleaves galectin-3 N-terminal domain to suppress its innate microbicidal activity. <i>Clinical and Experimental Immunology</i> , 2020, 199, 216-229.	2.6	3
1167	A Spirit of Trust: A Reading of Hegel's Phenomenology , by Robert Brandom. <i>Mind</i> , 2020, 129, 990-999.	0.6	1
1168	Impact of pharmaceutical care on the quality of life of patients with heart failure due to chronic Chagas disease: Randomized clinical trial. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 143-154.	2.4	15
1169	MicroRNAs: Biological Regulators in Pathogen-Host Interactions. <i>Cells</i> , 2020, 9, 113.	4.1	61
1170	Immune-neuroendocrine and metabolic disorders in human and experimental <i>T. cruzi</i> infection: New clues for understanding Chagas disease pathology. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2020, 1866, 165642.	3.8	9
1171	Economic costs of Chagas disease in Colombia in 2017: A social perspective. <i>International Journal of Infectious Diseases</i> , 2020, 91, 196-201.	3.3	24
1172	Update on Chagas disease in Venezuela during the period 2003-2018. A review. <i>Acta Tropica</i> , 2020, 203, 105310.	2.0	22
1173	Detecting sequence variants in clinically important protozoan parasites. <i>International Journal for Parasitology</i> , 2020, 50, 1-18.	3.1	2
1174	Gene expression profiling of <i>Trypanosoma cruzi</i> in the presence of heme points to glycosomal metabolic adaptation of epimastigotes inside the vector. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0007945.	3.0	9

#	ARTICLE	IF	CITATIONS
1175	PATHOLOGY AND DISCRETE TYPING UNIT ASSOCIATIONS OF TRYPANOSOMA CRUZI INFECTION IN COYOTES (CANIS LATRANS) AND RACCOONS (PROCYON LOTOR) OF TEXAS, USA. <i>Journal of Wildlife Diseases</i> , 2020, 56, 134.	0.8	13
1176	Tolerance to nifurtimox and benznidazole in adult patients with chronic Chagasâ€™ disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 690-696.	3.0	41
1177	Renin angiotensin system molecules and nitric oxide local interactions in the adrenal gland of <i>Trypanosoma cruzi</i> infected rats. <i>Parasitology Research</i> , 2020, 119, 333-337.	1.6	2
1178	Geographic distribution of <i>Trypanosoma cruzi</i> genotypes detected in chronic infected people from Argentina. Association with climatic variables and clinical manifestations of Chagas disease. <i>Infection, Genetics and Evolution</i> , 2020, 78, 104128.	2.3	10
1179	A Fluorinated Phenylbenzothiazole Arrests the <i>Trypanosoma cruzi</i> Cell Cycle and Diminishes the Infection of Mammalian Host Cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	9
1180	New perspectives for hydrogen peroxide in the amastigogenesis of <i>Trypanosoma cruzi</i> in vitro. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2020, 1866, 165951.	3.8	8
1181	Contributions of molecular techniques in the chronic phase of Chagas disease in the absence of treatment. <i>Enfermedades Infecciosas Y Microbiologia Clinica (English Ed)</i> , 2020, 38, 356-360.	0.3	3
1182	NOD2 receptor is crucial for protecting against the digestive form of Chagas disease. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008667.	3.0	3
1183	Radionuclide esophageal transit scintigraphy in chronic indeterminate and cardiac forms of Chagas disease. <i>Nuclear Medicine Communications</i> , 2020, 41, 510-516.	1.1	1
1184	Chagas Disease: Current View of an Ancient and Global Chemotherapy Challenge. <i>ACS Infectious Diseases</i> , 2020, 6, 2830-2843.	3.8	17
1185	Plasma-Derived Extracellular Vesicles as Potential Biomarkers in Heart Transplant Patient with Chronic Chagas Disease. <i>Emerging Infectious Diseases</i> , 2020, 26, 1846-1851.	4.3	11
1186	Presence of Acute Chagas Disease Among Febrile Patients in the Western Coast of Mexico. <i>Vector-Borne and Zoonotic Diseases</i> , 2020, 20, 657-663.	1.5	0
1187	Clinical Presentations of Chagas Cardiomyopathy. <i>Case Reports in Cardiology</i> , 2020, 2020, 1-4.	0.2	0
1188	Fragment-Based Identification of Ligands for Bromodomain-Containing Factor 3 of <i>Trypanosoma cruzi</i> . <i>ACS Infectious Diseases</i> , 2021, 7, 2238-2249.	3.8	14
1189	Host Genetics Background Influence in the Intra-gastric <i>Trypanosoma cruzi</i> Infection. <i>Frontiers in Immunology</i> , 2020, 11, 566476.	4.8	2
1190	Chagas Disease: Perspectives on the Past and Present and Challenges in Drug Discovery. <i>Molecules</i> , 2020, 25, 5483.	3.8	28
1191	Synthesis and biological evaluation in vitro and in silico of N-propionyl-Nâ€™-benzeneacylhydrazone derivatives as cruzain inhibitors of <i>Trypanosoma cruzi</i> . <i>Molecular Diversity</i> , 2020, , 1.	3.9	7
1192	Describing nearly two decades of Chagas disease in Germany and the lessons learned: a retrospective study on screening, detection, diagnosis, and treatment of <i>Trypanosoma cruzi</i> infection from 2000 â€” 2018. <i>BMC Infectious Diseases</i> , 2020, 20, 919.	2.9	14

#	ARTICLE	IF	CITATIONS
1193	The Strong Anti-Kinetoplastid Properties of Bee Propolis: Composition and Identification of the Active Agents and Their Biochemical Targets. <i>Molecules</i> , 2020, 25, 5155.	3.8	7
1194	Oral <i>Trypanosoma cruzi</i> Transmission Resulting in Advanced Chagasic Cardiomyopathy in an 11-Month-Old Male. <i>Case Reports in Infectious Diseases</i> , 2020, 2020, 1-4.	0.5	1
1195	High-Throughput Identification of the <i>Rhodnius prolixus</i> Midgut Proteome Unravels a Sophisticated Hematophagic Machinery. <i>Proteomes</i> , 2020, 8, 16.	3.5	25
1196	Human Chagas-Flow ATE-IgG1 for advanced universal and <i>Trypanosoma cruzi</i> Discrete Typing Units-specific serodiagnosis of Chagas disease. <i>Scientific Reports</i> , 2020, 10, 13296.	3.3	4
1197	Mapping of host-parasite-microbiome interactions reveals metabolic determinants of tropism and tolerance in Chagas disease. <i>Science Advances</i> , 2020, 6, eaaz2015.	10.3	39
1198	The role of imidazole and benzimidazole heterocycles in Chagas disease: A review. <i>European Journal of Medicinal Chemistry</i> , 2020, 206, 112692.	5.5	53
1199	A ferric reductase of <i>Trypanosoma cruzi</i> (TcFR) is involved in iron metabolism in the parasite. <i>Experimental Parasitology</i> , 2020, 217, 107962.	1.2	3
1200	Synthesis and Antitrypanosomal Activity of 1,4-Disubstituted Triazole Compounds Based on a 2-Nitroimidazole Scaffold: a Structure-Activity Relationship Study. <i>ChemMedChem</i> , 2020, 15, 2019-2028.	3.2	6
1201	Antiparasitic Activity of Bromotyrosine Alkaloids and New Analogues Isolated from the Fijian Marine Sponge <i>Aplysinella rha</i> . <i>Chemistry and Biodiversity</i> , 2020, 17, e2000335.	2.1	18
1202	Aportaciones de las técnicas moleculares en la fase crónica de la Enfermedad de Chagas en ausencia de tratamiento. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2020, 38, 356-360.	0.5	5
1203	The <i>Trypanosoma cruzi</i> TcTASV-C protein subfamily administrated with U-Omp19 promotes a protective response against a lethal challenge in mice. <i>Vaccine</i> , 2020, 38, 7645-7653.	3.8	6
1204	Role of FAK signaling in chagasic cardiac hypertrophy. <i>Brazilian Journal of Infectious Diseases</i> , 2020, 24, 386-397.	0.6	7
1205	Interaction of Signaling Lymphocytic Activation Molecule Family 1 (SLAMF1) receptor with <i>Trypanosoma cruzi</i> is strain-dependent and affects NADPH oxidase expression and activity. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008608.	3.0	6
1206	Synthetic and medicinal chemistry of phthalazines: Recent developments, opportunities and challenges. <i>Bioorganic Chemistry</i> , 2020, 105, 104425.	4.1	18
1207	Electrical Storm in Chagasic Cardiomyopathy. <i>JACC: Clinical Electrophysiology</i> , 2020, 6, 1238-1245.	3.2	3
1208	Risk of Chronic Cardiomyopathy Among Patients With the Acute Phase or Indeterminate Form of Chagas Disease. <i>JAMA Network Open</i> , 2020, 3, e2015072.	5.9	41
1209	Identification of blood-feeding sources in <i>Panstrongylus</i> , <i>Psammolestes</i> , <i>Rhodnius</i> and <i>Triatoma</i> using amplicon-based next-generation sequencing. <i>Parasites and Vectors</i> , 2020, 13, 434.	2.5	24
1210	Benznidazole as Prophylaxis for Chagas Disease Infection Reactivation in Heart Transplant Patients: A Case Series in Brazil. <i>Tropical Medicine and Infectious Disease</i> , 2020, 5, 132.	2.3	5

#	ARTICLE	IF	CITATIONS
1211	Development of a New Lateral Flow Assay Based on IBMP-8.1 and IBMP-8.4 Chimeric Antigens to Diagnose Chagas Disease. <i>BioMed Research International</i> , 2020, 2020, 1-9.	1.9	18
1212	<i>Trypanosoma cruzi</i> loop-mediated isothermal amplification (<i>Trypanosoma cruzi</i> Loopamp) kit for detection of congenital, acute and Chagas disease reactivation. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008402.	3.0	24
1213	Gut Dysbiosis in Chagas Disease. A Possible Link to the Pathogenesis. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 402.	3.9	11
1214	<i>Trypanosoma cruzi</i> Modulates PIWI-Interacting RNA Expression in Primary Human Cardiac Myocytes during the Early Phase of Infection. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9439.	4.1	9
1215	Trypanocidal drugs for late-stage, symptomatic Chagas disease (<i>Trypanosoma cruzi</i> infection). <i>The Cochrane Library</i> , 2020, 12, CD004102.	2.8	4
1216	Chagas cardiomyopathy and heart failure: From epidemiology to treatment. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2020, 39, 279-289.	0.2	1
1217	Extent of polymorphism and selection pressure on the <i>Trypanosoma cruzi</i> vaccine candidate antigen Tc24. <i>Evolutionary Applications</i> , 2020, 13, 2663-2672.	3.1	11
1218	C57BL/6 β -1,3-Galactosyltransferase Knockout Mouse as an Animal Model for Experimental Chagas Disease. <i>ACS Infectious Diseases</i> , 2020, 6, 1807-1815.	3.8	7
1219	Factors associated with quality of life in patients with Chagas disease: SaMi-Trop project. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008144.	3.0	10
1220	Chagas disease in the United Kingdom: A review of cases at the Hospital for Tropical Diseases London 1995–2018. The current state of detection of Chagas disease in the UK. <i>Travel Medicine and Infectious Disease</i> , 2020, 36, 101760.	3.0	9
1221	Strategies towards potent trypanocidal drugs: Application of Rh-catalyzed [2+2] cycloadditions, sulfonyl phthalide annulation and nitroalkene reactions for the synthesis of substituted quinones and their evaluation against <i>Trypanosoma cruzi</i> . <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115565.	3.0	13
1222	DNA Vaccine Treatment in Dogs Experimentally Infected with <i>Trypanosoma cruzi</i> . <i>Journal of Immunology Research</i> , 2020, 2020, 1-18.	2.2	8
1223	Structure and function of the stylets of hematophagous Triatominae (Hemiptera: Reduviidae), with special reference to <i>Dipetalogaster maxima</i> . <i>Arthropod Structure and Development</i> , 2020, 58, 100952.	1.4	8
1224	<i>Trypanosoma cruzi</i> Promotes Transcriptomic Remodeling of the JAK/STAT Signaling and Cell Cycle Pathways in Myoblasts. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 255.	3.9	11
1225	Computational Drug Repositioning for Chagas Disease Using Protein-Ligand Interaction Profiling. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4270.	4.1	16
1226	In vitro Treatment of a Murine Mammary Adenocarcinoma Cell Line with Recombinant <i>Trypanosoma cruzi</i> Calreticulin Promotes Immunogenicity and Phagocytosis. <i>Molecular Immunology</i> , 2020, 124, 51-60.	2.2	7
1227	Chagas cardiomyopathy and heart failure: From epidemiology to treatment. <i>Revista Portuguesa De Cardiologia</i> , 2020, 39, 279-289.	0.5	19
1228	Effect of the Tc13Tul antigen from <i>Trypanosoma cruzi</i> on splenocytes from naive mice. <i>Parasitology</i> , 2020, 147, 1114-1123.	1.5	0

#	ARTICLE	IF	CITATIONS
1229	Novel repellents for the blood-sucking insects <i>Rhodnius prolixus</i> and <i>Triatoma infestans</i> , vectors of Chagas disease. <i>Parasites and Vectors</i> , 2020, 13, 142.	2.5	11
1230	Mucosal Heterologous Prime/Boost Vaccination Induces Polyfunctional Systemic Immunity, Improving Protection Against <i>Trypanosoma cruzi</i> . <i>Frontiers in Immunology</i> , 2020, 11, 128.	4.8	22
1231	Reactive oxygen species and nitric oxide imbalances lead to in vivo and in vitro arrhythmogenic phenotype in acute phase of experimental Chagas disease. <i>PLoS Pathogens</i> , 2020, 16, e1008379.	4.7	15
1232	Comparative high-throughput analysis of the <i>Trypanosoma cruzi</i> response to organometallic compounds. <i>Metallomics</i> , 2020, 12, 813-828.	2.4	10
1233	Potential Role of Antioxidants as Adjunctive Therapy in Chagas Disease. <i>Oxidative Medicine and Cellular Longevity</i> , 2020, 2020, 1-13.	4.0	17
1234	Factors associated with Chagas screening among immigrants from an endemic country in Madrid, Spain. <i>PLoS ONE</i> , 2020, 15, e0230120.	2.5	8
1235	The Influence of Recombinational Processes to Induce Dormancy in <i>Trypanosoma cruzi</i> . <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 5.	3.9	23
1236	Elucidating the Mechanism of <i>Trypanosoma cruzi</i> Acquisition by Triatomine Insects: Evidence from a Large Field Survey of <i>Triatoma infestans</i> . <i>Tropical Medicine and Infectious Disease</i> , 2020, 5, 87.	2.3	3
1237	TLR4 agonist protects against <i>Trypanosoma cruzi</i> acute lethal infection by decreasing cardiac parasite burdens. <i>Parasite Immunology</i> , 2020, 42, e12769.	1.5	14
1238	Cardiac magnetic resonance imaging in Chagas™ disease: a parallel with electrophysiologic studies. <i>International Journal of Cardiovascular Imaging</i> , 2020, 36, 2209-2219.	1.5	9
1239	Anti-inflammatory Role of Galectin-8 During <i>Trypanosoma cruzi</i> Chronic Infection. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 285.	3.9	7
1240	Therapy with Cardiomyocytes Derived from Pluripotent Cells in Chronic Chagasic Cardiomyopathy. <i>Cells</i> , 2020, 9, 1629.	4.1	3
1241	Achalasia and cancer prevention and surveillance. <i>Annals of Esophagus</i> , 2020, 3, 19-19.	0.4	3
1242	Evidence in Favor of an Alternative Glucocorticoid Synthesis Pathway During Acute Experimental Chagas Disease. <i>Frontiers in Endocrinology</i> , 2020, 10, 866.	3.5	1
1243	Contemporary autochthonous human Chagas disease in the USA. <i>Acta Tropica</i> , 2020, 205, 105361.	2.0	52
1244	Discovery of 4-((1-(1H-imidazol-2-yl)alkoxy)methyl)pyridines as a new class of <i>Trypanosoma cruzi</i> growth inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127052.	2.2	0
1245	Efficacy and safety of combined endocardial/epicardial catheter ablation for ventricular tachycardia in Chagas disease: A randomized controlled study. <i>Heart Rhythm</i> , 2020, 17, 1510-1518.	0.7	22
1246	Morphological variability and ecological characterization of the Chagas disease vector <i>Triatoma dimidiata</i> (Hemiptera: Reduviidae) in El Salvador. <i>Acta Tropica</i> , 2020, 205, 105392.	2.0	9

#	ARTICLE	IF	CITATIONS
1247	Computational approaches for drug discovery against trypanosomatid-caused diseases. <i>Parasitology</i> , 2020, 147, 611-633.	1.5	17
1248	Semisynthetic and newly designed derivatives based on natural chemical scaffolds: moving beyond natural products to fight <i>Trypanosoma cruzi</i> . <i>Phytochemistry Reviews</i> , 2020, 19, 105-122.	6.5	18
1249	Association between circadian Holter ECG changes and sudden cardiac death in patients with Chagas heart disease. <i>Physiological Measurement</i> , 2020, 41, 025006.	2.1	9
1250	Expression of acyl-CoA-binding protein 5 from <i>Rhodnius prolixus</i> and its inhibition by RNA interference. <i>PLoS ONE</i> , 2020, 15, e0227685.	2.5	2
1251	The Pharmacopea within Triatomine Salivary Glands. <i>Trends in Parasitology</i> , 2020, 36, 250-265.	3.3	17
1252	A deadly feast: Elucidating the burden of orally acquired acute Chagas disease in Latin America – Public health and travel medicine importance. <i>Travel Medicine and Infectious Disease</i> , 2020, 36, 101565.	3.0	42
1253	Modelling triatomine bug population and <i>Trypanosoma rangeli</i> transmission dynamics: Co-feeding, pathogenic effect and linkage with chagas disease. <i>Mathematical Biosciences</i> , 2020, 324, 108326.	1.9	4
1254	Selected cardiac abnormalities in <i>Trypanosoma cruzi</i> serologically positive, discordant, and negative working dogs along the Texas-Mexico border. <i>BMC Veterinary Research</i> , 2020, 16, 101.	1.9	12
1255	The current drug discovery landscape for trypanosomiasis and leishmaniasis: Challenges and strategies to identify drug targets. <i>Drug Development Research</i> , 2022, 83, 225-252.	2.9	47
1256	Efficacy of continuous versus intermittent administration of nanoformulated benznidazole during the chronic phase of <i>Trypanosoma cruzi</i> Nicaragua infection in mice. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1906-1916.	3.0	10
1257	Transmigration of <i>Trypanosoma cruzi</i> trypomastigotes through 3D cultures resembling a physiological environment. <i>Cellular Microbiology</i> , 2020, 22, e13207.	2.1	9
1258	Tolerogenic Dendritic Cells Reduce Cardiac Inflammation and Fibrosis in Chronic Chagas Disease. <i>Frontiers in Immunology</i> , 2020, 11, 488.	4.8	22
1259	Echocardiographic Findings in Canine Model of Chagas Disease Immunized with DNA <i>Trypanosoma cruzi</i> Genes. <i>Animals</i> , 2020, 10, 648.	2.3	5
1260	Potential association of <i>Trypanosoma cruzi</i> DTUs TcV and TcVI with the digestive form of Chagas disease. <i>Infection, Genetics and Evolution</i> , 2020, 84, 104329.	2.3	5
1261	Chagas' heart disease: Descriptive analysis of 141 patients in a hospital of Madrid, Spain. <i>Travel Medicine and Infectious Disease</i> , 2020, 37, 101690.	3.0	5
1262	Prevalence of Chagas Heart Disease in a Region Endemic for <i>Trypanosoma Cruzi</i> : Evidence From a Central Bolivian Community. <i>Global Heart</i> , 2015, 10, 145.	2.3	8
1263	Opportunities and Challenges in Chronic Chagas Cardiomyopathy. <i>Global Heart</i> , 2015, 10, 203.	2.3	6
1264	After 100 Years, the Diagnosis, Treatment, and Control of Chagas Disease Remains a Challenge. <i>Global Heart</i> , 2020, 10, 137.	2.3	2

#	ARTICLE	IF	CITATIONS
1265	Diagnostic Challenges of Chagas Cardiomyopathy and CMR Imaging. <i>Global Heart</i> , 2020, 10, 181.	2.3	11
1266	Electrocardiographic and Echocardiographic Abnormalities in Chagas Disease: Findings in Residents of Rural Bolivian Communities Hyperendemic for Chagas Disease. <i>Global Heart</i> , 2015, 10, 159.	2.3	16
1267	Case-fatality From Orally-transmitted Acute Chagas Disease: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2021, 72, 1084-1092.	5.8	9
1268	Mining the Metabolome for New and Innovative Chagas Disease Treatments. <i>Trends in Pharmacological Sciences</i> , 2021, 42, 1-3.	8.7	3
1269	Electrochemical characterization of para- and meta-nitro substituents in aqueous media of new antichagasic pharmaceutical leaders. <i>Electrochimica Acta</i> , 2021, 368, 137582.	5.2	5
1270	Unraveling the Importance of Triatomine (Hemiptera: Reduviidae: Triatominae) Feeding Sources in the Chagas Disease Context. <i>Annals of the Entomological Society of America</i> , 2021, 114, 48-58.	2.5	7
1271	Polymorphism in the catalytic subunit of the PI3K β gene is associated with <i>Trypanosoma cruzi</i> -induced chronic chagasic cardiomyopathy. <i>Infection, Genetics and Evolution</i> , 2021, 88, 104671.	2.3	2
1272	Pharmacokinetics of Benznidazole in Experimental Chronic Chagas Disease Using the Swiss Mouse "Berenice-78" <i>Trypanosoma cruzi</i> Strain Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	3
1273	Glycosyl disulfides: importance, synthesis and application to chemical and biological systems. <i>Organic and Biomolecular Chemistry</i> , 2021, 19, 82-100.	2.8	16
1274	Survival after heart transplantation for Chagas cardiomyopathy using a conventional protocol: A 10-year experience in a single center. <i>Transplant Infectious Disease</i> , 2021, 23, e13549.	1.7	4
1275	<i>Trypanosoma cruzi</i> seroprevalence and associated factors in women in Casanare "Colombia. <i>Journal of Parasitic Diseases</i> , 2021, 45, 89-95.	1.0	1
1276	Host-parasite dynamics in Chagas disease from systemic to hyper-local scales. <i>Parasite Immunology</i> , 2021, 43, e12786.	1.5	19
1277	Effect of exercise training on cardiovascular autonomic and muscular function in subclinical Chagas cardiomyopathy: a randomized controlled trial. <i>Clinical Autonomic Research</i> , 2021, 31, 239-251.	2.5	4
1279	Chagas Disease: Chronic Chagas Cardiomyopathy. <i>Current Problems in Cardiology</i> , 2021, 46, 100507.	2.4	59
1280	Marine Natural Products with Bioactivity Against Neglected Tropical Diseases. <i>Topics in Heterocyclic Chemistry</i> , 2021, , 209-251.	0.2	0
1281	Recombinant antibody against <i>Trypanosoma cruzi</i> from patients with chronic Chagas heart disease recognizes mammalian nervous system.. <i>EBioMedicine</i> , 2021, 63, 103206.	6.1	4
1282	Participation of Central Muscarinic Receptors on the Nervous Form of Chagas Disease in Mice Infected via Intracerebroventricular with Colombian <i>Trypanosoma cruzi</i> Strain. <i>Pathogens</i> , 2021, 10, 121.	2.8	2
1283	The Case for the Development of a Chagas Disease Vaccine: Why? How? When?. <i>Tropical Medicine and Infectious Disease</i> , 2021, 6, 16.	2.3	17

#	ARTICLE	IF	CITATIONS
1284	Bats as Hosts of Important Unicellular Endoparasites. <i>Fascinating Life Sciences</i> , 2021, , 331-348.	0.9	3
1285	Correlação entre Cardiomegalia pela Radiografia de Tórax e Diâmetro do Ventrículo Esquerdo pela Ecocardiografia em Pacientes com Doença de Chagas. <i>Arquivos Brasileiros De Cardiologia</i> , 2021, 116, 68-74.	0.8	4
1286	Current situation of Chagas disease vectors (Hemiptera, Reduviidae) in Southern Rio Grande do Sul State, Brazil. <i>Revista Do Instituto De Medicina Tropical De Sao Paulo</i> , 2021, 63, e47.	1.1	4
1287	Quality of life in patients with Chagas disease and the instrument used: an integrative review. <i>Revista Do Instituto De Medicina Tropical De Sao Paulo</i> , 2021, 63, e46.	1.1	6
1288	Recognition and screening for Chagas disease in the USA. <i>Therapeutic Advances in Infectious Disease</i> , 2021, 8, 204993612110460.	1.8	7
1289	Analysis of Mummy Digestive Tract Contents with Examples of Relevance to Diet, Health, and Hospice. , 2021, , 1-35.		0
1290	Chagas Disease. <i>Neglected Tropical Diseases</i> , 2021, , 93-115.	0.4	0
1291	Chagas Disease: Coming to a Transplanted Patient Near You. , 2021, , 1293-1339.		0
1292	Risk factors for triatominae infestation in a municipality of Colombia. <i>Therapeutic Advances in Infectious Disease</i> , 2021, 8, 204993612110300.	1.8	1
1293	Nanomedicines against Chagas disease. , 2021, , 169-189.		2
1294	Deriving a parsimonious cardiac endpoint for use in epidemiological studies of Chagas disease: results from the Retrovirus Epidemiology Donor Study-II (REDS-II) cohort. <i>Revista Do Instituto De Medicina Tropical De Sao Paulo</i> , 2021, 63, e31.	1.1	3
1295	Neglected cardiovascular diseases and their significance in the Global North. <i>Herz</i> , 2021, 46, 129-137.	1.1	3
1296	Prospective, historically controlled study to evaluate the efficacy and safety of a new paediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas disease one year after treatment (CHICO). <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0008912.	3.0	28
1297	New Biomarker in Chagas Disease: Extracellular Vesicles Isolated from Peripheral Blood in Chronic Chagas Disease Patients Modulate the Human Immune Response. <i>Journal of Immunology Research</i> , 2021, 2021, 1-14.	2.2	15
1298	Nosocomial Infections: Do Not Forget the Parasites!. <i>Pathogens</i> , 2021, 10, 238.	2.8	13
1299	Surveillance of <i>Trypanosoma cruzi</i> infection in Triatomine vectors, feral dogs and cats, and wild animals in and around El Paso county, Texas, and New Mexico. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009147.	3.0	22
1300	Heterocycles in the Treatment of Neglected Tropical Diseases. <i>Current Medicinal Chemistry</i> , 2021, 28, 472-495.	2.4	8
1301	Diagnosis and Risk Prediction of Dilated Cardiomyopathy in the Era of Big Data and Genomics. <i>Journal of Clinical Medicine</i> , 2021, 10, 921.	2.4	16

#	ARTICLE	IF	CITATIONS
1302	A proportion of CD4+ T cells from patients with chronic Chagas disease undergo a dysfunctional process, which is partially reversed by benznidazole treatment. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009059.	3.0	9
1303	Pharmacogenomic Profile and Adverse Drug Reactions in a Prospective Therapeutic Cohort of Chagas Disease Patients Treated with Benznidazole. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1960.	4.1	1
1304	Measurement of multiple cytokines for discrimination and risk stratification in patients with Chagas disease and idiopathic dilated cardiomyopathy. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0008906.	3.0	4
1305	In vitro susceptibility of <i>Trypanosoma cruzi</i> discrete typing units (DTUs) to benznidazole: A systematic review and meta-analysis. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009269.	3.0	24
1306	The Role of Nitro (NO ₂ -), Chloro (Cl), and Fluoro (F) Substitution in the Design of Antileishmanial and Antichagasic Compounds. <i>Current Drug Targets</i> , 2021, 22, 379-398.	2.1	3
1307	Combination With Tomatidine Improves the Potency of Posaconazole Against <i>Trypanosoma cruzi</i> . <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 617917.	3.9	6
1308	Ficolin-3 in chronic Chagas disease: Low serum levels associated with the risk of cardiac insufficiency. <i>Parasite Immunology</i> , 2021, 43, e12829.	1.5	1
1309	Repeat-Driven Generation of Antigenic Diversity in a Major Human Pathogen, <i>Trypanosoma cruzi</i> . <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 614665.	3.9	25
1310	Characterization and trypanocidal activity of a β -lapachone-containing drug carrier. <i>PLoS ONE</i> , 2021, 16, e0246811.	2.5	3
1311	Functional Autoreactive Anti- β 2 Adrenergic Antibodies May Contribute to Insulin Resistance Profile in Patients with Chronic Chagas Disease. <i>Pathogens</i> , 2021, 10, 378.	2.8	0
1312	An Overview on the Therapeutics of Neglected Infectious Diseases—Leishmaniasis and Chagas Diseases. <i>Frontiers in Chemistry</i> , 2021, 9, 622286.	3.6	58
1315	Tryp-ing Up Metabolism: Role of Metabolic Adaptations in Kinetoplastid Disease Pathogenesis. <i>Infection and Immunity</i> , 2021, 89, .	2.2	9
1316	Autoantibodies against the immunodominant sCha epitope discriminate the risk of sudden death in chronic Chagas cardiomyopathy. <i>Annals of the New York Academy of Sciences</i> , 2021, 1497, 27-38.	3.8	0
1317	Natural and Semi-synthetic Licarins: Neolignans with Multi-functional Biological Properties. <i>Revista Brasileira De Farmacognosia</i> , 2021, 31, 257-271.	1.4	1
1318	Ex vivo characterization of Breg cells in patients with chronic Chagas disease. <i>Scientific Reports</i> , 2021, 11, 5511.	3.3	4
1319	Resveratrol impacts in oxidative stress in liver during <i>Trypanosoma cruzi</i> infection. <i>Microbial Pathogenesis</i> , 2021, 153, 104800.	2.9	13
1320	Management of Esophageal Dysphagia in Chagas Disease. <i>Dysphagia</i> , 2021, 36, 517-522.	1.8	8
1321	Early Post-Prandial Regulation of Protein Expression in the Midgut of Chagas Disease Vector <i>Rhodnius prolixus</i> Highlights New Potential Targets for Vector Control Strategy. <i>Microorganisms</i> , 2021, 9, 804.	3.6	7

#	ARTICLE	IF	CITATIONS
1322	Alterations to the Cardiac Metabolome Induced by Chronic <i>T. cruzi</i> Infection Relate to the Degree of Cardiac Pathology. <i>ACS Infectious Diseases</i> , 2021, 7, 1638-1649.	3.8	17
1323	DNA damage and oxidative stress in human cells infected by <i>Trypanosoma cruzi</i> . <i>PLoS Pathogens</i> , 2021, 17, e1009502.	4.7	18
1324	The Potent Trypanocidal Effect of LQB303, a Novel Redox-Active Phenyl-Tert-Butyl-Nitrone Derivate That Causes Mitochondrial Collapse in <i>Trypanosoma cruzi</i> . <i>Frontiers in Microbiology</i> , 2021, 12, 617504.	3.5	2
1325	Phylobioactive hotspots in plant resources used to treat Chagas disease. <i>IScience</i> , 2021, 24, 102310.	4.1	8
1326	Preliminary chemical characterization of ethanolic extracts from Colombian plants with promising anti - <i>Trypanosoma cruzi</i> activity. <i>Experimental Parasitology</i> , 2021, 223, 108079.	1.2	8
1327	Structure Activity Relationship of N-Substituted Phenyl-dihydropyrazolones Against <i>Trypanosoma cruzi</i> Amastigotes. <i>Frontiers in Chemistry</i> , 2021, 9, 608438.	3.6	1
1328	The First Contact of Human Dendritic Cells With <i>Trypanosoma cruzi</i> Reveals Response to Virus as an Unexplored Central Pathway. <i>Frontiers in Immunology</i> , 2021, 12, 638020.	4.8	5
1329	Key Chagas disease missing knowledge among at-risk population in Spain affecting diagnosis and treatment. <i>Infectious Diseases of Poverty</i> , 2021, 10, 55.	3.7	9
1330	Risk of COVID-19 in Chagas Disease Patients: What Happen with Cardiac Affectations?. <i>Biology</i> , 2021, 10, 411.	2.8	7
1331	The neuropeptide RhoprCCHamide2 inhibits serotonin-stimulated transcellular Na ⁺ transport across the anterior midgut of the vector of Chagas disease, <i>Rhodnius prolixus</i> . <i>Journal of Experimental Biology</i> , 2021, 224, .	1.7	2
1333	Prediction of echocardiographic parameters in Chagas disease using heart rate variability and machine learning. <i>Biomedical Signal Processing and Control</i> , 2021, 67, 102513.	5.7	8
1334	Metal organic frameworks (MOFs) with therapeutic and biomedical applications: a patent review. <i>Expert Opinion on Therapeutic Patents</i> , 2021, 31, 937-949.	5.0	10
1335	Tambjamines and Prodiginines: Biocidal Activity against <i>Trypanosoma cruzi</i> . <i>Pharmaceutics</i> , 2021, 13, 705.	4.5	6
1336	NMR structure and dynamics of Q4DY78, a conserved kinetoplast-specific protein from <i>Trypanosoma cruzi</i> . <i>Journal of Structural Biology</i> , 2021, 213, 107715.	2.8	0
1337	Transcriptional Studies on <i>Trypanosoma cruzi</i> – Host Cell Interactions: A Complex Puzzle of Variables. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 692134.	3.9	5
1338	Image-Based In Vitro Screening Reveals the Trypanostatic Activity of Hydroxymethylnitrofurazone against <i>Trypanosoma cruzi</i> . <i>International Journal of Molecular Sciences</i> , 2021, 22, 6930.	4.1	6
1339	Ruthenium(II)- and Palladium(II)-catalyzed position-divergent C-H oxygenations of arylated quinones: Identification of hydroxylated quinonoid compounds with potent trypanocidal activity. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 40, 116164.	3.0	2
1340	IgG Subclass Analysis in Patients with Chagas Disease 4 Years After Benznidazole Treatment. <i>Acta Parasitologica</i> , 2021, 66, 1499-1509.	1.1	2

#	ARTICLE	IF	CITATIONS
1341	Th17 Cells Provide Mucosal Protection against Gastric <i>Trypanosoma cruzi</i> Infection. <i>Infection and Immunity</i> , 2021, 89, e0073820.	2.2	4
1342	Acrylonitrile Derivatives against <i>Trypanosoma cruzi</i> : In Vitro Activity and Programmed Cell Death Study. <i>Pharmaceuticals</i> , 2021, 14, 552.	3.8	9
1343	Chromatic and Morphological Differentiation of <i>Triatoma dimidiata</i> (Hemiptera: Reduviidae) with Land Use Diversity in El Salvador. <i>Pathogens</i> , 2021, 10, 753.	2.8	2
1344	Where was my patient born? The Intersection of tropical medicine and migrant health. <i>Current Opinion in Infectious Diseases</i> , 2021, 34, 447-454.	3.1	3
1345	In vitro and in vivo trypanocidal activity of a benzofuroxan derivative against <i>Trypanosoma cruzi</i> . <i>Experimental Parasitology</i> , 2021, 226-227, 108125.	1.2	5
1346	Î±-Gal immunization positively impacts <i>Trypanosoma cruzi</i> colonization of heart tissue in a mouse model. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009613.	3.0	7
1347	Phenotypic and Functional Signatures of Peripheral Blood and Spleen Compartments of <i>Cynomolgus</i> Macaques Infected With <i>T. cruzi</i> : Associations With Cardiac Histopathological Characteristics. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 701930.	3.9	1
1348	Phenylbenzothiazole derivatives: effects against a <i>Trypanosoma cruzi</i> infection and toxicological profiles. <i>Parasitology Research</i> , 2021, 120, 2905-2918.	1.6	4
1349	Multiple Strokes in a Latin American Patient. <i>Case Reports in Neurology</i> , 2021, 13, 441-445.	0.7	0
1350	Comparative analyses of the venom components in the salivary gland transcriptomes and saliva proteomes of some heteropteran insects. <i>Insect Science</i> , 2022, 29, 411-429.	3.0	7
1351	Local association of <i>Trypanosoma cruzi</i> chronic infection foci and enteric neuropathic lesions at the tissue micro-domain scale. <i>PLoS Pathogens</i> , 2021, 17, e1009864.	4.7	13
1352	Parasitological cure in children infected with <i>Trypanosoma cruzi</i> . <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1058-1059.	9.1	0
1353	Signal Transducer and Activator of Transcription-3 Modulation of Cardiac Pathology in Chronic Chagasic Cardiomyopathy. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 708325.	3.9	9
1354	Serological reactivity against <i>T. cruzi</i> -derived antigens: Evaluation of their suitability for the assessment of response to treatment in chronic Chagas disease.. <i>Acta Tropica</i> , 2021, 221, 105990.	2.0	6
1355	Location and expression kinetics of Tc24 in different life stages of <i>Trypanosoma cruzi</i> . <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009689.	3.0	9
1356	Validation of a documentary on Chagas disease by a population living in an endemic area. <i>Brazilian Journal of Biology</i> , 2021, 81, 665-673.	0.9	3
1357	Different infective forms trigger distinct lesions in the colon during experimental Chagas disease. <i>Parasitology Research</i> , 2021, 120, 3475-3486.	1.6	0
1361	Parasitic Load Correlates With Left Ventricular Dysfunction in Patients With Chronic Chagas Cardiomyopathy. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 741347.	2.4	1

#	ARTICLE	IF	CITATIONS
1366	Prospective analysis of myocardial strain through the evolution of Chagas disease in the hamster animal model. <i>International Journal of Cardiovascular Imaging</i> , 2022, 38, 117-129.	1.5	2
1367	<i>Trypanosoma cruzi</i> Exploits E- and P-Selectins To Migrate Across Endothelial Cells and Extracellular Matrix Proteins. <i>Infection and Immunity</i> , 2021, 89, e0017821.	2.2	1
1372	Geographic Variations in Test Reactivity for the Serological Diagnosis of <i>Trypanosoma cruzi</i> Infection. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0106221.	3.9	24
1373	The gene repertoire of the main cysteine protease of <i>Trypanosoma cruzi</i> , cruzipain, reveals four sub-types with distinct active sites. <i>Scientific Reports</i> , 2021, 11, 18231.	3.3	16
1374	Differential Expression of Immune Response Genes in Asymptomatic Chronic Chagas Disease Patients Versus Healthy Subjects. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 722984.	3.9	7
1376	Insight into Recent Drug Discoveries against Trypanosomatids and Plasmodium spp Parasites: New Metal-based Compounds. <i>Current Medicinal Chemistry</i> , 2021, 28, .	2.4	1
1377	Community-based screening of Chagas disease among Latin American migrants in a non-endemic country: an observational study. <i>Infectious Diseases of Poverty</i> , 2021, 10, 117.	3.7	7
1380	IgG Subclasses and Congenital Transmission of Chagas Disease. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, . .	1.4	3
1381	Cysteine proteases as potential targets for anti-trypanosomatid drug discovery. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 46, 116365.	3.0	3
1384	Feasibility of a Combined Mobile-Health Electrocardiographic and Rapid Diagnostic Test Screening for Chagas-Related Cardiac Alterations. <i>Microorganisms</i> , 2021, 9, 1889.	3.6	4
1385	In vitro, ex vivo and in vivo short-term screening of DHEA nitrate derivatives activity over <i>Trypanosoma cruzi</i> Ninoa and TH strains from Oaxaca State, MÃ©xico. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 48, 116417.	3.0	3
1386	Genotypic <i>Trypanosoma cruzi</i> distribution and parasite load differ ecotypically and according to parasite genotypes in <i>Triatoma brasiliensis</i> from endemic and outbreak areas in Northeastern Brazil. <i>Acta Tropica</i> , 2021, 222, 106054.	2.0	7
1387	Clinical investigation of the biopharmaceutical characteristics of nifurtimox tablets â€“ Implications for quality control and application. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 166, 105940.	4.0	6
1388	Role of formyl peptide receptor 2 (FPR2) in modulating immune response and heart inflammation in an experimental model of acute and chronic Chagas disease. <i>Cellular Immunology</i> , 2021, 369, 104427.	3.0	6
1389	In vitro anti- <i>Trypanosoma cruzi</i> activity enhancement of curcumin by its monoketone tetramethoxy analog diveratralacetone. <i>Current Research in Parasitology and Vector-borne Diseases</i> , 2021, 1, 100031.	1.9	4
1390	A new <i>Trypanosoma cruzi</i> genotyping method enables high resolution evolutionary analyses. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2021, 116, e200538.	1.6	3
1392	The Ecology and Natural History of Wild Triatominae in the Americas. <i>True Bugs (Heteroptera) of the Neotropics</i> , 2021, , 387-445.	1.2	14
1393	Chagas disease reactivation in rheumatologic patients: association with immunosuppressive therapy and humoral response. <i>Clinical Rheumatology</i> , 2021, 40, 2955-2963.	2.2	6

#	ARTICLE	IF	CITATIONS
1395	HIF-1 α and CD73 expression in cardiac leukocytes correlates with the severity of myocarditis in end-stage Chagas disease patients. <i>Journal of Leukocyte Biology</i> , 2021, 109, 233-244.	3.3	6
1396	Unstable Dynamics of Vector-Borne Diseases: Modeling Through Delay-Differential Equations. , 2013, , 43-75.		8
1397	Clinical Pharmacology of Drugs for the Treatment of Chagas Disease. <i>Birkhauser Advances in Infectious Diseases</i> , 2019, , 299-312.	0.3	2
1398	Chagas Disease: An Unknown and Neglected Disease. , 2020, , 1-26.		2
1399	Chagas Disease: A Parasitic Infection in an Immunosuppressed Host. , 2020, , 213-234.		5
1400	Arthropods and Human Disease. , 2017, , 247-268.		1
1401	Siccanin Is a Novel Selective Inhibitor of Trypanosomatid Complex II (Succinate-Ubiquinone Reductase) and a Potent Broad-Spectrum Anti-trypanosomatid Drug Candidate. , 2016, , 101-122.		4
1402	Role of ROS in <i>T. cruzi</i> Intracellular Development. , 2019, , 83-95.		1
1403	Chagas Disease Knowledge and Risk Behaviors of the Homeless Population in Houston, TX. <i>Journal of Racial and Ethnic Health Disparities</i> , 2018, 5, 229-234.	3.2	5
1404	Myocarditis and Pericarditis. , 2015, , 1066-1079.e8.		3
1405	Trends of Seroprevalence of Chagas's diseases in healthy blood donors, solid organ donors and heart transplant recipients: experience of a single health care center in Colombia.. <i>Epidemiology and Infection</i> , 2020, , 1-25.	2.1	1
1406	Assembly of highly repetitive genomes using short reads: the genome of discrete typing unit III <i>Trypanosoma cruzi</i> strain 231. <i>Microbial Genomics</i> , 2018, 4, .	2.0	24
1413	Parasites. , 0, , 411-466.		1
1414	Parasitic Loads in Tissues of Mice Infected with <i>Trypanosoma cruzi</i> and Treated with AmBisome. <i>PLoS Neglected Tropical Diseases</i> , 2011, 5, e1216.	3.0	58
1415	The Short Non-Coding Transcriptome of the Protozoan Parasite <i>Trypanosoma cruzi</i> . <i>PLoS Neglected Tropical Diseases</i> , 2011, 5, e1283.	3.0	35
1416	Activity In Vivo of Anti- <i>Trypanosoma cruzi</i> Compounds Selected from a High Throughput Screening. <i>PLoS Neglected Tropical Diseases</i> , 2011, 5, e1298.	3.0	65
1417	Antigenicity and Diagnostic Potential of Vaccine Candidates in Human Chagas Disease. <i>PLoS Neglected Tropical Diseases</i> , 2013, 7, e2018.	3.0	22
1418	Early Regulation of Profibrotic Genes in Primary Human Cardiac Myocytes by <i>Trypanosoma cruzi</i> . <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0003747.	3.0	42

#	ARTICLE	IF	CITATIONS
1419	Trypanosoma cruzi Infection through the Oral Route Promotes a Severe Infection in Mice: New Disease Form from an Old Infection?. PLoS Neglected Tropical Diseases, 2015, 9, e0003849.	3.0	58
1420	Molecular Design, Synthesis and Trypanocidal Activity of Dipeptidyl Nitriles as Cruzain Inhibitors. PLoS Neglected Tropical Diseases, 2015, 9, e0003916.	3.0	49
1421	Galectin-1 Prevents Infection and Damage Induced by Trypanosoma cruzi on Cardiac Cells. PLoS Neglected Tropical Diseases, 2015, 9, e0004148.	3.0	39
1422	Preventive Chemotherapy Versus Innovative and Intensified Disease Management in Neglected Tropical Diseases: A Distinction Whose Shelf Life Has Expired. PLoS Neglected Tropical Diseases, 2016, 10, e0004521.	3.0	23
1423	IL18 Gene Variants Influence the Susceptibility to Chagas Disease. PLoS Neglected Tropical Diseases, 2016, 10, e0004583.	3.0	24
1424	Identification of Trypanocidal Activity for Known Clinical Compounds Using a New Trypanosoma cruzi Hit-Discovery Screening Cascade. PLoS Neglected Tropical Diseases, 2016, 10, e0004584.	3.0	57
1425	Development of a Novel Multiplex Immunoassay Multi-cruzi for the Serological Confirmation of Chagas Disease. PLoS Neglected Tropical Diseases, 2016, 10, e0004596.	3.0	33
1426	Electrocardiographic Abnormalities and Treatment with Benznidazole among Children with Chronic Infection by Trypanosoma cruzi: A Retrospective Cohort Study. PLoS Neglected Tropical Diseases, 2016, 10, e0004651.	3.0	13
1427	Impact of Helminth Infection on the Clinical and Microbiological Presentation of Chagas Diseases in Chronically Infected Patients. PLoS Neglected Tropical Diseases, 2016, 10, e0004663.	3.0	17
1428	Prevalence of Chagas Disease in a U.S. Population of Latin American Immigrants with Conduction Abnormalities on Electrocardiogram. PLoS Neglected Tropical Diseases, 2017, 11, e0005244.	3.0	34
1429	Immunization with Tc52 or its amino terminal domain adjuvanted with c-di-AMP induces Th17+Th1 specific immune responses and confers protection against Trypanosoma cruzi. PLoS Neglected Tropical Diseases, 2017, 11, e0005300.	3.0	31
1430	Anti-trypanosomal activity of non-peptidic nitrile-based cysteine protease inhibitors. PLoS Neglected Tropical Diseases, 2017, 11, e0005343.	3.0	26
1431	Rapid diagnostic tests duo as alternative to conventional serological assays for conclusive Chagas disease diagnosis. PLoS Neglected Tropical Diseases, 2017, 11, e0005501.	3.0	50
1432	Mortality among blood donors seropositive and seronegative for Chagas disease (1996–2000) in São Paulo, Brazil: A death certificate linkage study. PLoS Neglected Tropical Diseases, 2017, 11, e0005542.	3.0	24
1433	Expression of inhibitory receptors and polyfunctional responses of T cells are linked to the risk of congenital transmission of T. cruzi. PLoS Neglected Tropical Diseases, 2017, 11, e0005627.	3.0	11
1434	The Trypomastigote Small Surface Antigen (TSSA) regulates Trypanosoma cruzi infectivity and differentiation. PLoS Neglected Tropical Diseases, 2017, 11, e0005856.	3.0	21
1435	Epidemiological consequences of immune sensitisation by pre-exposure to vector saliva. PLoS Neglected Tropical Diseases, 2017, 11, e0005956.	3.0	5
1436	Next-generation ELISA diagnostic assay for Chagas Disease based on the combination of short peptidic epitopes. PLoS Neglected Tropical Diseases, 2017, 11, e0005972.	3.0	31

#	ARTICLE	IF	CITATIONS
1437	Polyclonal antibodies for the detection of <i>Trypanosoma cruzi</i> circulating antigens. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0006069.	3.0	8
1438	Accomplishing the genotype-specific serodiagnosis of single and dual <i>Trypanosoma cruzi</i> infections by flow cytometry Chagas-Flow ATE-IgG2a. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006140.	3.0	7
1439	High prevalence of <i>S. Stercoralis</i> infection among patients with Chagas disease: A retrospective case-control study. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006199.	3.0	17
1440	A novel antibody surrogate biomarker to monitor parasite persistence in <i>Trypanosoma cruzi</i> -infected patients. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006226.	3.0	32
1441	<i>Trypanosoma cruzi</i> vaccine candidate antigens Tc24 and TSA-1 recall memory immune response associated with HLA-A and -B supertypes in Chagasic chronic patients from Mexico. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006240.	3.0	31
1442	Socioeconomic benefit to individuals of achieving 2020 targets for four neglected tropical diseases controlled/eliminated by innovative and intensified disease management: Human African trypanosomiasis, leprosy, visceral leishmaniasis, Chagas disease. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006250.	3.0	29
1443	Are the London Declaration's 2020 goals sufficient to control Chagas disease?: Modeling scenarios for the Yucatan Peninsula. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006337.	3.0	16
1444	Experimental Chagas disease-induced perturbations of the fecal microbiome and metabolome. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006344.	3.0	39
1445	Early impairment of myocardial deformation assessed by regional speckle-tracking echocardiography in the indeterminate form of Chagas disease without fibrosis detected by cardiac magnetic resonance. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008795.	3.0	11
1446	A voluntary use of insecticide treated nets can stop the vector transmission of Chagas disease. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008833.	3.0	7
1447	An Essential Nuclear Protein in Trypanosomes Is a Component of mRNA Transcription/Export Pathway. <i>PLoS ONE</i> , 2011, 6, e20730.	2.5	24
1448	Genome Size, Karyotype Polymorphism and Chromosomal Evolution in <i>Trypanosoma cruzi</i> . <i>PLoS ONE</i> , 2011, 6, e23042.	2.5	62
1449	IL-12p40 Deficiency Leads to Uncontrolled <i>Trypanosoma cruzi</i> Dissemination in the Spinal Cord Resulting in Neuronal Death and Motor Dysfunction. <i>PLoS ONE</i> , 2012, 7, e49022.	2.5	13
1450	Differential Distribution of Genes Encoding the Virulence Factor Trans-Sialidase along <i>Trypanosoma cruzi</i> Discrete Typing Units. <i>PLoS ONE</i> , 2013, 8, e58967.	2.5	36
1451	Differential Expression Profiles in the Midgut of <i>Triatoma infestans</i> Infected with <i>Trypanosoma cruzi</i> . <i>PLoS ONE</i> , 2013, 8, e61203.	2.5	39
1452	Vaccination Using Recombinants Influenza and Adenoviruses Encoding Amastigote Surface Protein-2 Are Highly Effective on Protection against <i>Trypanosoma cruzi</i> Infection. <i>PLoS ONE</i> , 2013, 8, e61795.	2.5	20
1453	Oral Exposure to <i>Phytomonas serpens</i> Attenuates Thrombocytopenia and Leukopenia during Acute Infection with <i>Trypanosoma cruzi</i> . <i>PLoS ONE</i> , 2013, 8, e68299.	2.5	10
1454	Polymorphic Sites at the Immunoregulatory CTLA-4 Gene Are Associated with Chronic Chagas Disease and Its Clinical Manifestations. <i>PLoS ONE</i> , 2013, 8, e78367.	2.5	19

#	ARTICLE	IF	CITATIONS
1455	Genetic Profiling of the Isoprenoid and Sterol Biosynthesis Pathway Genes of <i>Trypanosoma cruzi</i> . PLoS ONE, 2014, 9, e96762.	2.5	19
1456	Interferon-Gamma Promotes Infection of Astrocytes by <i>Trypanosoma cruzi</i> . PLoS ONE, 2015, 10, e0118600.	2.5	30
1457	Therapeutic Efficacy of a Subunit Vaccine in Controlling Chronic <i>Trypanosoma cruzi</i> Infection and Chagas Disease Is Enhanced by Glutathione Peroxidase Over-Expression. PLoS ONE, 2015, 10, e0130562.	2.5	19
1458	A Novel Method for Inducing Amastigote-To-Trypomastigote Transformation In Vitro in <i>Trypanosoma cruzi</i> Reveals the Importance of Inositol 1,4,5-Trisphosphate Receptor. PLoS ONE, 2015, 10, e0135726.	2.5	7
1459	Bats, Trypanosomes, and Triatomines in Ecuador: New Insights into the Diversity, Transmission, and Origins of <i>Trypanosoma cruzi</i> and Chagas Disease. PLoS ONE, 2015, 10, e0139999.	2.5	59
1460	The <i>Trypanosoma cruzi</i> Diamine Transporter Is Essential for Robust Infection of Mammalian Cells. PLoS ONE, 2016, 11, e0152715.	2.5	14
1461	Comparative Transcriptome Profiling of Human Foreskin Fibroblasts Infected with the Sylvio and Y Strains of <i>Trypanosoma cruzi</i> . PLoS ONE, 2016, 11, e0159197.	2.5	25
1462	Specific Endocytosis Blockade of <i>Trypanosoma cruzi</i> Exposed to a Poly-LAcNAc Binding Lectin Suggests that Lectin-Sugar Interactions Participate to Receptor-Mediated Endocytosis. PLoS ONE, 2016, 11, e0163302.	2.5	8
1463	Benznidazole Use among Patients with Chronic Chagas' Cardiomyopathy in an Endemic Region of Brazil. PLoS ONE, 2016, 11, e0165950.	2.5	5
1464	Chagas disease vector blood meal sources identified by protein mass spectrometry. PLoS ONE, 2017, 12, e0189647.	2.5	13
1465	Genetic association study of NLRP1, CARD, and CASP1 inflammasome genes with chronic Chagas cardiomyopathy among <i>Trypanosoma cruzi</i> seropositive patients in Bolivia. PLoS ONE, 2018, 13, e0192378.	2.5	13
1466	Species-dependent variation of the gut bacterial communities across <i>Trypanosoma cruzi</i> insect vectors. PLoS ONE, 2020, 15, e0240916.	2.5	6
1467	Mixed infections by different <i>Trypanosoma cruzi</i> discrete typing units among Chagas disease patients in an endemic community in Panama. PLoS ONE, 2020, 15, e0241921.	2.5	9
1468	Transcriptome Remodeling in <i>Trypanosoma cruzi</i> and Human Cells during Intracellular Infection. PLoS Pathogens, 2016, 12, e1005511.	4.7	157
1469	Th17 Cells Are More Protective Than Th1 Cells Against the Intracellular Parasite <i>Trypanosoma cruzi</i> . PLoS Pathogens, 2016, 12, e1005902.	4.7	81
1470	Resveratrol Reverses Functional Chagas Heart Disease in Mice. PLoS Pathogens, 2016, 12, e1005947.	4.7	64
1471	Modulation of host central carbon metabolism and in situ glucose uptake by intracellular <i>Trypanosoma cruzi</i> amastigotes. PLoS Pathogens, 2017, 13, e1006747.	4.7	53
1472	Sudden Cardiac Death Risk Stratification and Prevention in Chagas Disease: A Non-systematic Review of the Literature. Arrhythmia and Electrophysiology Review, 2020, 9, 175-181.	2.4	10

#	ARTICLE	IF	CITATIONS
1473	Efficacy of the Benznidazole+Posaconazole combination therapy in parasitemia reduction: An experimental murine model of acute Chagas. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2020, 53, e20190477.	0.9	7
1474	Human acute Chagas disease: changes in factor VII, activated protein C and hepatic enzymes from patients of oral outbreaks in Pará State (Brazilian Amazon). <i>Memórias Do Instituto Oswaldo Cruz</i> , 2020, 115, e190364.	1.6	6
1475	Reações adversas ao benznidazol no tratamento da Doença de Chagas: revisão sistemática de ensaios clínicos randomizados e controlados. <i>Cadernos Saude Coletiva</i> , 2019, 27, 354-362.	0.6	1
1476	DNA lesions and repair in trypanosomatids infection. <i>Genetics and Molecular Biology</i> , 2020, 43, e20190163.	1.3	8
1477	Avaliação das atividades antibacteriana, tripanocida e citotóxica do extrato hidroalcoólico das raízes de <i>Tradescantia sillamontana</i> Matuda (Veludo Branco) (Commelinaceae). <i>Revista Brasileira De Plantas Mediciniais</i> , 2016, 18, 415-422.	0.3	2
1478	Aspectos nutricionais associados à infecção crônica pelo <i>Trypanosoma cruzi</i> (Chagas 1909) entre idosos: Projeto Bambuí. <i>Cadernos De Saude Publica</i> , 2013, 29, 1141-1148.	1.0	5
1479	Awareness of Chagas disease and socioeconomic characteristics of Bolivian immigrants living in Sao Paulo, Brazil. <i>Revista Do Instituto De Medicina Tropical De Sao Paulo</i> , 2020, 62, e39.	1.1	4
1480	Structural Heart Diseases. , 2017, , 191-208.		4
1481	Benznidazole/Poloxamer 407 Solid Dispersion as a New Strategy to Improve the Treatment of Experimental <i>Trypanosoma cruzi</i> Infection. <i>Journal of Parasitology</i> , 2020, 106, 323.	0.7	4
1482	New Diagnostic Algorithm for Chagas Disease: Impact on Access to Diagnosis and Out of Pocket Expenditures in Colombia. <i>Iranian Journal of Public Health</i> , 0, , .	0.5	3
1483	An exploration of land use and poverty as an integrative model for mitigating Chagas disease in El Salvador. <i>Bios</i> , 2020, 91, .	0.0	2
1484	Epitope Capsid-Incorporation: New Effective Approach for Vaccine Development for Chagas Disease. <i>Pathogens and Immunity</i> , 2016, 1, 214.	3.1	7
1485	Potential Triazole-based Molecules for the Treatment of Neglected Diseases. <i>Current Medicinal Chemistry</i> , 2019, 26, 4403-4434.	2.4	13
1486	The Thiol-polyamine Metabolism of <i>Trypanosoma cruzi</i> : Molecular Targets and Drug Repurposing Strategies. <i>Current Medicinal Chemistry</i> , 2019, 26, 6614-6635.	2.4	22
1487	Amino Acid and Polyamine Membrane Transporters in <i>Trypanosoma cruzi</i> : Biological Function and Evaluation as Drug Targets. <i>Current Medicinal Chemistry</i> , 2019, 26, 6636-6651.	2.4	4
1488	Lipophilic Guanylhydrazone Analogues as Promising Trypanocidal Agents: An Extended SAR Study. <i>Current Pharmaceutical Design</i> , 2020, 26, 838-866.	1.9	4
1489	Reporting of adverse reactions to benznidazole: does medical expertise matter?. <i>Revista Panamericana De Salud Publica/Pan American Journal of Public Health</i> , 2018, 42, 1-8.	1.1	2
1490	A four-step process for building sustainable access to diagnosis and treatment of Chagas disease. <i>Revista Panamericana De Salud Publica/Pan American Journal of Public Health</i> , 2019, 43, 1.	1.1	7

#	ARTICLE	IF	CITATIONS
1491	Epidemiology of congenital Chagas disease 6 years after implementation of a public health surveillance system, Catalonia, 2010 to 2015. <i>Eurosurveillance</i> , 2019, 24, .	7.0	29
1492	Although with intact mucosa at colonoscopy, chagasic megacolons have an overexpression of Gal-3. <i>Einstein (Sao Paulo, Brazil)</i> , 2020, 18, eAO5105.	0.7	3
1493	Detection of Human Anti-Trypanosoma cruzi Antibody with Recombinant Fragmented Ribosomal P Protein. <i>Korean Journal of Parasitology</i> , 2019, 57, 435-437.	1.3	1
1494	A Novel Calcium-Activated Potassium Channel Controls Membrane Potential and Intracellular pH in Trypanosoma cruzi. <i>Frontiers in Cellular and Infection Microbiology</i> , 2019, 9, 464.	3.9	4
1495	Pyridinecarboxylic Acid Derivative Stimulates Pro-Angiogenic Mediators by PI3K/AKT/mTOR and Inhibits Reactive Nitrogen and Oxygen Species and NF- κ B Activation Through a PPAR γ -Dependent Pathway in T. cruzi-Infected Macrophages. <i>Frontiers in Immunology</i> , 2019, 10, 2955.	4.8	16
1496	Role of Cardiac Macrophages on Cardiac Inflammation, Fibrosis and Tissue Repair. <i>Cells</i> , 2021, 10, 51.	4.1	159
1497	AtualizaçãŁo da Diretriz Brasileira de Cardiologia Nuclear â€“ 2020. <i>Arquivos Brasileiros De Cardiologia</i> , 2020, 114, 325-429.	0.8	10
1498	Estudo Comparativo da Doenãsa Coronariana Microvascular Causada por Doenãsa de Chagas e por Outras Etiologias. <i>Arquivos Brasileiros De Cardiologia</i> , 2020, 115, 1094-1101.	0.8	12
1499	Glycosylphosphatidylinositols of Protozoan Parasites. <i>Trends in Glycoscience and Glycotechnology</i> , 2012, 24, 231-243.	0.1	11
1500	Experimental Chemotherapy for Chagas Disease: A Morphological, Biochemical, and Proteomic Overview of Potential Trypanosoma cruzi Targets of Amidines Derivatives and Naphthoquinones. <i>Molecular Biology International</i> , 2011, 2011, 1-13.	1.7	15
1501	Impact of Chagas Disease on Human Evolution: The Challenges Continue. <i>Advances in Anthropology</i> , 2013, 03, 1-6.	0.2	2
1502	Chagas Disease Infection among Migrants at the Mexico/Guatemala Border. <i>American Journal of Tropical Medicine and Hygiene</i> , 2017, 97, 1134-1140.	1.4	10
1503	The Prevalence of Chagas Disease Among Latin American Immigrants with Pacemakers in Los Angeles, California. <i>American Journal of Tropical Medicine and Hygiene</i> , 2017, 96, 1139-1142.	1.4	16
1504	Prevalence and Seroprevalence of Trypanosoma cruzi Infection in a Military Population in Texas. <i>American Journal of Tropical Medicine and Hygiene</i> , 2017, 97, 1477-1481.	1.4	9
1505	Trypanosoma cruzi Infection Induces Pannexin-1 Channel Opening in Cardiac Myocytes. <i>American Journal of Tropical Medicine and Hygiene</i> , 2018, 98, 105-112.	1.4	15
1506	cDNA Isolation and Expression of Nicotinamide Adenine Dinucleotide Phosphateâ€“Dependent Cytochrome P450 Reductase Gene in the Chagas Disease Vector Triatoma infestans. <i>American Journal of Tropical Medicine and Hygiene</i> , 2018, 98, 710-716.	1.4	3
1507	Parasiteâ€“Vector Interaction of Chagas Disease: A Mini-Review. <i>American Journal of Tropical Medicine and Hygiene</i> , 2018, 98, 653-655.	1.4	28
1508	â€œItâ€™s Like a Phantom Diseaseâ€“ Patient Perspectives on Access to Treatment for Chagas Disease in the United States. <i>American Journal of Tropical Medicine and Hygiene</i> , 2018, 98, 735-741.	1.4	28

#	ARTICLE	IF	CITATIONS
1509	Case Report: High Mannose-Binding Lectin Serum Determined by MBL2 Genotype and Risk for Clinical Progression to Chagasic Cardiomyopathy: A Case Report of Three Patients. American Journal of Tropical Medicine and Hygiene, 2019, 100, 93-96.	1.4	1
1510	Prevalence of Chagas Disease among Solid Organ Transplanted Patients in a Nonendemic Country. American Journal of Tropical Medicine and Hygiene, 2018, 98, 742-746.	1.4	17
1511	Congenital Chagas Disease in the United States: Cost Savings through Maternal Screening. American Journal of Tropical Medicine and Hygiene, 2018, 98, 1733-1742.	1.4	40
1512	ELISA Saliva for Trypanosoma cruzi Antibody Detection: An Alternative for Serological Surveys in Endemic Regions. American Journal of Tropical Medicine and Hygiene, 2020, 102, 800-803.	1.4	2
1513	Chagas Disease in Southern Coastal Ecuador: Coinfections with Arboviruses and a Comparison of Serological Assays for Chagas Disease Diagnosis. American Journal of Tropical Medicine and Hygiene, 2018, 99, 1530-1533.	1.4	5
1514	Leveraging Technology to Manage Chagas Disease by Tracking Domestic and Sylvatic Animal Hosts as Sentinels: A Systematic Review. American Journal of Tropical Medicine and Hygiene, 2019, 101, 1126-1134.	1.4	5
1515	Congenital Chagas Disease in the United States: The Effect of Commercially Priced Benznidazole on Costs and Benefits of Maternal Screening. American Journal of Tropical Medicine and Hygiene, 2020, 102, 1086-1089.	1.4	17
1516	Associations between Cardiac Magnetic Resonance T1 Mapping Parameters and Ventricular Arrhythmia in Patients with Chagas Disease. American Journal of Tropical Medicine and Hygiene, 2020, 103, 745-751.	1.4	8
1517	Trypanosoma cruzi-Derived Neurotrophic Factor: Role in Neural Repair and Neuroprotection. Journal of Neuroparasitology, 2010, 1, 1-6.	0.6	7
1518	Emerging and under-recognized Chagas cardiomyopathy in non-endemic countries. World Journal of Cardiology, 2012, 4, 234.	1.5	4
1519	Regulation of RNA binding proteins in trypanosomatid protozoan parasites. World Journal of Biological Chemistry, 2016, 7, 146.	4.3	20
1520	WHF IASC Roadmap on Chagas Disease. Global Heart, 2020, 15, 26.	2.3	75
1521	COVID-19: Implications for People with Chagas Disease. Global Heart, 2020, 15, 69.	2.3	39
1522	The Journey of <i>Trypanosoma cruzi</i> under the Redox Baton. , 0, , .		1
1523	ECG Manifestations of the Biggest Outbreak of Chagas Disease due to Oral Infection in Latin-America. Arquivos Brasileiros De Cardiologia, 2013, 101, 249-54.	0.8	16
1524	Cardiac Magnetic Resonance-Verified Myocardial Fibrosis in Chagas Disease: Clinical Correlates and Risk Stratification. Arquivos Brasileiros De Cardiologia, 2016, 107, 460-466.	0.8	24
1525	The effect of beta-blockade on myocardial remodelling in Chagas' cardiomyopathy. Clinics, 2012, 67, 1063-1069.	1.5	14
1526	Glutamine metabolism modulates azole susceptibility in Trypanosoma cruzi amastigotes. ELife, 2020, 9, .	6.0	21

#	ARTICLE	IF	CITATIONS
1527	Trypanosoma cruzi reservoirâ€™triatomine vector co-occurrence networks reveal meta-community effects by synanthropic mammals on geographic dispersal. PeerJ, 2017, 5, e3152.	2.0	21
1528	Towards global control of parasitic diseases in the Covid-19 era: One Health and the future of multisectoral global health governance. Advances in Parasitology, 2021, 114, 1-26.	3.2	12
1529	A Terpenoid-Rich Extract from <i>Clethra Fimbriata</i> Exhibits anti- <i>Trypanosoma cruzi</i> Activity and Induces T Cell Cytokine Production. SSRN Electronic Journal, 0, , .	0.4	0
1530	Serological response to nifurtimox in adult patients with chronic Chagas disease: An observational comparative study in Argentina. PLoS Neglected Tropical Diseases, 2021, 15, e0009801.	3.0	3
1531	New Insights Into Blue Light Phototherapy in Experimental Trypanosoma cruzi Infection. Frontiers in Cellular and Infection Microbiology, 2021, 11, 673070.	3.9	0
1532	Antiprotozoal agents: How have they changed over a decade?. Archiv Der Pharmazie, 2022, 355, e2100338.	4.1	8
1533	Recommendations for Screening and Diagnosis of Chagas Disease in the United States. Journal of Infectious Diseases, 2022, 225, 1601-1610.	4.0	35
1534	Frequency of Human Papillomavirus Detection in Chagasic Megaesophagus Associated or Not with Esophageal Squamous Cell Carcinoma. Pathobiology, 2021, , 1-9.	3.8	1
1535	In vitro Leishmanicidal and Trypanosomicidal Properties of Imidazoleâ€™Containing Azine and Benzoazine Derivatives. ChemMedChem, 2021, 16, 3600-3614.	3.2	1
1536	Assessing antibody decline after chemotherapy of early chronic Chagas disease patients. Parasites and Vectors, 2021, 14, 543.	2.5	6
1537	Chagas disease: Immunology of the disease at a glance. Cytokine and Growth Factor Reviews, 2021, 62, 15-22.	7.2	18
1538	Spatial metabolomics identifies localized chemical changes in heart tissue during chronic cardiac Chagas Disease. PLoS Neglected Tropical Diseases, 2021, 15, e0009819.	3.0	18
1539	Lipid and fatty acid metabolism in trypanosomatids. Microbial Cell, 2021, 8, 262-275.	3.2	16
1542	Chagasâ€™ Disease. , 2012, , e173-e177.		0
1544	Trypanosoma Species (Trypanosomiasis). , 2012, , 1319-1326.e2.		0
1546	Infectious Emergencies in Dermatology. , 2013, , 19-41.		0
1547	Bugs (The True Bugs). , 2012, , .		0
1548	Toward a Safer Blood Supply: The Impact of Molecular Testing. , 2014, , 121-145.		0

#	ARTICLE	IF	CITATIONS
1549	Trypanosomiasis and Cardiac Disease. , 2014, , 2407-2419.		0
1550	Bradykarde. , 2014, , 1-20.		0
1551	Intestinal Motor Disorders. , 2014, , 249-316.		6
1553	Antiparasitic Agents. , 0, , 2527-2549.		0
1554	New Perspectives for Therapeutic Intervention during the Chronic Phase of Trypanosoma Cruzi Infection. Journal of Immunology and Serum Biology, 2016, 2, 1-2.	0.0	0
1555	Immunity to Trypanosoma cruzi. , 2016, , 108-113.		1
1556	Case 2/2016 - 76-Year-Old Male with Hypertensive Heart Disease, Renal Tumor and Shock. Arquivos Brasileiros De Cardiologia, 2016, 106, 439-46.	0.8	0
1557	Aliphatic Polyester Micro- and Nanosystems for Treating HIV, Tuberculosis, and Malaria. , 2016, , 563-594.		0
1558	Chronic Heart Disease after Treatment of Oral Acute Chagas Disease. Arquivos Brasileiros De Cardiologia, 2016, 107, 184-6.	0.8	4
1560	Pacemaker Implants in Children and Adolescents with Chagas Disease in Brazil: 18-Year Incidence. Arquivos Brasileiros De Cardiologia, 2017, 108, 546-551.	0.8	3
1562	Soroprevalência da doença de Chagas em cardiopatas internados em um hospital de referência da região Serrana do estado do Rio de Janeiro, Brasil.. Cadernos UniFOA, 2017, 12, 131-138.	0.1	0
1563	Ventricular Arrhythmias and Sudden Cardiac Death in Patients with Chagas Disease. Journal of Cardiology & Current Research, 2017, 8, .	0.1	0
1564	Patients with Chagas Disease and Cardiac Arrest Treated at the Emergency Department of a Reference Hospital in Brazil. Archives of Clinical Infectious Diseases, 2017, 12, .	0.2	1
1565	13: Essential Oil-Based Nanomedicines against Trypanosomatides. , 2017, , 258-278.		0
1566	Chagas Disease, Heart. , 2018, , 62-65.		0
1567	Other Protozoan Infections. , 2018, , 398-403.		0
1568	Foodborne Giardia duodenalis and Typanosoma cruzi. , 2018, , 17-40.		0
1569	Chronic Chagas Cardiomyopathy Patients and Resynchronization Therapy: a Survival Analysis. Brazilian Journal of Cardiovascular Surgery, 2018, 33, 82-88.	0.6	7

#	ARTICLE	IF	CITATIONS
1570	Different molecular conformations in the crystal structures of three 5-nitroimidazolyl derivatives. <i>Acta Crystallographica Section E: Crystallographic Communications</i> , 2018, 74, 380-384.	0.5	0
1576	Impacto dos Modos de Estimulaç�o DDD e VVIR na Capacidade Funcional e Qualidade de Vida de Pacientes Chag�sicos. <i>Journal of Cardiac Arrhythmias</i> , 2019, 32, 30-37.	0.1	0
1577	Impact of DDD and VVIR Stimulation Modes on Functional Capacity and Quality of Life of Chagasic Patients. <i>Journal of Cardiac Arrhythmias</i> , 2019, 32, 30-37.	0.1	0
1578	Consumo de a�sa�e perfil nutricional em universit�rios da �rea da sa�de de Bel�m-PA. <i>Par� Research Medical Journal</i> , 2019, 3, .	0.2	0
1579	The Biological Impact of Oxidative Metabolism in Trypanosomatid Parasites: What Is the Perfect Balance Between Reactive Species Production and Antioxidant Defenses?. , 2019, , 127-173.		0
1580	Orally Transmitted Chagas Disease: Biology, Epidemiology, and Clinical Aspects of a Foodborne Infection. <i>Birkhauser Advances in Infectious Diseases</i> , 2019, , 225-241.	0.3	1
1581	Current prevalence and risk factors related to Chagas disease in Bolivia. <i>Revista Bionatura</i> , 2019, 02, .	0.4	0
1587	Dynamics of T Cells Repertoire During <i>Trypanosoma cruzi</i> Infection and its Post-Treatment Modulation. <i>Current Medicinal Chemistry</i> , 2019, 26, 6519-6543.	2.4	4
1588	Tackling Exposure to Chagas Disease in the Yucatan from a Human Ecology Perspective. , 2020, , 293-309.		1
1590	Death due to acute Chagas -related myocarditis in a child: a case report. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2020, 53, e20190406.	0.9	0
1591	Chagas Disease: Coming to a Transplanted Patient Near You. , 2020, , 1-47.		0
1593	Aus�ncia de Descenso da Press�o Arterial Detectada pela Monitoriza�o Ambulatorial da Press�o Arterial em Pacientes com Doen�a de Chagas Aguda Transmitida por Via Oral. <i>Arquivos Brasileiros De Cardiologia</i> , 2020, 114, 711-715.	0.8	2
1594	Reproductive Outcomes in Rhesus Macaques (<i>Macaca mulatta</i>) with Naturally-acquired <i>Trypanosoma cruzi</i> Infection. <i>Comparative Medicine</i> , 2020, 70, 152-159.	1.0	4
1596	GWAS loci associated with Chagas cardiomyopathy influences DNA methylation levels. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009874.	3.0	5
1597	Mortality risk in chronic Chagas cardiomyopathy: a systematic review and meta�analysis. <i>ESC Heart Failure</i> , 2021, 8, 5466-5481.	3.1	12
1598	Transplantation for Chagas Heart Disease: a Comprehensive Review. <i>Current Transplantation Reports</i> , 2021, 8, 344-350.	2.0	1
1599	On-Site Experience of a Project to Increase Access to Diagnosis and Treatment of Chagas Disease in High-risk Endemic Areas of Colombia. <i>Acta Tropica</i> , 2021, 226, 106219.	2.0	5
1600	Enhanced Migratory Capacity of T Lymphocytes in Severe Chagasic Patients Is Correlated With VLA-4 and TNF-� Expression. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 713150.	3.9	6

#	ARTICLE	IF	CITATIONS
1601	Chagas Disease – An Underestimated Global Public Health Challenge. <i>China CDC Weekly</i> , 2020, 2, 362-363.	2.3	1
1602	Chagas Disease: South American Trypanosomiasis. , 2020, , 301-305.		0
1603	Analysis of Mummy Digestive Tract Contents with Examples of Relevance to Diet, Health, and Hospice. , 2020, , 1-35.		0
1604	Preliminary study between Y chromosome haplogroups and chagasic cardiomyopathy manifestations in patients with Chagas disease. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2020, 53, e20190566.	0.9	0
1605	Metabolic and immunological evaluation of patients with indeterminate and cardiac forms of Chagas disease. <i>Medicine (United States)</i> , 2020, 99, e23773.	1.0	5
1606	Association between <i>Trypanosoma cruzi</i> DTU TcII and chronic Chagas disease clinical presentation and outcome in an urban cohort in Brazil. <i>PLoS ONE</i> , 2020, 15, e0243008.	2.5	12
1607	Dogs as a Model for Chemotherapy of Chagas Disease and Leishmaniasis. <i>Current Pharmaceutical Design</i> , 2021, 27, 1741-1756.	1.9	7
1608	CD8 ^{low} T cells expanded following acute <i>Trypanosoma cruzi</i> infection and benznidazole treatment are a relevant subset of IFN- γ producers. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008969.	3.0	3
1609	Drawing inferences from classifications and ontologies. , 2020, , 187-208.		0
1610	Recent trends in hospital admissions and outcomes of cardiac Chagas disease in the United States. <i>International Journal of Critical Illness and Injury Science</i> , 2020, 10, 134.	0.6	0
1611	The Role of Surgery in Treating Parasitic Diseases of the Gastrointestinal Tract from Protozoa. , 2020, , 49-63.		0
1612	Cardiac Magnetic Resonance in the Assessment of Chagas Disease and its Complications. <i>International Journal of Cardiovascular Sciences</i> , 2020, 33, 705-712.	0.1	0
1613	Adverse drug events and the associated factors in patients with chronic Chagas disease. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2020, 53, e20190443.	0.9	1
1614	Images Analysis Method for the Detection of Chagas Parasite in Blood Image. <i>STEAM-H: Science, Technology, Engineering, Agriculture, Mathematics & Health</i> , 2020, , 63-72.	0.0	0
1615	Clinical and epidemiological aspects of chronic Chagas disease from Southern Brazil. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2020, 53, e20200225.	0.9	8
1616	Influence of Angiotensin-converting Enzyme Insertion/Deletion Gene Polymorphism in Progression of Chagas Heart Disease. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2020, 53, e20190488.	0.9	4
1617	Thiazolidinone-Related Heterocyclic Compounds as Potential Antitrypanosomal Agents. , 0, , .		4
1619	Structural Optimization and Biological Activity of Pyrazole Derivatives: Virtual Computational Analysis, Recovery Assay and 3D Culture Model as Potential Predictive Tools of Effectiveness against <i>Trypanosoma cruzi</i> . <i>Molecules</i> , 2021, 26, 6742.	3.8	7

#	ARTICLE	IF	CITATIONS
1620	Physical Exercise Promotes a Reduction in Cardiac Fibrosis in the Chronic Indeterminate Form of Experimental Chagas Disease. <i>Frontiers in Immunology</i> , 2021, 12, 712034.	4.8	4
1621	<i>Rhodnius prolixus</i> Colonization and <i>Trypanosoma cruzi</i> Transmission in Oil Palm (<i>Elaeis guineensis</i>) Plantations in the Orinoco Basin, Colombia. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 103, 428-436.	1.4	4
1623	Blood culture positivity rate for <i>Trypanosoma cruzi</i> in patients with chronic Chagas disease differs among different clinical forms. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2021, 115, 720-725.	1.8	4
1625	Identification of Novel Functionalized Carbohydrazonamides Designed as Chagas Disease Drug Candidates. <i>Medicinal Chemistry</i> , 2020, 16, 774-783.	1.5	1
1626	Laboratory Techniques and Procedures. , 2023, , 147-166.		0
1627	Transmission of Chagas disease via blood transfusions in 2 immunosuppressed pigtailed macaques (<i>Macaca nemestrina</i>). <i>Comparative Medicine</i> , 2014, 64, 63-7.	1.0	2
1628	Chagas disease: are we there yet?. <i>Blood Transfusion</i> , 2015, 13, 539.	0.4	0
1629	Chagas Cardiomyopathy in New Orleans and the Southeastern United States. <i>Ochsner Journal</i> , 2016, 16, 304-8.	1.1	4
1630	Clinical Disease after Cardiac Transplantation in a <i>Cynomolgus</i> Macaque (). <i>Comparative Medicine</i> , 2016, 66, 494-498.	1.0	4
1631	New Diagnostic Algorithm for Chagas Disease: Impact on Access to Diagnosis and Out-of-Pocket Expenditures in Colombia. <i>Iranian Journal of Public Health</i> , 2019, 48, 1379-1381.	0.5	4
1633	Cardiovascular Biomarkers and Diastolic Dysfunction in Patients With Chronic Chagas Cardiomyopathy. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 751415.	2.4	1
1634	Chagas Disease Ecology in the United States: Recent Advances in Understanding <i>Trypanosoma cruzi</i> Transmission Among Triatomines, Wildlife, and Domestic Animals and a Quantitative Synthesis of Vector-Host Interactions. <i>Annual Review of Animal Biosciences</i> , 2022, 10, 325-348.	7.4	20
1635	Antitrypanosomal activity of hydromethanol extract of leaves of <i>Cymbopogon citratus</i> and seeds of <i>Lepidium sativum</i> : in-vivo mice model. <i>BMC Complementary Medicine and Therapies</i> , 2021, 21, 290.	2.7	3
1636	Occurrence and spatial distribution of triatomines (Hemiptera: Reduviidae) in the urban area of the municipality of Montes Claros, Northern Minas Gerais, Brazil. <i>Zoonoses and Public Health</i> , 2022, 69, 83-94.	2.2	1
1637	Epidemiologic, Clinical and Immunological Consequences of Co-Infections during Canine Leishmaniosis. <i>Animals</i> , 2021, 11, 3206.	2.3	5
1638	Screening for Chagas Disease during Pregnancy in the United States—A Literature Review. <i>Tropical Medicine and Infectious Disease</i> , 2021, 6, 202.	2.3	2
1639	Comprehensive analysis of miRNA-mRNA regulatory network and potential drugs in chronic chagasic cardiomyopathy across human and mouse. <i>BMC Medical Genomics</i> , 2021, 14, 283.	1.5	13
1640	Immunomodulation for the Treatment of Chronic Chagas Disease Cardiomyopathy: A New Approach to an Old Enemy. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 765879.	3.9	10

#	ARTICLE	IF	CITATIONS
1641	The Blockade of Interleukin-2 During the Acute Phase of <i>Trypanosoma cruzi</i> Infection Reveals Its Dominant Regulatory Role. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 758273.	3.9	3
1642	Analysis of Mummy Digestive Tract Contents with Examples of Relevance to Diet, Health, and Hospice. , 2021, , 461-494.		0
1644	Aspirin plus verapamil relieves angina and perfusion abnormalities in patients with coronary microvascular dysfunction and Chagas disease: a pilot non-randomized study. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2021, 54, e0181.	0.9	4
1645	Dr. Anis Rassi (ã...September 15, 1929; â€June 6, 2021). <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 0, 54, .	0.9	0
1646	Myocardial function reclassification: Echocardiographic strain patterns in patients with chronic Chagas cardiomyopathy and intraventricular dyssynchrony. <i>International Journal of Cardiology</i> , 2022, 348, 102-107.	1.7	1
1648	Effect of <i>Triatoma Infestans</i> Saliva on Mouse Immune System Cells: The Role of the Pore-Forming Salivary Protein Trialysin. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1649	Detection of <i>Trypanosoma lewisi</i> DNA from <i>Rattus norvegicus</i> and <i>Rattus rattus</i> in Hanoi, Vietnam. <i>Vector-Borne and Zoonotic Diseases</i> , 2022, , .	1.5	1
1650	Elucidating the 3D Structure of a Surface Membrane Antigen from <i>Trypanosoma cruzi</i> as a Serodiagnostic Biomarker of Chagas Disease. <i>Vaccines</i> , 2022, 10, 71.	4.4	0
1651	Chagas Disease in Pregnant Women from Endemic Regions Attending the Hospital General de Mexico, Mexico City. <i>Tropical Medicine and Infectious Disease</i> , 2022, 7, 8.	2.3	4
1652	Re: â€œImmunothrombotic dysregulation in chagas disease and COVIDâ€™19: a comparative study of anticoagulationâ€. <i>Molecular and Cellular Biochemistry</i> , 2022, 477, 1093.	3.1	1
1653	Specific Recognition of Î²-Galactofuranose-Containing Glycans of Synthetic Neoglycoproteins by Sera of Chronic Chagas Disease Patients. <i>Molecules</i> , 2022, 27, 411.	3.8	4
1654	C57BL/6 Mice Pretreated With Alpha-Tocopherol Show a Better Outcome of <i>Trypanosoma cruzi</i> Infection With Less Tissue Inflammation and Fibrosis. <i>Frontiers in Immunology</i> , 2022, 13, 833560.	4.8	0
1655	The Role of Extracellular Vesicles in Immunomodulation and Pathogenesis of <i>Leishmania</i> and Other Protozoan Infections. <i>Physiology</i> , 0, , .	10.0	1
1656	Epicardial and Endocardial Ablation Based on Channel Mapping in Patients With Ventricular Tachycardia and Chronic Chagasic Cardiomyopathy: Importance of Late Potential Mapping During Sinus Rhythm to Recognize the Critical Substrate. <i>Journal of the American Heart Association</i> , 2022, 11, e021889.	3.7	1
1657	<i>Zelus renardii</i> Roaming in Southern Italy. <i>Insects</i> , 2022, 13, 158.	2.2	9
1658	STING Signaling Drives Production of Innate Cytokines, Generation of CD8+ T Cells and Enhanced Protection Against <i>Trypanosoma cruzi</i> Infection. <i>Frontiers in Immunology</i> , 2021, 12, 775346.	4.8	5
1659	Identification of Leucinostatins from <i>Ophiocordyceps</i> sp. as Antiparasitic Agents against <i>Trypanosoma cruzi</i> . <i>ACS Omega</i> , 2022, 7, 7675-7682.	3.5	3
1660	Ecdysteroid ester derivatives. , 2022, , .		0

#	ARTICLE	IF	CITATIONS
1661	Parasites causing cutaneous wounds: Theory and practice from a dermatological point of view. <i>Acta Tropica</i> , 2022, 228, 106332.	2.0	1
1662	The Search for Biomarkers and Treatments in Chagas Disease: Insights From TGF-Beta Studies and Immunogenetics. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 767576.	3.9	8
1663	Experimental Combination Therapy with Amiodarone and Low-Dose Benznidazole in a Mouse Model of <i>Trypanosoma cruzi</i> Acute Infection. <i>Microbiology Spectrum</i> , 2022, 10, e0185221.	3.0	4
1664	Dynamics of <i>Triatoma infestans</i> populations in the Paraguayan Chaco: Population genetic analysis of household reinfestation following vector control. <i>PLoS ONE</i> , 2022, 17, e0263465.	2.5	7
1665	<i>Strongyloides stercoralis</i> and <i>Trypanosoma cruzi</i> coinfections in a highly endemic area in Argentina. <i>PLoS Neglected Tropical Diseases</i> , 2022, 16, e0010179.	3.0	4
1666	<i>Trypanosoma cruzi</i> Mitochondrial Peroxiredoxin Promotes Infectivity in Macrophages and Attenuates Nifurtimox Toxicity. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 749476.	3.9	3
1667	Effect of <i>Triatoma infestans</i> saliva on mouse immune system cells: The role of the pore-forming salivary protein trialysin. <i>Insect Biochemistry and Molecular Biology</i> , 2022, 143, 103739.	2.7	0
1668	New chemotherapy regimens and biomarkers for Chagas disease: the rationale and design of the TESEO study, an open-label, randomised, prospective, phase-2 clinical trial in the Plurinational State of Bolivia. <i>BMJ Open</i> , 2021, 11, e052897.	1.9	14
1669	Prognosis of chronic Chagas heart disease and other pending clinical challenges. <i>Memorias Do Instituto Oswaldo Cruz</i> , 0, 117, .	1.6	10
1670	Neglected Parasitic Infections: What Family Physicians Need to Know-A CDC Update. <i>American Family Physician</i> , 2021, 104, 277-287.	0.1	1
1671	Ecomorphological Variation of the <i>Triatoma Guasayana</i> Wing Shape in Semi-Arid Chaco Region. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1672	Results and evaluation of the expansion of a model of comprehensive care for Chagas disease within the National Health System: The Bolivian Chagas network. <i>PLoS Neglected Tropical Diseases</i> , 2022, 16, e0010072.	3.0	2
1674	Oral <i>Trypanosoma cruzi</i> Acute Infection in Mice Targets Primary Lymphoid Organs and Triggers Extramedullary Hematopoiesis. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 800395.	3.9	2
1675	Machine Learning-Based Feature Selection and Classification for the Experimental Diagnosis of <i>Trypanosoma cruzi</i> . <i>Electronics (Switzerland)</i> , 2022, 11, 785.	3.1	4
1676	Worldwide Control and Management of Chagas Disease in a New Era of Globalization: a Close Look at Congenital <i>Trypanosoma cruzi</i> Infection. <i>Clinical Microbiology Reviews</i> , 2022, 35, e0015221.	13.6	26
1677	Matrix Metalloproteinase 2 and 9 Enzymatic Activities are Selectively Increased in the Myocardium of Chronic Chagas Disease Cardiomyopathy Patients: Role of TIMPs. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 836242.	3.9	8
1678	Double-antigen sandwich ELISA based on chimeric antigens for detection of antibodies to <i>Trypanosoma cruzi</i> in human sera. <i>PLoS Neglected Tropical Diseases</i> , 2022, 16, e0010290.	3.0	8
1679	A terpenoid-rich extract from <i>Clethra fimbriata</i> exhibits anti- <i>Trypanosoma cruzi</i> activity and induces T cell cytokine production. <i>Heliyon</i> , 2022, 8, e09182.	3.2	2

#	ARTICLE	IF	CITATIONS
1680	Signs of Urban Evolution? Morpho-Functional Traits Co-variation Along a Nature-Urban Gradient in a Chagas Disease Vector. <i>Frontiers in Ecology and Evolution</i> , 2022, 10, .	2.2	7
1681	Different Drugs, Same End: Ultrastructural Hallmarks of Autophagy in Pathogenic Protozoa. <i>Frontiers in Microbiology</i> , 2022, 13, 856686.	3.5	5
1682	Parasite load evaluation by qPCR and blood culture in Chagas disease and HIV co-infected patients under antiretroviral therapy. <i>PLoS Neglected Tropical Diseases</i> , 2022, 16, e0010317.	3.0	2
1683	The Screen of a Phage Display Library Identifies a Peptide That Binds to the Surface of <i>Trypanosoma cruzi</i> Trypomastigotes and Impairs Their Infection of Mammalian Cells. <i>Frontiers in Microbiology</i> , 2022, 13, 864788.	3.5	1
1684	Variation in the Mitochondrial Genome of the Chagas Disease Vector <i>Triatoma infestans</i> (Hemiptera: Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.2	0
1685	Quinoxaline: A comprehension of current pharmacological advancement in medicinal chemistry. <i>European Journal of Medicinal Chemistry Reports</i> , 2022, 5, 100040.	1.4	15
1686	Nasal immunization with a <i>L. lactis</i> -derived trans-sialidase antigen plus c-di-AMP protects against acute oral <i>T. cruzi</i> infection. <i>Vaccine</i> , 2022, 40, 2311-2323.	3.8	7
1687	Semisynthetic ecdysteroid-cinnamic derivatives against <i>Trypanosoma cruzi</i> . <i>Planta Medica</i> , 2021, 87, .	1.3	1
1688	Extracellular Vesicles: Potential Role in Remote Signaling and Inflammation in <i>Trypanosoma cruzi</i> -Triggered Disease. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 798054.	3.7	10
1690	Chagas heart disease: An overview of diagnosis, manifestations, treatment, and care. <i>World Journal of Cardiology</i> , 2021, 13, 654-675.	1.5	25
1691	Advanced management of ventricular arrhythmias in chronic Chagas cardiomyopathy. <i>Heart Rhythm</i> O2, 2021, 2, 807-818.	1.7	1
1692	Genetic polymorphism of <i>Trypanosoma cruzi</i> bloodstream populations in adult chronic indeterminate Chagas disease patients from the E1224 clinical trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 578-584.	3.0	3
1694	Effects of algae bioactive compounds on <i>Trypanosoma cruzi</i> : A systematic review. <i>Algal Research</i> , 2021, 60, 102559.	4.6	4
1695	Digestive Disorders in Chagas Disease: Megaesophagus and Chagasic Megacolon. , 0, , .		2
1696	The esophagus. , 0, , 1805-1852.		0
1722	A safe, effective, and reliable vaccine against Chagas disease should be described!. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2022, 117, e210314chgsa.	1.6	0
1723	Loop-Mediated Isothermal Amplification of <i>Trypanosoma cruzi</i> DNA for Point-of-Care Follow-Up of Anti-Parasitic Treatment of Chagas Disease. <i>Microorganisms</i> , 2022, 10, 909.	3.6	9
1724	Bioactivity of Novel Pyrazole-Thiazolines Scaffolds against <i>Trypanosoma cruzi</i> : Computational Approaches and 3D Spheroid Model on Drug Discovery for Chagas Disease. <i>Pharmaceutics</i> , 2022, 14, 995.	4.5	3

#	ARTICLE	IF	CITATIONS
1725	Deciphering the Molecular Mechanism Underlying African Animal Trypanosomiasis by Means of the 1000 Bull Genomes Project Genomic Dataset. <i>Biology</i> , 2022, 11, 742.	2.8	1
1726	Modulation of Host Cell Apoptosis by <i>Trypanosoma cruzi</i> : Repercussions in the Development of Chronic Chagasic Cardiomyopathy. , 0, .		0
1727	Ecomorphological variation of the <i>Triatoma guasayana</i> wing shape in semi-arid Chaco region. <i>Acta Tropica</i> , 2022, 232, 106488.	2.0	3
1728	New 4-nitro-imidazole-N-glyciny-hydrazones designed as trypanocidal analogues of benznidazole. <i>Letters in Drug Design and Discovery</i> , 2022, 19, .	0.7	1
1729	Systemic Diseases. , 2016, , 739-804.		0
1730	First-degree Atrioventricular Block as an Early Marker of Advanced Disease of the Conduction System in a Patient with Hereditary Val142Ile Cardiac Amyloidosis. <i>International Journal of Cardiovascular Sciences</i> , 2022, , .	0.1	0
1731	Dysautonomia Evaluation by Holter in Chagas Heart Disease. <i>International Journal of Cardiovascular Sciences</i> , 2022, , .	0.1	0
1732	Early identification of patients with Chagas disease at risk of developing cardiomyopathy using 2-D speckle tracking strain. <i>IJC Heart and Vasculature</i> , 2022, 41, 101060.	1.1	0
1733	Parasitological, serological and molecular diagnosis of acute and chronic Chagas disease: from field to laboratory. <i>Memorias Do Instituto Oswaldo Cruz</i> , 0, 117, .	1.6	11
1734	In the Acute Phase of <i>Trypanosoma cruzi</i> Infection, Liver Lymphoid and Myeloid Cells Display an Ambiguous Phenotype Combining Pro- and Anti-Inflammatory Markers. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	2
1735	Evaluation of Selective Deltamethrin Application with Household and Community Awareness for the Control of Chagas Disease in Southern Ecuador. <i>Journal of Medical Entomology</i> , 0, , .	1.8	0
1736	An Updated View of the <i>Trypanosoma cruzi</i> Life Cycle: Intervention Points for an Effective Treatment. <i>ACS Infectious Diseases</i> , 2022, 8, 1107-1115.	3.8	24
1737	Contextual influence on poor self-rated health in patients with Chagas disease: multilevel study. <i>Ciencia E Saude Coletiva</i> , 2022, 27, 2827-2842.	0.5	2
1738	Electrochemical Impedance Biosensor for Chagas Disease Diagnosis in Clinical Samples. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1740	Potential distributions of the parasite <i>Trypanosoma cruzi</i> and its vector <i>Dipetalogaster maxima</i> highlight areas at risk of Chagas disease transmission in Baja California Sur, Mexico, under climate change. <i>Medical and Veterinary Entomology</i> , 0, , .	1.5	3
1741	Towards environmental detection of Chagas disease vectors and pathogen. <i>Scientific Reports</i> , 2022, 12, .	3.3	3
1742	Preclinical advances and the immunophysiology of a new therapeutic Chagas disease vaccine. <i>Expert Review of Vaccines</i> , 2022, 21, 1185-1203.	4.4	3
1743	Diffuse Myocardial Fibrosis and Cardiomyocyte Diameter Are Associated With Heart Failure Symptoms in Chagas Cardiomyopathy. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	4

#	ARTICLE	IF	CITATIONS
1745	Efficacy and Safety of Granulocyte-Colony Stimulating Factor Therapy in Chagas Cardiomyopathy: A Phase II Double-Blind, Randomized, Placebo-Controlled Clinical Trial. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	1
1746	The entrance route: Oral, mucous, cutaneous, or systemic has a marked influence on the outcome of <i>Trypanosoma cruzi</i> experimental infection. <i>Acta Tropica</i> , 2022, 234, 106581.	2.0	0
1747	Insights into IL-33 on inflammatory response during in vitro infection by <i>Trypanosoma cruzi</i> . <i>Immunobiology</i> , 2022, 227, 152243.	1.9	0
1748	Call for Consensus in the Evaluation of Circulating Matrix Metalloproteinases in Chagas Disease. <i>American Journal of Tropical Medicine and Hygiene</i> , 2022, , .	1.4	0
1749	Heart Failure in Chronic Infectious and Inflammatory Conditions: Mechanistic Insights from Clinical Heterogeneity. <i>Current Heart Failure Reports</i> , 2022, 19, 267-278.	3.3	2
1750	Geospatial analysis as a tool to identify target areas for Chagas disease education for healthcare providers. <i>BMC Infectious Diseases</i> , 2022, 22, .	2.9	0
1751	The Role of the Na ⁺ /Ca ²⁺ Exchanger in Aberrant Intracellular Ca ²⁺ in Cardiomyocytes of Chagas-Infected Rodents. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	3.9	1
1752	How Do Mouse Strains and Inoculation Routes Influence the Course of Experimental <i>Trypanosoma cruzi</i> Infection?. , 0, , .		0
1753	Cardiopatia Chagásica: A Evoluçãõ da Doençã e seus Exames Complementares. <i>Arquivos Brasileiros De Cardiologia</i> , 2022, 119, 12-13.	0.8	0
1754	Diagnosis and Prevalence of Chagas Disease in an Indigenous Population of Colombia. <i>Microorganisms</i> , 2022, 10, 1427.	3.6	3
1755	<i>Trypanosoma cruzi</i> blood trypomastigotes induce intense skeletal and cardiac muscle damage and Th1/Th2 immune response in the acute phase of mice infected by the oral route. <i>Acta Tropica</i> , 2022, 234, 106605.	2.0	2
1756	InÂvitro evaluation of Resveratrol as a potential pre-exposure prophylactic drug against <i>Trypanosoma cruzi</i> infection. <i>International Journal for Parasitology: Drugs and Drug Resistance</i> , 2022, 20, 54-64.	3.4	5
1757	Benznidazole and amiodarone combined treatment attenuates cytoskeletal damage in <i>Trypanosoma cruzi</i> -infected cardiac cells. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	3.9	3
1759	Synthesis, Design, and Structure-Activity Relationship of a Benzenesulfonylpiperazine Series Against <i>Trypanosoma Cruzi</i> . <i>ChemMedChem</i> , 0, , .	3.2	2
1760	Transplantation for chagasâ€™ disease: closing the knowledge gap. <i>Current Opinion in Infectious Diseases</i> , 2022, 35, 397-403.	3.1	3
1761	Stress-Induced Cardiomyopathy. , 0, , .		0
1762	Genetic diversity in peridomiliary populations of <i>Triatoma mexicana</i> (Hemiptera: Reduviidae): Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 102	1.6	4
1763	Challenges of addressing neglected tropical diseases amidst the COVID-19 pandemic in Africa: A case of Chagas Disease. <i>Annals of Medicine and Surgery</i> , 2022, 81, .	1.1	3

#	ARTICLE	IF	CITATIONS
1764	Protective immunity triggered by ectonucleoside triphosphate diphosphohydrolase-based biopharmaceuticals attenuates cardiac parasitism and prevents mortality in <i>Trypanosoma cruzi</i> infection. <i>Bioorganic and Medicinal Chemistry</i> , 2022, 72, 116966.	3.0	0
1765	Molecular detection and parasite load of <i>Trypanosoma cruzi</i> in digestive tract tissue of Chagas disease patients affected by megacolon. <i>Acta Tropica</i> , 2022, 235, 106632.	2.0	3
1766	Tele-entomology and tele-parasitology: A citizen science-based approach for surveillance and control of Chagas disease in Venezuela. <i>Parasite Epidemiology and Control</i> , 2022, 19, e00273.	1.8	4
1767	Biological characteristics of the <i>Trypanosoma cruzi</i> Arequipa strain make it a good model for Chagas disease drug discovery. <i>Acta Tropica</i> , 2022, 236, 106679.	2.0	1
1768	Comparison of 1-year healthcare resource utilization and related costs for patients with heart failure in the Chagas and non-Chagas matched cohorts. <i>Therapeutic Advances in Infectious Disease</i> , 2022, 9, 204993612211142.	1.8	0
1769	Epigenetic signature of exposure to maternal <i>Trypanosoma cruzi</i> infection in cord blood cells from uninfected newborns. <i>Epigenomics</i> , 2022, 14, 913-927.	2.1	3
1770	que vivimos en el sur porque hay más monte. <i>Revista De Antropología Experimental</i> , 2022, , 371-386.	0.0	0
1771	Vaccine-linked chemotherapy with a low dose of benznidazole plus a bivalent recombinant protein vaccine prevents the development of cardiac fibrosis caused by <i>Trypanosoma cruzi</i> in chronically-infected BALB/c mice. <i>PLoS Neglected Tropical Diseases</i> , 2022, 16, e0010258.	3.0	8
1772	Southwestern national park service employee risk, knowledge, and concern for triatomine exposure: A qualitative analysis using a novel knowledge, attitudes, and practices survey. <i>PLoS Neglected Tropical Diseases</i> , 2022, 16, e0010744.	3.0	0
1773	Toward New Epidemiological Landscapes of <i>Trypanosoma cruzi</i> (Kinetoplastida, Trypanosomatidae) Transmission under Future Human-Modified Land Cover and Climatic Change in Mexico. <i>Tropical Medicine and Infectious Disease</i> , 2022, 7, 221.	2.3	1
1774	Mechanism of action and implication of naphthoquinone as potent anti-trypanosomal drugs. <i>Current Topics in Medicinal Chemistry</i> , 2022, 22, .	2.1	0
1775	A Branched and Double Alpha-Gal-Bearing Synthetic Neoglycoprotein as a Biomarker for Chagas Disease. <i>Molecules</i> , 2022, 27, 5714.	3.8	1
1776	Electrochemical impedance biosensor for Chagas Disease diagnosis in clinical samples. <i>Biosensors and Bioelectronics: X</i> , 2022, 12, 100261.	1.7	1
1777	Structure-based design, synthesis and evaluation of a novel family of PEX5-PEX14 interaction inhibitors against <i>Trypanosoma</i> . <i>European Journal of Medicinal Chemistry</i> , 2022, 243, 114778.	5.5	3
1778	Emergence of infectious diseases and role of advanced nanomaterials in point-of-care diagnostics: a review. <i>Biotechnology and Genetic Engineering Reviews</i> , 0, , 1-89.	6.2	15
1779	Consumption of Galactose by <i>Trypanosoma cruzi</i> Epimastigotes Generates Resistance against Oxidative Stress. <i>Pathogens</i> , 2022, 11, 1174.	2.8	1
1780	Assessing the Variability of Multicopy Genes in Complex Genomes using Unassembled Next-Generation Sequencing Reads: The Case of <i>Trypanosoma cruzi</i> Multigene Families. <i>MBio</i> , 2022, 13, .	4.1	3
1781	From drugs to targets: Reverse engineering the virtual screening process on a proteomic scale. <i>Frontiers in Drug Discovery</i> , 0, 2, .	2.8	3

#	ARTICLE	IF	CITATIONS
1782	Trends in evolution of the Triatomini tribe (Hemiptera, Triatominae): reproductive incompatibility between four species of geniculatus clade. <i>Parasites and Vectors</i> , 2022, 15, .	2.5	4
1783	Association of left ventricular abnormalities with incident cerebrovascular events and sources of thromboembolism in patients with chronic Chagas cardiomyopathy. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2022, 24, .	3.3	3
1784	<i>Triatoma costalimai</i> , a neglected vector of <i>Trypanosoma cruzi</i> in the Cerrado savannas of South America: A comprehensive review. <i>Current Research in Parasitology and Vector-borne Diseases</i> , 2022, , 100102.	1.9	1
1785	<i>Trypanosoma</i> Species (<i>Trypanosomiasis</i>). , 2023, , 1402-1409.e3.		0
1786	AvaliaÃ§Ã£o do conhecimento sobre a doenÃ§a de Chagas em escolares das zonas rural e urbana de municÃpios endÃamicos em Minas Gerais. <i>Physis</i> , 2022, 32, .	0.3	0
1787	Western blot using <i>Trypanosoma cruzi</i> chimeric recombinant proteins for the serodiagnosis of chronic Chagas disease: A proof-of-concept study. <i>PLoS Neglected Tropical Diseases</i> , 2022, 16, e0010944.	3.0	3
1788	In Chagas disease, transforming growth factor beta neutralization reduces <i>Trypanosoma cruzi</i> infection and improves cardiac performance. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	3.9	3
1789	Antiparasitic potential of asteraceae plants: A comprehensive review on therapeutic and mechanistic aspects for biocompatible drug discovery. <i>Phytomedicine Plus</i> , 2022, 2, 100377.	2.0	5
1790	Phenotypic Evaluation of Nucleoside Analogues against <i>Trypanosoma cruzi</i> Infection: In Vitro and In Vivo Approaches. <i>Molecules</i> , 2022, 27, 8087.	3.8	7
1791	Chapter 10: Olfactory-driven behaviours in kissing bugs. , 2022, , 277-296.		5
1792	Correlation of TcII discrete typing units with severe chronic Chagas cardiomyopathy in patients from various Brazilian geographic regions. <i>PLoS Neglected Tropical Diseases</i> , 2022, 16, e0010713.	3.0	4
1793	Chagas Heart Disease: Beyond a Single Complication, from Asymptomatic Disease to Heart Failure. <i>Journal of Clinical Medicine</i> , 2022, 11, 7262.	2.4	4
1794	2,3-Diketopiperazine as potential scaffold to develop new anti-Chagasic agents. <i>Medicinal Chemistry Research</i> , 0, , .	2.4	0
1795	Effect of benznidazole on cerebral microcirculation during acute <i>Trypanosoma cruzi</i> infection in mice. <i>Scientific Reports</i> , 2022, 12, .	3.3	2
1796	Epitopes in the Glycosylphosphatidylinositol Attachment Signal Peptide of <i>Trypanosoma cruzi</i> Mucin Proteins Generate Robust But Delayed and Nonprotective CD8+ T Cell Responses. <i>Journal of Immunology</i> , 0, , .	0.8	1
1797	Effect of statins on inflammation and cardiac function in patients with chronic Chagas disease: A protocol for pathophysiological studies in a multicenter, placebo-controlled, proof-of-concept phase II trial. <i>PLoS ONE</i> , 2023, 18, e0280335.	2.5	2
1798	A Questionnaire Integrated with the Digital Medical Record Improved the Coverage of a Control Program for Congenital Chagas Disease in Tuscany, Italy. <i>Microorganisms</i> , 2023, 11, 154.	3.6	1
1800	Nutritional Heart Disease and Cardiomyopathies. <i>Journal of the American College of Cardiology</i> , 2023, 81, 187-202.	2.8	4

#	ARTICLE	IF	CITATIONS
1801	Case report: diagnosis of chronic Chagas cardiomyopathy using a multimodality imaging approach. <i>European Heart Journal - Case Reports</i> , 2022, 7, .	0.6	0
1802	Diretriz Brasileira de Dispositivos Cardíacos Eletrônicos Implantáveis “ 2023. <i>Arquivos Brasileiros De Cardiologia</i> , 2023, 120, .	0.8	1
1803	Intestinal permeability evaluation in patients with chronic Chagas heart failure. <i>ESC Heart Failure</i> , 0, , .	3.1	1
1804	Perspectives of vector management in the control and elimination of vector-borne zoonoses. <i>Frontiers in Microbiology</i> , 0, 14, .	3.5	0
1805	Function and regulation of cGAS-STING signaling in infectious diseases. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	10
1806	Vaccine-linked chemotherapy improves cardiac structure and function in a mouse model of chronic Chagas disease. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 13, .	3.9	5
1807	Peroxisome Proliferator-Activated Receptor-Targeted Therapies: Challenges upon Infectious Diseases. <i>Cells</i> , 2023, 12, 650.	4.1	3
1808	The Low Variability of Tc24 in <i>Trypanosoma cruzi</i> TcI as an Advantage for Chagas Disease Prophylaxis and Diagnosis in Mexico. <i>Pathogens</i> , 2023, 12, 368.	2.8	2
1810	A multicenter comparative study of the performance of four rapid immunochromatographic tests for the detection of anti- <i>Trypanosoma cruzi</i> antibodies in Brazil. <i>Frontiers in Medicine</i> , 0, 10, .	2.6	2
1811	<i>Trypanosoma cruzi</i> dysregulates expression profile of piRNAs in primary human cardiac fibroblasts during early infection phase. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 13, .	3.9	1
1812	ECG Marker Evaluation for the Machine-Learning-Based Classification of Acute and Chronic Phases of <i>Trypanosoma cruzi</i> Infection in a Murine Model. <i>Tropical Medicine and Infectious Disease</i> , 2023, 8, 157.	2.3	2
1813	<sc>Pfizer&BioNTech</sc> vaccine induces the production of cross&reactive antibodies against <i>Trypanosoma cruzi</i> proteins: A preliminary study. <i>Tropical Medicine and International Health</i> , 0, , .	2.3	0
1814	Murine colon organoids as a novel model to study <i>Trypanosoma cruzi</i> infection and interactions with the intestinal epithelium. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 13, .	3.9	2
1815	<i>Trypanosoma cruzi</i> DTU II coinfection with bacteria producing prolonged cutaneous lesion in a healthy young male. <i>Revista Do Instituto De Medicina Tropical De Sao Paulo</i> , 0, 65, .	1.1	0
1816	Vector mapping and bloodmeal metabarcoding demonstrate risk of urban Chagas disease transmission in Caracas, Venezuela. <i>PLoS Neglected Tropical Diseases</i> , 2023, 17, e0010613.	3.0	1
1817	Treatment with benznidazole and pentoxifylline regulates microRNA transcriptomic profile in a murine model of Chagas chronic cardiomyopathy. <i>PLoS Neglected Tropical Diseases</i> , 2023, 17, e0011223.	3.0	4
1818	Karyotype Evolution in Triatominae (Hemiptera, Reduviidae): The Role of Chromosomal Rearrangements in the Diversification of Chagas Disease Vectors. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6350.	4.1	1
1819	Parasitic and Protozoal Infections. , 2023, , 339-360.		0

#	ARTICLE	IF	CITATIONS
1821	Structural Modelling of Platelet Activating Factor Acetyl Hydrolase in <i>Leishmania donovani</i> , <i>Trypanosoma cruzi</i> , and <i>Trypanosoma brucei</i> : Implications on Therapeutics for Leishmaniasis, Chagas Disease, and Sleeping Sickness. <i>Infection and Drug Resistance</i> , 0, Volume 16, 2117-2128.	2.7	0
1822	Plasma-derived exosomal miRNA as potential biomarker for diagnosis and prognosis of vector-borne diseases: A review. <i>Frontiers in Microbiology</i> , 0, 14, .	3.5	1
1823	Climate and Environmental Changes and Their Potential Effects on the Dynamics of Chagas Disease: Hybridization in <i>Rhodniini</i> (Hemiptera, Triatominae). <i>Insects</i> , 2023, 14, 378.	2.2	2
1824	Identifying Barriers and Facilitators for Home Reconstruction for Prevention of Chagas Disease: An Interview Study in Rural Loja Province, Ecuador. <i>Tropical Medicine and Infectious Disease</i> , 2023, 8, 228.	2.3	1
1825	Elucidating the complexation of nifurtimox with cyclodextrins. <i>Journal of Molecular Liquids</i> , 2023, 382, 121852.	4.9	3
1826	Antiparasitic Activity of <i>Plumbago auriculata</i> Extracts and Its Naphthoquinone Plumbagin against <i>Trypanosoma cruzi</i> . <i>Pharmaceutics</i> , 2023, 15, 1535.	4.5	3
1827	Impact of the Recognition Part of Dipeptidyl Nitroalkene Compounds on the Inhibition Mechanism of Cysteine Proteases Cruzain and Cathepsin L. <i>ACS Catalysis</i> , 2023, 13, 6289-6300.	11.2	1
1828	Iron Uptake Controls <i>Trypanosoma cruzi</i> Metabolic Shift and Cell Proliferation. <i>Antioxidants</i> , 2023, 12, 984.	5.1	2
1829	Prevalence of <i>Trypanosoma cruzi</i> infection in a cohort of people living with HIV/AIDS from an urban area. <i>Epidemiology and Infection</i> , 2023, 151, .	2.1	0
1830	Close Encounters: Pathogenic Protists-Host Cell Interactions. <i>Physiology</i> , 0, , .	10.0	1
1831	Lupeol Acetate and \pm -Amyrin Terpenes Activity against <i>Trypanosoma cruzi</i> : Insights into Toxicity and Potential Mechanisms of Action. <i>Tropical Medicine and Infectious Disease</i> , 2023, 8, 263.	2.3	0
1832	Microbiome Alterations Driven by <i>Trypanosoma cruzi</i> Infection in Two Disjunctive Murine Models. <i>Microbiology Spectrum</i> , 2023, 11, .	3.0	4
1833	Arylimidamides Have Potential for Chemoprophylaxis against Blood-Transmitted Chagas Disease. <i>Pathogens</i> , 2023, 12, 701.	2.8	1
1834	Chagas Disease Cardiomyopathy. <i>Dimensions of Critical Care Nursing</i> , 2023, 42, 202-210.	0.9	0
1835	Autonomic denervation, myocardial hypoperfusion and fibrosis may predict ventricular arrhythmia in the early stages of Chagas cardiomyopathy. <i>Journal of Nuclear Cardiology</i> , 2023, 30, 2379-2388.	2.1	1
1836	A phase II trial of nifurtimox combined with topotecan and cyclophosphamide for refractory or relapsed neuroblastoma and medulloblastoma. <i>International Journal of Cancer</i> , 0, , .	5.1	1
1837	Acute Phase Proteins in Dogs with Natural Infection by <i>Trypanosoma cruzi</i> . <i>Tropical Medicine and Infectious Disease</i> , 2023, 8, 299.	2.3	1
1838	In vitro activity and mechanism of cell death induction of cyanomethyl vinyl ethers derivatives against <i>Trypanosoma cruzi</i> . <i>International Journal for Parasitology: Drugs and Drug Resistance</i> , 2023, 22, 72-80.	3.4	3

#	ARTICLE	IF	CITATIONS
1839	ASP-2/Trans-sialidase chimeric protein induces robust protective immunity in experimental models of Chagasâ€™ disease. <i>Npj Vaccines</i> , 2023, 8, .	6.0	1
1841	WHF Recommendations for the Use of Echocardiography in Chagas Disease. <i>Global Heart</i> , 2023, 18, .	2.3	3
1843	Hemoglobin uptake and utilization by human protozoan parasites: a review. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 13, .	3.9	2
1844	Myocarditis: Etiology, Pathogenesis, and Their Implications in Clinical Practice. <i>Biology</i> , 2023, 12, 874.	2.8	4
1845	Experimental <i>Trypanosoma cruzi</i> Infection and Chagas Diseaseâ€™A Word of Caution. <i>Microorganisms</i> , 2023, 11, 1613.	3.6	0
1846	Diretriz da SBC sobre DiagnÃ³stico e Tratamento de Pacientes com Cardiomiopatia da DoenÃ§a de Chagas â€“ 2023. <i>Arquivos Brasileiros De Cardiologia</i> , 2023, 120, .	0.8	4
1847	Design, synthesis and antitrypanosomatid activity of 2-nitroimidazole-3,5-disubstituted isoxazole compounds based on benzimidazole. <i>European Journal of Medicinal Chemistry</i> , 2023, 260, 115451.	5.5	3
1848	Coronary microvascular dysfunction due to Chagas disease: where are we now?. <i>Expert Review of Cardiovascular Therapy</i> , 2023, 21, 379-387.	1.5	0
1850	Characterization of Latin American migrants at risk for <i>Trypanosoma cruzi</i> infection in a non-endemic setting. Insights into initial evaluation of cardiac and digestive involvement. <i>PLoS Neglected Tropical Diseases</i> , 2023, 17, e0011330.	3.0	2
1851	Differential expression profile of genes involved in the immune response associated to progression of chronic Chagas disease. <i>PLoS Neglected Tropical Diseases</i> , 2023, 17, e0011474.	3.0	1
1852	Emerging infectious diseases of the skin: a review of clinical and histologic findings. <i>Human Pathology</i> , 2023, 140, 196-213.	2.0	2
1853	Diagnosis and management of chagasic cardiomyopathy patients in several institutions in Argentina. , 0, 2, .		0
1854	Oral transmission of Chagas disease from a One Health approach: A systematic review. <i>Tropical Medicine and International Health</i> , 2023, 28, 689-698.	2.3	5
1855	Motherâ€™toâ€™child Chagas disease transmission: The challenge of detection and prevention in areas without the risk of vectorial transmission. <i>International Journal of Gynecology and Obstetrics</i> , 2024, 164, 835-842.	2.3	1
1856	Antiprotozoal Activity of Benzoylthiourea Derivatives against <i>Trypanosoma cruzi</i> : Insights into Mechanism of Action. <i>Pathogens</i> , 2023, 12, 1012.	2.8	1
1857	American Trypanosomiasis: Chagas Disease. , 2024, , 636-645.		0
1859	Novel diamides inspired by protein kinase inhibitorsÂ’s anti- <i>Trypanosoma cruzi</i> agents: <i>in vitro</i> and <i>in vivo</i> evaluations. <i>Future Medicinal Chemistry</i> , 0, , .	2.3	0
1860	Effectiveness of Systemic Insecticide Dog Treatment for the Control of Chagas Disease in the Tropics. <i>Biology</i> , 2023, 12, 1235.	2.8	0

#	ARTICLE	IF	CITATIONS
1861	From Benznidazole to New Drugs: Nanotechnology Contribution in Chagas Disease. <i>International Journal of Molecular Sciences</i> , 2023, 24, 13778.	4.1	0
1862	Clethra fimbriata hexanic extract triggers alteration in the energy metabolism in epimastigotes of <i>Trypanosoma cruzi</i> . <i>Frontiers in Molecular Biosciences</i> , 0, 10, .	3.5	0
1863	Signature of cardiac alterations in early and late chronic infections with <i>Trypanosoma cruzi</i> in mice. <i>PLoS ONE</i> , 2023, 18, e0292520.	2.5	0
1864	Piplartine Synthetic Analogs: In Silico Analysis and Antiparasitic Study against <i>Trypanosoma cruzi</i> . <i>Applied Sciences (Switzerland)</i> , 2023, 13, 11585.	2.5	0
1865	cGAS/STING Pathway Activation during <i>Trypanosoma cruzi</i> Infection Leads to Tissue-Dependent Parasite Control. <i>Journal of Immunology</i> , 2023, 211, 1123-1133.	0.8	2
1866	Identifying inhibitors of <i>Trypanosoma cruzi</i> nucleoside diphosphate kinase 1 as potential repurposed drugs for Chagas disease. <i>Biochemical Pharmacology</i> , 2023, 216, 115766.	4.4	0
1867	Breastfeeding and Maternal Parasitic Infections. , 2023, , 399-414.		0
1868	Vibrational characterization of active drug to the treatment of chagas disease, benznidazole by using force fields and internal coordinates. , 2023, 1, 64-92.		0
1869	Cafeteria diet-induced obesity remodels immune response in acute <i>Trypanosoma cruzi</i> infection. <i>Immunobiology</i> , 2023, 228, 152747.	1.9	0
1870	Development of Novel Drugs for the Treatment of Chagas Disease. , 0, , .		0
1871	Disruption of the inositol phosphorylceramide synthase gene affects <i>Trypanosoma cruzi</i> differentiation and infection capacity. <i>PLoS Neglected Tropical Diseases</i> , 2023, 17, e0011646.	3.0	0
1872	Urbanization and Emergence of Infectious Diseases. <i>Health Information Systems and the Advancement of Medical Practice in Developing Countries</i> , 2023, , 43-67.	0.1	0
1873	<i>Akkermansia muciniphila</i> participates in the host protection against helminth-induced cardiac fibrosis via TLR2. <i>PLoS Pathogens</i> , 2023, 19, e1011683.	4.7	0
1875	Molecular diagnosis of Chagas disease: a systematic review and meta-analysis. <i>Infectious Diseases of Poverty</i> , 2023, 12, .	3.7	0
1876	<i>Trypanosoma cruzi</i> amastigote transcriptome analysis reveals heterogenous populations with replicating and dormant parasites. <i>Microbes and Infection</i> , 2024, 26, 105240.	1.9	0
1877	Looking through the lens of social science approaches: A scoping review of leishmaniasis and Chagas disease research. <i>Acta Tropica</i> , 2024, 249, 107059.	2.0	0
1878	Therapeutic Potential of Marine-Derived Cyclic Peptides as Antiparasitic Agents. <i>Marine Drugs</i> , 2023, 21, 609.	4.6	0
1879	Synthesis of new non-natural l-glycosidic flavonoid derivatives and their evaluation as inhibitors of <i>Trypanosoma cruzi</i> ecto-nucleoside triphosphate diphosphohydrolase 1 (TcNTPDase1). <i>Purinergic Signalling</i> , 0, , .	2.2	0

#	ARTICLE	IF	CITATIONS
1880	Nanomedicines for the Treatment of Trypanosomiasis. AAPS Advances in the Pharmaceutical Sciences Series, 2023, , 239-263.	0.6	0
1881	Strategies and Challenges for Developing Plant-Based Therapeutics Against Protozoans. , 2023, , 287-305.		0
1882	Persistent Biofluid Small-Molecule Alterations Induced by <i>Trypanosoma cruzi</i> Infection Are Not Restored by Parasite Elimination. ACS Infectious Diseases, 2023, 9, 2173-2189.	3.8	2
1883	The economic burden of Chagas disease: A systematic review. PLoS Neglected Tropical Diseases, 2023, 17, e0011757.	3.0	0
1884	Chagas disease and perceived quality of life: a cross-sectional study. Revista Da Sociedade Brasileira De Medicina Tropical, 0, 56, .	0.9	0
1885	Clinical use of molecular methods for <i>Trypanosoma cruzi</i> infection in endemic and non-endemic countries: Benefits, limitations and challenges. , 0, 2, .		0
1886	Promising Compounds of Plant Origin and Their Synthetic Analogs Against Trypanosomes. , 2023, , 411-429.		0
1887	Pathogenesis and Immune Response in <i>T. cruzi</i> Infection: Quest for Natural Compound-Based Drugs. , 2023, , 431-450.		0
1888	El misterio de la enfermedad de Chagas. Revista Ciencia UANL, 2023, 26, 26-33.	0.1	0
1889	Neglected Tropical Diseases: A Case for Promoting Innovation and Transdisciplinary Perspectives in Liberal Arts Education. Journal of College Science Teaching, 2020, 49, 23-27.	0.4	0
1890	Chagas disease. Lancet, The, 2023, , .	13.7	0
1891	Short-course combination treatment for experimental chronic Chagas disease. Science Translational Medicine, 2023, 15, .	12.4	2
1892	Circulating microRNAs as biomarkers of Chagas cardiomyopathy. Frontiers in Cardiovascular Medicine, 0, 10, .	2.4	0
1893	Possible Chemotherapeutic Potential of Inhibiting N-Alpha Terminal Acetylation Activities to Combat Trypanosome Infections. Infectious Diseases, 0, , .	4.0	0
1894	Characterization of Novel <i>Trypanosoma cruzi</i> -Specific Antigen with Potential Use in the Diagnosis of Chagas Disease. International Journal of Molecular Sciences, 2024, 25, 1202.	4.1	0
1895	PERFIL CLÍNICO-EPIDEMIOLÓGICO DE PACIENTES DETECTADOS COM A DOENÇA DE CHAGAS NA TRIAGEM DO HEMOCENTRO DE JATAÍ-GO, BRASIL. , 2023, 3, 32599-32612.		0
1896	Structure-activity relationships of novel <i>N</i> -imidazolylpiperazines with potent anti- <i>Trypanosoma cruzi</i> activity. Future Medicinal Chemistry, 2024, 16, 253-269.	2.3	0
1897	Efficacy and safety of fexinidazole for treatment of chronic indeterminate Chagas disease (FEXI-12): a multicentre, randomised, double-blind, phase 2 trial. Lancet Infectious Diseases, The, 2024, 24, 395-403.	9.1	1

#	ARTICLE	IF	CITATIONS
1898	Discovery of circulating miRNAs as biomarkers of chronic Chagas heart disease via a small RNA-Seq approach. <i>Scientific Reports</i> , 2024, 14, .	3.3	0
1899	Unraveling the role of miRNAs as biomarkers in Chagas cardiomyopathy: Insights into molecular pathophysiology. <i>PLoS Neglected Tropical Diseases</i> , 2024, 18, e0011865.	3.0	0
1900	Design and Synthesis of Novel 3-Nitro-1 <i>H</i> -1,2,4-triazole-1,2,3-triazole-1,4-disubstituted Analogs as Promising Antitrypanosomatid Agents: Evaluation of In Vitro Activity against Chagas Disease and Leishmaniasis. <i>Journal of Medicinal Chemistry</i> , 2024, 67, 2584-2601.	6.4	0
1901	The Potential Use of Peptides in the Fight against Chagas Disease and Leishmaniasis. <i>Pharmaceutics</i> , 2024, 16, 227.	4.5	0
1902	Exploring the latency period in Chagas disease: duration and determinants in a cohort from Colombia. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 0, , .	1.8	0
1903	Oral infectivity through carnivorem in murine model of <i>Trypanosoma cruzi</i> infection. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 14, .	3.9	0
1904	Rodents as Key Hosts of Zoonotic Pathogens and Parasites in the Neotropics. , 2024, , 143-184.		0
1905	Chagas Disease: History, Pathophysiology and Therapeutic Treatment. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1906	Post-therapeutic cure criterion in chronic Chagas disease using <i>Trypanosoma cruzi</i> chimeric proteins. <i>Folia Parasitologica</i> , 0, 71, .	1.3	0